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1 Summary 
 
Aromatic amines are known to be strong carcinogens. After metabolic activation, they react as 
electrophilic arylnitrenium ions with nucleophilic functionalities of the DNA duplex 
interfering and disrupting DNA and RNA synthesis and leading to mutations. Preferred 
reaction sites are the amino groups of adenine and guanine and particularly the C8-position of 
guanine. During metabolic activation, aromatic amines are enzymatically acetylated at 
N8 position.[16, 17] The non-acetylated lesions reduce the replication efficiency, but are in 
general faithfully bypassed by high fidelity polymerases. In contrast, the acetylated 
derivatives block replicative polymerases but can be bypassed with special low-fidelity 
polymerases. [51, 120, 122]  
The translesion synthesis DNA polymerase η, for instance, is able to bypass C8 bulky adduct 
lesions such as the widely studied 2-aminofluorene-dG (AF-dG, Figure 1, 15) and its 
acetylated analogue (AAF-dG, Figure 1, 14) mainly in an error-free manner.[56-58, 91] The 
distinct mutagenic properties of the acetylated and non-acetylated aromatic amine lesions are 
presumably caused by their different conformational preferences. While the non-acetylated 
lesions exist in both syn and anti conformation, the corresponding acetylated lesion seems to 
adopt the syn-conformation with high preference (Figure 1). [52-54] The mechanism that allows 
low-fidelity polymerases such as Pol η to replicate past acetylated AAF-dG lesions is still 
unknown. Computational modeling studies of the Y-family polymerase Dpo4 suggested that 
the bypass reaction requires rotation of the lesion into the base pairing anti conformation.[123] 
However, in light of the strong syn preference of the adducted base, this rotation is 
energetically demanding, which may force the enzyme to use a different, still unknown 
mechanism for accurate lesion bypass.  
 
Figure 1. Syn and anti conformation of the C8-AF/AAF-dG adducts. The acetylated C8-adduct 
(R = Ac, AAF-dG) is restricted to syn-conformation. 
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In this thesis work, the mechanism of the error-free bypass of acetylated aromatic amine dG 
adducts such as the acetylaminofluorene-dG (AAF-dG) by Pol η is investigated. For that 
reason, AAF-dG as well as the guanine adducts of other aromatic amines (aniline, 
2-aminonaphthalene, 2-aminoanthracene and 1-aminopyrene) were synthesized and converted 
to phosphoramidites, suitably protected for DNA synthesis (Figure 2). 
 
Figure 2. C8-dG adducts: AAB-dG 22, AAN-dG 23, AAF-dG 14, AAA-dG 24 and AAP-dG 25. 
Derivatives, suitably protected for solid-phase DNA synthesis, were prepared in this thesis work and 
incorporated into oligonucleotides. 
The synthesized dG adducts were successfully incorporated into various oligonucleotides via 
automated solid-phase DNA synthesis. The oligonucleotides were purified by HPL-
chromatography and characterized via MALDI-Tof mass spectrometry and enzymatic 
digestion analysis.  
 
Figure 3. Example of the purification and characterization of bulky adduct containing oligonucleotides. 
A) HPL-chromatogram of a purified oligonucleotide containing the AAF-dG lesion. B) MALDI-Tof mass 
spectrum of the purified AAF-dG oligonucleotide.  
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The synthesized bulky adduct containing oligonucleotides were used for crystallization and 
for primer extension studies with the translesion synthesis (TLS) polymerase η from 
S. cerevisiae in order to get insights into the bypass mechanism of bulky adducts by this 
enzyme. In the present work, structural evidence is provided that yeast Pol η bypasses the 
bulky adducts AAF-dG and 2-acetylaminoanthracene-dG (AAA-dG) by rotation of the DNA 
around the bulky moiety, while keeping the AAF-dG in syn conformation. Two crystal 
structures of AAF-dG and AAA-dG containing DNA in complex with Pol η were obtained. 
There are two Pol η molecules in the asymmetric unit cell of both crystals, showing the 
enzyme-DNA complexes in two different states (A and B).  In complex A, the aromatic units 
stack on top of the Watson-Crick base pair formed by the dG:dC base pair 3' to the lesion 
(Figure 4). The bulky aromatic units therefore fully block the active site for the incoming 
dCTP.  
 
Figure 4. Crystal structure of S. cerevisiae Pol η with the AAF-dG oligonucleotide in complex A. The 
overall folding topology is depicted with the enzyme as cartoon representation and the DNA as stick 
model (gold) and the AAF-dG adduct in orange. 
In complex B the situation is surprisingly different (Figure 5 B). First of all, a relatively small 
movement of the DNA template strand compared to complex A is observed. However, the 
primer DNA strand is rotated in complex B relative to the aromatic moiety resulting in a 
displacement of the primer end by 6 Å. In both structures, this primer rotation brings the dG 
part into the active site despite their prevalent syn-conformation. Thus the dG-lesion packs 
above the Watson-Crick base pair formed by the primer end and the template strand. The 
primer strand displacement results in a partial opening of the active site for the putative dCTP 
to bind. Hence TLS is accomplished without rotation of the lesion into the anti conformation 
 
 
 
  1. Summary  
 
XI 
 
as previously thought. In this situation correct dCTP incorporation opposite the lesion can be 
envisioned by formation of one hydrogen bond between the dCTP and the lesion (Figure 5 C).  
 
Figure 5. Model for AAF-dG bypass by Pol η. A) In complex A, the fluorene mojety of the AAF-dG 
adduct stacks onto the previous Watson-Crick base pair, blocking the active site for the incoming 
nucleotide. B) In contrast, the DNA in complex B is rotated in respect to the aromatic unit, with the 
adducted dG moved towards the templating position, partially freeing the active site. C) Hypothetical 
model of the AAF bypass by Pol η. The dG : dC basepair 3' of the lesion in the AAF-dG-Pol η 
complex B was replaced by the AAF-dG adduct and the dCTP triphosphate. Thus the active site for 
the incoming dCTP opens, which may form one critical hydrogen bond to the adducted nucleobase in 
syn conformation. 
The model was further supported by biochemical studies using synthetic zebularine 
triphosphate which is not incorporated opposite the AAF-dG lesion due to the lacking ability 
to form the critical hydrogen bond. Moreover, TLS of dG adducts containing aromatic units 
of different sizes (benzene, naphthalene, pyrene) was investigated. It could be shown that the 
TLS efficiency of Pol η depends critically on the size of the bulky adduct forming the lesion.  
Another part of this thesis work involves the investigation of frameshift mutations. Bulky 
adduct DNA lesions, such as the AAF-dG lesion, induce frameshift mutations if they are 
placed in special gene sequences.[16, 53, 61-64] By inserting the AAF-dG lesion into different 
repetitive frameshift prone sequences and perfoming primer extension studies, the molecular 
basis of the frameshifting event was determined. Primer extension studies were analyzed 
using PAA-gels. The composition of the elongated primer strands was determined by 
MALDI-Tof mass spectrometry. It could be shown that frameshifting starts with correct dCTP 
incorporation opposite the lesion. Then, the DNA polymerase induces a primer-slippage 
followed by primer misalignment and extension of the misaligned primer-template complex. 
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The mechanisms of -I, -II and –III frameshifts were deciphered. An example is shown in 
Figure 6. 
 
Figure 6. Schematic overview of the sequence dependent bypass products occurring during primer 
extension of AAF-dG adducts of a sequence allowing a –III frameshift. The MALDI-Tof mass spectrum 
(right) confirms the observed frameshifting products observed on the PAA gel (left).  
In an additional part of this thesis, the catalytic core of the human low fidelity polymerase κ 
was cloned, overexpressed and purified for primer extension studies. It could be shown, that 
Pol κ is, like Pol η, able to replicate across the synthesized C8 bulky DNA adducts. However, 
bypass seems to be more error-prone for Pol κ, the incorporation of nucleotides opposite the 
AAF-dG lesion is not selective. First crystallization screenings were performed with Pol κ in 
complex with an AAF-dG oligonucleotide in order to get insights into the bypass mechanism 
of bulky adducts by Pol κ.  
This thesis work also includes crystallization of the yeast NER protein Rad14 and its human 
homologue XPA together with AAF-dG containing oligonucleotides. The mechanism of 
lesion recognition in the NER pathway is still not well understood. It has been shown that the 
Rad14 and XPA bind specifically to DNA strands containing bulky adducts.[139] In this thesis, 
the minimal DNA binding domains were overexpressed, purified and crystallized in complex 
with AAF-dG containing DNA. Crystals of Rad14 could be obtained diffracting X-rays to 3 – 
4.5 Å. As no Rad14 crystal structure is known, phase information had to be obtained using 
heavy atom derivatized protein/DNA complex crystals. Selenomethionine labeled Rad14 was 
prepared and crystals were grown with either selenomethionine labeled protein or DNA 
containing 5-Br-dU. Some phase information was derived from SAD experiments using these 
crystals. However, structure solution was not successful up to now due to anisotropic 
diffraction and radiation damage.  
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Figure 7. A) Crystals of Rad14 in complex with AAF-dG containing DNA. B) Diffraction images of a 
Rad14 crystal in complex with an AAF-dG containing DNA duplex taken at the microfocus beamline 
ID23-2 at the ESRF (France). 
In summary, the combination of organic synthesis, biochemical studies and macromolecular 
crystallography in this thesis work provides mechanistic insights into the error-free and error-
prone bypass of bulky DNA adducts during replication.  
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2 Zusammenfassung 
 
Aromatische Amine sind starke Karzinogene. Nach metabolischer Aktivierung reagieren sie 
als elektrophile Arylnitreniumionen mit nucleophilen Gruppen der DNA Doppelhelix. Eine 
Störung der DNA und RNA Synthese durch so gebildete Addukte kann zu Mutationen im 
Genom führen. Aromatische Amine reagieren bevorzugt mit den Aminogruppen der Basen 
Adenin und Guanin und vor allem mit der C8-Position von Guanin. Während der 
metabolischen Aktivierung werden aromatische Amine enzymatisch an der N8 Position 
acetyliert.[16, 17] Nicht acetylierte Adduktschäden reduzieren die Replikationseffizienz von 
DNA Polymerasen, werden aber normalerweise korrekt überlesen. Im Gegensatz hierzu 
stellen die acetylierten Derivate eine Blockade für replikative Polymerasen dar und müssen 
von speziellen, sogenannten low-fidelity Polymerasen überlesen werden. [51, 120, 122]  
Die DNA Polymerase η, beteiligt an der Translesion-Synthese (TLS), ist in der Lage, sterisch 
anspruchsvolle C8-Addukte, wie zum Beispiel das gut untersuchte 2-Aminofluoren-dG (AF-
dG, Figure 1, 15) und sein acetyliertes Derivat (AAF-dG, Figure 1, 14), meist fehlerfrei zu 
überlesen.[56-58, 91] Die unterschiedlichen mutagenen Eigenschaften der acetylierten und nicht 
acetylierten Adduktschäden werden vermutlich durch ihre unterschiedlichen konformellen 
Präferenzen hervorgerufen. Nicht acetylierte Schäden können in syn und anti Konformation 
auftreten, die ensprechenden acetylierten Addukte scheinen mit hoher Präferenz in syn-
Konformation vorzuliegen (Abbildung 1).[52-54]  
 
Abbildung 1. Syn und anti Konformation der C8-AF/AAF-dG Addukte. Das acetylierte C8-Addukt 
(R = Ac, AAF-dG) liegt nur in syn-Konformation vor.  
Der Mechanismus, der es low-fidelity Polymerasen wie Pol η erlaubt, über acetylierte 
Adduktschäden wie AAF-dG Schäden hinwegzulesen, ist unbekannt. Gestützt auf 
molekulardynamische Rechnungen mit der zur Y-Familie gehörenden Polymerase Dpo4 
wurde vorgeschlagen, dass für das Überlesen der Adduktschäden eine Rotation des Schadens 
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in die anti-Konformation zur Ausbildung der Watson-Crick Basenpaarung notwendig ist.[123] 
Aufgrund der starken syn Präferenz der geschädigten Base ist dies energetisch ungünstig. 
Daher verwendet das Enzym vermutlich einen anderen, noch unbekannten Mechanismus für 
das akkurate Überlesen der Adduktschäden.   
In dieser Arbeit wird die fehlerfreie Replikation von acetylierten dG Addukten wie 
Acetylaminofluoren-dG (AAF-dG) durch Pol η untersucht. Hierfür wurden AAF-dG und die 
Guanin-Addukte anderer aromatischer Amine (Anilin, 2-Naphthylamin, 2-Aminoanthracen 
und 1-Aminopyren) synthetisiert und in Phosphoramidite, entsprechend geschützt für die 
automatisierte DNA Festphasensynthese, umgewandelt (Abbildung 2).  
 
Abbildung 2. C8-dG Addukte: AAB-dG 22, AAN-dG 23, AAF-dG 14, AAA-dG 24 und AAP-dG 25. In 
dieser Arbeit wurden Derivate, entsprechend geschützt für die automatisierte DNA 
Festphasensynthese, hergestellt und in Oligonukleotide eingebaut. 
Die synthetisierten dG Addukte wurden erfolgreich über automatisierte DNA 
Festphasensynthese in verschiedene Oligonukleotide eingebaut. Die Aufreinigung der 
Oligonukleotide erfolgte über HPL-Chromatographie. Anschließend wurden die 
Oligonukleotide mittels MALDI-Tof Massenspektrometrie und enzymatischem Verdau 
charakterisiert (Abbildung 3). Die synthetisierten, Adduktschäden enthaltenden 
Oligonukleotide wurden für die Kristallisation und für Primerverlängerungsstudien mit der 
TLS Polymerase η aus S. cerevisiae verwendet. Aus den Ergebnissen konnten Rückschlüsse 
auf den Mechanismus des Überlesens von Adduktschäden durch dieses Enzym gezogen 
werden. 
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Abbildung 3. Beispiel der  Aufreinigung und Charakterisierung eines Oligonukleotides mit  
Adduktschaden. A) HPL-Chromatogramm eines aufgereinigten AAF-dG Oligonukleotides. B) MALDI-
Tof Massenspektrum eines aufgereinigten AAF-dG Oligonukleotides.   
Die in dieser Arbeit enthaltenen Kristallstrukturen von Pol η in Komplex mit den 
Adduktschäden AAF-dG und 2-Aminoanthracen-dG (AAA-dG) lassen Rückschlüsse auf den 
Mechanismus der Schadensüberlesung zu. Pol η liest über den AAF-dG und den AAA-dG 
Schaden hinweg, indem die DNA um den Schaden rotiert wird. Der Schaden selbst verbleibt 
in syn-Konformation. Bei beiden Pol η Kristallstrukturen mit dem AAF-dG und dem AAA-
dG Addukt werden zwei Pol η Moleküle pro asymmetrische Einheitszelle gefunden, welche 
die Enzym-DNA Komplexe in zwei verschiedenen Zuständen zeigen (A und B). In Komplex 
A gehen die aromatischen Reste π-Wechselwirkungen mit dem Watson-Crick Basenpaar 3' 
des Schadens ein und sind oberhalb des Basenpaars positioniert (Abbildung 4). Das aktive 
Zentrum ist somit für ein ankommendes dCTP vollständig blockiert.  
 
Abbildung 4. Co-Kristallstruktur von S. cerevisiae Pol η mit einem AAF-dG Oligonukleotid in Komplex 
A. Die DNA ist als goldenes Stab-Modell dargestellt, das AAF-dG ist orange eingefärbt.  
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In Komplex B ist die Situation deutlich unterschiedlich (Abbildung 5 B). Zum einen wird ein 
geringe Bewegung des DNA Templatstranges im Vergleich zu Komplex A beobachtet. Für 
den Primerstrang hingegen wird eine grössere Bewegung erfasst. Der Primerstrang rotiert 
relativ zum aromatischen Rest. Dies ergibt eine Verschiebung des Primer-Endes um 6 Å. In 
beiden Strukturen bringt diese Primerrotation den dG Teil des Schadens in das aktive 
Zentrum, obwohl sich dieser in syn-Konformation befindet. Der Schaden sitzt oberhalb des 
Watson-Crick Basenpaars, welches durch das Primerende und den Templatstrang gebildet 
wird. Die Bewegung des Primerstranges ergibt eine partielle Öffnung des aktiven Zentrums 
für ein dCTP. Aus diesen Strukturen lässt sich erkennen, dass die TLS ohne Rotation des 
Schadens in die anti-Konformation stattfinden kann. In dieser Situation kann der Einbau eines 
korrekten dCTPs gegenüber dem Schaden durch die Bildung einer einzelnen 
Wasserstoffbrückenbindung zwischen dem dCTP und dem Schaden erklärt werden 
(Abbildung 5 C).  
 
Abbildung 5. Modell für das Überlesen des AAF-dG Schadens durch Pol η. A) Im Komplex A ist der 
Fluorenrest oberhalb des letzten Basenpaares positioniert und geht mit diesem π-Wechselwirkungen 
ein. Das aktive Zentrum ist blockiert. B) Im Komplex B hingegen ist die DNA um den aromatischen 
Rest gedreht. Das Addukt-dG bewegt sich auf die Templatposition zu und das aktive Zentrum ist 
partiell geöffnet. C) Hypothetisches Modell der Replikation über den AAF-dG Schaden. Das dG : dC 
Basenpaar 3' des Schadens wurde durch das AAF-dG Addukt und das dCTP Triphosphat ersetzt. Das 
aktive Zentrum ist für das dCTP geöffnet, dieses kann eine kritische Wasserstoffbrückenbindung zur 
geschädigten Nukleobase in syn-Konformation ausbilden.  
Das Modell wurde zusätzlich durch biochemische Studien mit synthetischem Zebularin-
Triphosphat überprüft. Dieses kann die essentielle Wasserstoffbrücke nicht ausbilden und 
wird deshalb nicht gegenüber dem AAF-dG Schaden eingebaut. Zusätzlich wurde der 
Einfluss der Grösse des aromatischen Restes (Anilin, Naphthalin, Pyren) auf die TLS 
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untersucht. Es konnte gezeigt werden, dass die TLS Effizienz sehr stark von der Grösse des 
aromatischen Restes abhängt.  
Ein weiterer Teil dieser Arbeit umfasst die Untersuchung von Leseraster-Mutationen. Sterisch 
anspruchsvolle Adduktschäden, wie der AAF-dG Schaden, induzieren Leseraster-Mutationen, 
wenn sie in speziellen Gensequenzen vorkommen.[16, 53, 61-64] Der AAF-dG Schaden wurde in 
verschiedene repetitive Oligonukleotidsequenzen eingebaut. Mit diesen Sequenzen wurden 
Primerverlängerungsstudien durchgeführt. Die molekulare Basis der Entstehung von 
Leseraster-Mutationen konnte somit geklärt werden. Die Primerverlängerungsstudien wurden 
auf PAA-Gelen analysiert, die Zusammensetzung der verlängerten Primerstränge wurde über 
MALDI-Tof Massenspektrometrie untersucht. Es konnte gezeigt werden, dass alle 
Leserasterverschiebungen mit dem korrekten Einbau eines dCTPs gegenüber dem Schaden 
beginnen. Anschliessend rutscht der Primer am Templatstrang entlang, und ein oder mehrere 
Nukleotide des Templatstranges formen eine Blase. Verlängerung dieses falsch gepaarten 
Komplexes führt zur Manifestierung der Leseraster-Mutation. Die Mechanismen der 
Entstehung von -I, -II und -III Leserasterverschiebungen konnten aufgeklärt werden. Ein 
Beispiel wird in Abbildung 6 gezeigt.  
 
Abbildung 6. Schematische Darstellung der sequenzabhängigen Replikation des AAF-dG Schadens. 
Die gezeigte Sequenz erlaubt die Entstehung einer –III Leserasterverschiebung. Das MALDI-Tof 
Massenspektrum (rechts) bestätigt die Entstehung einer –III Leseraster-Mutation (links) während einer 
Primerverlängerungsstudie.  
Ein weiterer Teil dieser Arbeit umfasst die Klonierung, Expression und Reinigung des 
katalytisch aktiven Teils der humanen low-fidelity Polymerase κ für Primer-
verlängerungsstudien. Es konnte gezeigt werden, dass Pol κ, ebenso wie Pol η, in der Lage ist, 
die synthetisierten C8 Adduktschäden zu überlesen. Die Replikation scheint jedoch im Falle 
von Pol κ fehlerhafter zu sein. Der Einbau von Nukleotiden gegenüber dem AAF-dG Schaden 
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ist nicht selektiv. Erste Kristallisationsversuche wurden mit Pol κ in Komplex mit einem 
AAF-dG Oligonukleotid durchgeführt, um den Mechanismus des Überlesen der 
Adduktschäden durch Pol κ genauer zu verstehen.  
In dieser Arbeit wurde ausserdem das an der Nukleotidexzisionsreparatur beteiligte Hefe 
Protein Rad14 und sein humanes Homolog XPA zusammen mit AAF-dG Oligonukleotiden 
kristallisiert. Der Mechanismus der Schadenserkennung in der Nukleotidexzisionsreparatur ist 
bisher nicht bekannt. Es wurde gezeigt, dass Rad14 und XPA spezifisch an DNA Stränge, die 
Adduktschäden enthalten, binden.[139] In dieser Arbeit wurden die minimalen DNA 
Bindedomänen überexprimiert, gereinigt und im Komplex mit AAF-dG DNA kristallisiert. Es 
konnten Rad14 Kristalle erhalten werden, die Röntgenstrahlen bis 3 – 4.5 Å beugten. Da 
bisher keine Rad14 Struktur bekannt ist, mussten Informationen über die Phasen über 
Schweratomderivatisierung erhalten werden. Es wurde Selenomethionin-markiertes Rad14 
hergestellt und Kristalle mit entweder Selenomethionin-markiertem Protein oder DNA, 
welche 5-Br-dU beinhaltete, erhalten. Einige Informationen über die Phasen konnten bei SAD 
Experimenten mit diesen Kristallen gesammelt werden. Durch anisotrophe Streuung und 
Strahlenschäden war die Strukturlösung bisher nicht erfolgreich.  
 
Abbildung 7.  A) Rad14 Kristalle im Komplex mit einem AAF-dG DNA Duplex. B) Diffraktionsbild eines 
Rad14 Kristalls in Komplex mit AAF-dG DNA aufgenommen an der Mikrofocus Strahlungsquelle 
ID23-2 am ESRF (Frankreich). 
Zusammenfassend ergibt die Kombination von organischer Synthese, biochemischen Studien 
und makromolekularer Kristallographie in dieser Arbeit mechanistische Einsichten in die 
fehlerfreie und fehlerhafte Replikation von sterisch anspruchsvollen DNA Addukten.  
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3 Introduction 
3.1 Chemically induced DNA damage  
 
DNA damages form by various exogenous and endogenous processes. They are a constant 
challenge for DNA polymerases that ensure accurate transmission of genomic information in 
all living organisms. Several ways lead to DNA lesions. Within the cell, spontaneous 
hydrolysis of the phosphodiester, N-glycosidic and C-NH2 bonds within DNA can occur.[1, 2] 
Moreover, DNA bases are constantly damaged by UV-light,[3, 4] various oxygen species,[5] 
free radicals and chemical pollutants.[6] UV-light, for instance, produces crosslinks between 
adjacent pyrimidine bases to form cyclobutane thymine dimers (CPD).[3, 4] In total, each cell 
accumulates about 106 DNA damages per day.[7] If these damages are not removed, they can 
lead to mutations or replication arrest and consequently to apoptosis or cancer. Dependent on 
the type of lesion, the cell uses multiple pathways to overcome these damages such as 
nucleotide excision repair (NER), base excision repair (BER), homologous recombination, 
non-homologous end joining or direct mutagenic or non-mutagenic bypass of the lesion 
during replication, entitled as translesion synthesis (TLS).  
Mutagenic TLS can ultimately cause the development of cancer. A variety of chemical 
compounds in the environment are well known to induce cancer in humans. Already in 1775, 
a connection between certain chemicals and tumorigenesis has been formulated for the first 
time.[6]  P. Pott reported the increase of verrucas caused by carbon black and tar on the skin of 
chimney sweepers. Carcinogenic substances, which turned out to be aromatic amines, were 
first identified in 1895 when an increase of urinary bladder carcinomas of employees working 
in the production of aniline red dyes (fuchsine) was observed.[6]  The term “aniline-cancer” 
was used during this time. Later, several byproducts of the aniline dye production were 
identified as strong carcinogens such as 2-naphthylamine 2 or benzidine 3 (Figure 8).[8, 9]  
 
 
Figure 8. Prospective carcinogenic aromatic amines: 1 = aniline, 2 = 2-naphthylamine, 3 = benzidine 
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Since then, a wide range of chemical compounds are classified as carcinogens in addition to 
aromatic amines such as polycyclic aromatic hydrocarbons (PAH),[10, 11] heterocyclic aromatic 
amines,[12] N-nitroso compounds and other alkylation reagents.[13] Nevertheless, these 
compounds play a major role in several industrial processes, for example in the production of 
dyes, synthetics, pharmaceuticals or explosives.[14] They therefore represent ubiquitous 
environmental hazards.  Nitropyrenes, for instance, can be found in urban air particles, coal 
fly ash and automobile exhaust.[15] Moreover, heterocyclic aromatic amines have been 
detected in heat-cooked meat and fish, originated from pyrolysis of amino acids, sugars and 
fats (Figure 9).[12] 
 
Figure 9. Food carcinogens: Heterocyclic aromatic amines found in cooked meat and fish. 4 = 2-
Amino-3-methyl-imidazo[4,5-f]quinoline (IQ) 5 = 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
(PhIP)  
Two well investigated aromatic amine compounds, serving as model substances for the 
investigation of carcinogenesis by aromatic amines, are 2-aminofluorene 6 (AF) and N-acetyl-
2-aminofluorene 7 (AAF).[16, 17] 
 
Figure 10. 2-aminofluorene (6, AF) and N-acetyl-2-aminofluorene (7, AAF)  
These compounds were originally developed as insecticides, but they were never used for 
such purposes after early studies revealed the strong carcinogenic activity of AAF.[17] 
Although these compounds are not environmental hazards per se, they have served as 
prototypes of DNA lesions formed by various aromatic amines, for example by food 
mutagens such as IQ 4 and PhIP 5 (Figure 9).  
These bulky aromatic amine compounds do not react directly with cellular DNA, but require 
metabolic activation in the liver, leading to the formation of electrophilic nitrenium ions, 
which form covalent adducts with DNA bases.[18, 19] If these adducts are not recognized and 
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repaired by cellular repair mechanisms, they induce mutations during replication and 
transcription which may cause the development of cancer.[16, 20-22] 
 
3.2 Formation of bulky DNA adducts 
 
3.2.1 Formation of DNA adducts by aromatic amines 
 
Procarcinogenic arylamines/amides, aminoazo dyes or heterocyclic amines form adducts with 
DNA bases especially at the C8-position of 2'-deoxyguanosine.[18, 19, 23] A minor adduct 
formed is the C8-2'-deoxyadenosine lesion. Additionally, N2-2'-deoxyguanosine adducts or 
N6-2'-deoxyadenosine adducts can also be found.[19, 23] The aromatic amines are metabolically 
converted to reactive hydroxylamine derivatives by cyctochrom P450 monooxygenases 
(CYPs) in the liver. These species undergo further activation such as protonation, 
O-acetylation or O-sulfonation followed by cleavage of the created leaving group. The 
resulting nitrenium ion then reacts with nucleophilic functions of DNA bases forming 
covalent DNA adducts.[19] 
If aromatic amines are taken up in the human body, a complex detoxification mechanism 
ensures excretion of these substances by converting them into water-soluble derivatives. The 
first step involves an enzymatic oxidation at the aromatic ring to phenol derivatives (C-
oxidation).[24-26] The second step is mostly the esterification of the hydroxyl group to a water-
soluble substance, which can be excreted via the urinary tract. It was found that the first 
oxidation step is also responsible for the genotoxicity of aromatic amines.[27] Due to the 
unspecific nature of the CYP enzymes, oxidation can not only occur at the aromatic unit but 
also at the nitrogen (N-oxidation). At present, 57 genes encoding these enzymes have been 
identified in the human genome. CYP enzymes, which are most important for the activation 
of carcinogens, belong to the families 1-3 and have broad and overlapping substrate 
specificities.[27-30] AAF 7 is converted by CYP1A2 into the proximate carcinogen N -hydroxy-
AAF 8. Enzymatic deacetylation of AAF and acetylation of AF can also occur at all stages of 
their metabolic activation resulting in acetylated and non-acetylated bulky DNA adduct 
lesions.  
The AF and AAF derivatives 8 and 9 are capable of undergoing subsequent transferase-
catalysed conjugation to polar molecules such as glutathione by glutathione S -transferases 
(GSTases), to glucuronic acid by glucuronosyltransferases,[31] or to small residues such as 
sulphate by sulphotransferases (STases)[32-34] and acetic acid by O-acetyltransferases 
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(O-ATases)[35-40] (Figure 11). These reactions generate the ultimate genotoxcic forms of the 
AF and AAF derivatives such as N-sulphoxy-AF/AAF or N-acetoxy-AF/AAF 11 and 10.[37, 41] 
These ultimate carcinogens can bind covalently to DNA and RNA via an arylnitrenium ion 
intermediate (12, 13).  
 
Figure 11. Metabolic activation of AF and AAF by cyctochrom P450 monooxygenases (CYP) and 
O-acetyltransferases (O-ATases). 
The major AAF adducts formed in vivo with DNA bases are 8-(N-acetyl-2-aminofluorene)-2'-
deoxyguanosine (AAF-dG) 14 and the deacetylated derivative 8-(N-2-aminofluorene)-2'-
deoxyguanosine (AF-dG) 15, followed by the minor 3-(deoxyguanosin-N2-yl)-N-2-
acetylaminofluorene (N2-AAF-dG) adduct 16 and the corresponding C8-dA adducts (Figure 
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12).[23, 42]  The ratio between the generated adducts depends strongly on the type of cells and 
organism.  
 
 
Figure 12. DNA adducts formed by AF and AAF. C8-AAF-dG adduct 14, C8-AF-dG adduct 15 and 
N2-AAF-dG adduct 16. 
The mechanism of the C8-dG adduct formation is not completely clarified. The C8 position of 
deoxyguanosine is not the most nucleophilic function within the molecule. The most basic 
and nucleophilic position is the nitrogen at N7 position. Alkylation agents such as methyl 
iodide for instance, react with the N7 position in high yields.[43] Thus, a mechanism was 
postulated which includes the preliminary attack of the electrophile at the N7 position (Figure 
13).[44, 45] The resulting positive charge is delocalized via the N7, C8 and N9 positions. 
Deprotonation of the C8 carbon gives an ylide allowing a Stevens rearrangement type of 
migration of the aryl fragment to the C8 position. Further rearomatisation results in the C8-
adduct (Figure 13).  
 
Figure 13. Postulated mechanism of the electrophilic arylamination at the C8-position of 2'-
deoxyguanosine 
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3.2.2 Formation of other bulky adducts 
 
Cytochrome-P450-dependent monooxygenases are also involved in the activation of other 
aromatic compounds such as polycyclic aromatic hydrocarbons (e.g. benzo[a]pyrene 19 (BP)) 
or the strong mycotoxin aflatoxin B1 (AFB1, 17). CYP3A4 activates AFB1 at its 8,9-bond, 
resulting in the AFB1 exo-8,9-oxide 18 (Figure 14). The endo-diastereomer is not formed by 
CYP3A4, but might be formed in small amounts by CYP1A2. The primary DNA adduct of 
AFB1 is 8,9-dihydro-8-(N7-guanosyl)-9-hydroxyaflatoxin B1 (AFB1-N7-dG), which is 
converted naturally to two secondary lesions, an apurinic site and an AFB1-
formamidopyrimidine (AFB1-FAPY) adduct.[46] 
 
Figure 14. Metabolic activation of aflatoxin B1 17 and benzo[a]pyrene 19 by CYPs. The red arrows 
highlight the position of the nucleophile attack (DNA).  
BP 19 is initially converted mainly by CYP1A1 or CYP1B1 into the 7,8-epoxide.[11] This 
epoxide is a substrate of microsomal epoxide hydrolase (mEH), which produces the R,R-7,8-
dihydrodiol 20 (Figure 14). Further epoxidation at the vicinal double bond catalysed by 
CYP1A1, CYP1B1 and CYP3A4 generates the ultimate genotoxic diol-epoxide of BP 
(BPDE) 21. Of the four possible resulting diastereomers, the (+)-anti-BPDE 21 is formed 
with highest amounts. The N2 or N6 amino groups of guanines or adenines are able to attack 
the epoxides to give the corresponding covalent adducts (major adducts: 10S (+)-trans-anti-
BP-N2-dG, [BP]-dG;  10R (+)-cis-anti-BP-N6-dA, [BP]-dA).[47] 
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3.3 The bulky C8-dG adducts are mutagenic  
 
Bulky adducts are normally repaired by the cellular repair systems. Some aromatic amine 
DNA adducts are repaired faster than others.[48] This can be traced back to the fact that the 
DNA adducts influence the DNA conformation in various ways. The aromatic system plays a 
major role, some aromatic units do not disturb the helical structure of the DNA, others 
promote conversion from B-DNA to Z-DNA or lead to denaturation of the DNA.[48-50] A 
correlation between the conformational change and the persistence of the adducts in vivo can 
be found. Adducts with denaturing conformation are repaired faster than adducts which do not 
disturb the DNA helix. The mutagenicity of these bulky aromatic amine DNA lesions is 
established, when they are encountered by DNA polymerases. Due to constant damage 
formation there are always lesions present during replication of the genome in the S phase, 
which were not removed by the various repair mechanisms of the cell.  
The mutagenic potential of the model compounds 8-(N-acetyl-2-aminofluorene)-2'-
deoxyguanosine 14 (AAF-dG) and 8-(N-2-aminofluorene)-2'-deoxyguanosine 15 (AF-dG) are 
well established.[19] Surprisingly they exhibit, despite their close chemical relationship, 
strongly different mutagenic characteristics. The non-acetylated AF-dG lesion is a lesion with 
low mutagenic potential. It is correctly replicated by high fidelity polymerases in most cases, 
which base pair AF-dG with dC.[51] The basis for the low mutagenicity is probably the ability 
of the lesion to exist in anti-conformation, which allows formation of a correct Watson-Crick 
base pair (Figure 15).[51] The acetylated bulky adducts in contrast, are not bypassed by high 
fidelity polymerases because these lesions are restricted to syn-conformation due to the steric 
hindrance caused by their acetyl group (Figure 15).[52-54] This places the aromatic unit at C8 in 
the active site of the polymerase. This fact is independent of the size of the aromatic unit 
attached to the C8 portion of the dG base.[55]  
 
Figure 15. Syn and anti conformation of the C8-AF/AAF-dG adducts. The acetylated C8-adduct 
(R = Ac, AAF-dG) is restricted to syn-conformation. 
 
 
 
  3. Introduction  
 
8 
 
TLS of the acetylated lesions in vivo is achieved by low-fidelity TLS polymerases.[56-60] 
However, the bypass of the AAF-dG lesion is often accompanied by a frameshift event (-I or 
–II frameshift).[16, 19] These mutations are fatal for the cell, because they induce a shift of the 
genetic reading frame. If the shift involves one or two bases, the corresponding frameshift 
mutations cause the loss of the information content of the whole gene. Since stop codons can 
be affected as well, a single frameshift mutation can disrupt the information content of 
neighboring genes as well. The mechanisms that lead to frameshift mutations are not well 
understood but it is known that they are produced in consequence of the mutagenic effect of 
aromatic amines.[16, 19, 53, 61-64]  
The induction of frameshift mutations through AAF was first observed and investigated in a 
frameshift mutation hot spot sequence, the so called NarI sequence.[53] A single AAF adduct 
at the third guanine in this sequence (5'-G1G2CG3AAFCC-3') increases the -II frameshift event 
by more than 107-fold over the spontaneous mutation frequency in Escherichia coli.[61] 
However, this observation is neither restricted to the complete NarI sequence nor to the AAF-
dG adduct. Two GpC repeats combined with a variety of bulky aromatic amines within this 
sequence are sufficient for the induction of a -II frameshift.[61, 64]  
 
Figure 16. Schematic illustration of how a –II frameshift mutation occurs in the NarI sequence. G* 
highlights the adducted dG. It is proposed that the dC 3’ to the lesion forms the two nucleotide bulge 
together with the adducted dG.[19, 64] 
Nevertheless, these mechanisms are still under investigation. The postulated mechanism for 
the –II frameshift involves a two nucleotide primer-template misalignment event during 
replication of the AAF-dG where the misaligned DNA duplex is stabilized by the AAF 
(Figure 16).[21, 62, 65-68] For -I frameshifts, it was shown that nucleotide misinsertion can also 
initiate frameshift mutations via formation of a misaligned intermediate lesion extension 
product.[63, 69, 70] 
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3.4 Eukaryotic low fidelity DNA Polymerases 
 
The bypass of bulky adducts requires specialized translesion synthesis (TLS) polymerases 
which enable replication through the damaged DNA structures. This mobilizes stalled 
replication forks, thus inhibiting the activation of apoptotic pathways.[71] In eukaryotes, DNA 
polymerases belonging to the Y-family (Pol η, Pol κ, Pol ι, Rev1) and the B-family DNA 
polymerase ζ promote replication through DNA lesions.[72, 73] The Y-family polymerases are 
divided into five subfamilies.[74] The three polymerases Pol η, Pol ι and Rev1 are found 
exclusively in eukaryotes, Pol κ belongs to the DinB branch with the prokaryote homologue 
E. coli Pol IV and the archaea homologue Dpo4. The fifth branch, the UmuC branch (E. coli 
Pol V) is only found in prokaryotes. Furthermore, Pol ζ is exclusively present in 
eukaryotes.[74] 
In contrast to high fidelity polymerases, the TLS polymerases have much higher error rates if 
they operate on undamaged template DNA.[75] Their error rate during normal DNA synthesis 
is 10-2 to 10-4, which is 1 to 2 orders of magnitude higher than those of replicative 
polymerases (A- and B-family) even after removal of their 3′ → 5′ exonuclease activity.[75] 
But TLS polymerases are able to synthesize DNA through lesions which block high fidelity 
polymerases.[76, 77] This fact can be assigned to their flexible structure and more open active 
site allowing mostly faithful bypass of distorted DNA structures. High fidelity polymerases 
use an induced fit conformational change as active mechanism to discriminate between 
correct and incorrect base pairs. For low fidelity polymerases, hardly any conformational 
changes are observed in their active sites. The active site is located at the N-terminal part of 
the Y-family polymerases, the C-terminus is variable and involved in localization, recruitment 
and protein-protein interactions. All members of the Y-family exhibit the conserved structural 
motif of the right-hand structure of DNA polymerases consisting of palm, thumb and finger 
domain. However, finger and thumb domain are smaller and stubby compared to high-fidelity 
polymerases. In all polymerases, the palm domain harbours the three conserved acidic 
residues that coordinate the two divalent metal ions. This domain also contributes to the 
binding of the incoming dNTP. Additionally, the Y-family polymerases own a specialized 
PAD (polymerase associated domain or “little finger domain”). This domain increases the 
DNA binding surface area of the polymerase. Nevertheless, DNA interaction is still weak in 
comparison to high-fidelity polymerases. In addition, Y-family polymerases lack a 3′ → 5′ 
exonuclease activity, which is an integral part of all replicative polymerases.[76, 77]  
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3.4.1 Polymerase switch 
 
When replicative polymerases present in the replication fork are stalled at a lesion such as 
AAF-dG, TLS polymerases have to be recruited and directed to the lesion site. This process 
has to be tightly regulated in order to prevent accumulation of mutations caused by 
unrestricted activity of the error-prone low fidelity polymerases. The key regulator of this 
process is the replication sliding clamp proliferative cell nuclear antigen (PCNA). The 
trimeric PCNA binds multiple proteins involved in both normal replication and TLS.[78] This 
is largely regulated by ubiquitylation and sumoylation of PCNA (Figure 17). Stalling of the 
replication fork by bulky DNA adducts for instance, results in monoubiquitylation of PCNA 
by enzymes of the Rad6/Rad18 group, which increases the affinity of TLS DNA polymerases 
such as Pol η, Pol κ or Pol ι to the replication clamp (Figure 8).[79-81] These polymerases 
possess ubiquitin-binding domains which interact with monoubiquitin on PCNA. The small 
ubiquitin-like modifier (SUMO) can also target PCNA and bind to the same site as 
ubiquitin.[82] The role of sumoylation in eukaryotes is still unclear and sumoylation in humans 
has not been observed yet. It is suggested that PCNA sumoylation favors the repair of fork 
blocking lesions by a mutagenic TLS pathway over an error-free recombination based 
pathway.[83]  
 
Figure 17. Simplified model for translesion DNA 
synthesis.[84] 
A) Replication is stalled at a lesion site (black 
square) and the high fidelity polymerase δ is 
blocked by the lesion. Rad18 is activated by single-
stranded DNA regions and the de-ubiquitinating 
isopeptide USP1 undergoes autocleavage. B) 
Rad18 binds to Rad6 and the complex ubiquitinates 
PCNA (only one PCNA monomer of the trimeric 
PCNA complex is shown ubiquitinated in this 
scheme, although all three monomers of the 
trimeric molecule are most likely ubiquitinated). 
C) The affinity for TLS polymerases to bind to 
PCNA is increased and one of them, in this case 
Pol η[79], bypasses the lesion. D) Pol η dissociates 
and replication restarts.  
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In summary, polymerase switch at sites of stalled replications forks enable bypass of 
replication blocking lesions. Some lesions can be replicated by a single TLS polymerase. 
After the lesion is bypassed, replication by Pol δ restarts. Nevertheless, depending on the 
lesion, more than one TLS polymerase may be needed for the bypass process.[84] It is still 
debatable, how certain TLS polymerases, assigned to a specific DNA lesion, are recruited to 
the lesion site and if TLS polymerases compete for the bypass of other lesions. Possibly, 
different polymerases bind briefly to PCNA and more tightly if the clamp is ubiquitinated 
(Figure 17). If the polymerase is able to accommodate the lesion in its active site, it will carry 
out TLS synthesis. Alternatively, the polymerase might only be able to insert a nucleotide 
opposite the lesion but not to extend from the lesion. Now, a second switch occurs and 
another polymerase catalyzes the extension from the lesion.[85] A general model suggests, that 
Pol η, Pol κ, Pol ι and Rev 1 insert nucleotides opposite a lesion and Pol ζ is responsible for 
the extension from the lesion.[86, 87] Concluding, error-free and error-prone bypass of DNA 
lesions depends on the interplay of several TLS polymerases and is not entirely understood so 
far.  
In the following section, recent literature covering the bypass of bulky DNA adducts by TLS 
polymerases will be discussed in detail.  
 
3.4.2 Pol η 
 
The Y-family DNA polymerase η is a key player in the replicative bypass of UV lesions such 
as CPD lesions in DNA. Inactivation of Pol η in humans results in the variant form of 
Xeroderma Pigmentosum (XPV) which is associated with a high risk of developing skin 
cancer. Lately, this bypass process was investigated on the molecular level explaining the 
efficient CPD lesion bypass by both human and yeast Pol η.[88, 89] Moreover, cisplatin induced 
1,2-d(GpG) adducts (Pt-GGs), which are formed in a typical cancer therapy with cisplatin, 
can be processed by Pol η (Figure 18).[90] The bypass of such intrastrand crosslinks by high 
fidelity DNA polymerases is particularly difficult because the linked bases are strongly helix 
deforming. Pol η possesses an open and flexible active site. It is able to accommodate the full 
Pt-GG adduct in the active site where it correctly base pairs the 3' G of the Pt-GG lesion with 
a dCTP (Figure 18).  
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Figure 18. Crystal structure of DNA Polymerase η from Saccharomyces cerevisiae in complex with an 
intrastrand cisplatinum GG adduct.[90] Pol η possesses the typical right-hand polymerase structure with 
palm, thumb and finger domain and the additional PAD domain which is unique for Y-family 
polymerases. The DNA helix is colored in gold, the cisplatinum adduct in grey and the incoming dCTP 
in orange. The catalytically active Ca2+ ions are depicted as red spheres.  
Moreover, recent in vivo experiments revealed that Pol η also plays a major role in the 
replication through acetylated aromatic amine lesions such as AAF-dG.[91] Data from 
Saccharomyces cerevisiae strains with a Pol η deficiency show that the enzyme participates in 
TLS of the AAF-dG adduct in vivo. In the absence of Pol η, the sequence dependent accurate 
and inaccurate bypass of AAF lesions is reduced up to 8-fold.[91]  Further in vitro studies have 
shown that both human and yeast Pol η base pair the AAF-dG lesion correctly with dC[56-58, 91] 
and are able to catalyze the extension from the lesion but with reduced efficiency.[57] In 
addition, Pol η also incorporates a correct dCTP opposite the N2-AAF-dG adduct.[20] 
It was also shown that Pol η is responsible for the occurrence of frameshift mutations in 
response to the presence of aromatic amine lesions during replication.[91, 92] Its flexible and 
open active site is able to accommodate bulge structures formed by slipped mispairing of 
primer-template constructs. Nevertheless, the occurrence of frameshift mutations seems to be 
strongly sequence dependent and is not systematically investigated and understood so far.  
 
3.4.3 Pol κ 
 
As mentioned before, Pol κ belongs to the DinB subfamily of Y-family polymerases, which 
includes E. coli Pol IV and the archeal polymerase Dpo4. In contrast to the prokaryotic and 
archaeal DinB proteins, human Pol κ and other eukaryotic homologs possess unique 
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N-terminal and C-terminal extension.[74, 93] The C-terminus, involved in binding to other 
proteins, is not required for polymerase activity. The N-terminal region, however, is 
obligatory for the activity of Pol κ and removing of this extension gives a completely inactive 
polymerase.[93]  
Pol κ is the most faithful of all Y-family DNA polymerases with an error rate of about 10-3 to 
10-4 on undamaged template DNA.[74] However, Pol κ is, in addition to Pol η, involved in the 
generation of frameshift errors, particularly -I frameshift mutations.[94] Insertion of 
nucleotides opposite some DNA lesions can be difficult for Pol κ, but the polymerase is also 
able to extend from nucleotides inserted by another DNA polymerase. For instance, Pol κ is 
unable to replicate through a CPD lesion. But it is capable to extend a primer after a dG was 
inserted opposite the 3'dT of the lesion.  
Pol κ can bypass the AAF-dG lesion in vitro in an error-free as well as in an error-prone 
manner incorporating dTTP with the same ratio as the correct dCTP opposite the 
lesion.[20, 95, 96] Extension from the lesion occurs with reduced efficiency compared to 
undamaged template DNA, nevertheless, the contribution of Pol κ to the generation of 
frameshift mutations during bypass of the AAF-dG adduct has not been entirely clarified 
yet.[96] In vivo studies revealed, that Pol κ is involved in the error-prone bypass of the AAF-
dG lesion. In simian kidney cells, A, G and T are misincorporated opposite the AAF-dG 
lesion and single two-base deletion have been observed.[97] On the contrary, Pol κ correctly 
bypasses the N2-[BP]-dG adduct, incorporating a dCTP opposite the lesion with high 
selectivity.[96]  
 
3.4.4 Pol ι 
 
Pol ι replicates undamaged DNA with different velocity and accuracy. Opposite purine 
template bases, incorporation of nucleotides occurs with much higher efficiency and fidelity 
than opposite pyrimidine bases.[86, 98-100] Bypass of dC and dT is highly mutagenic and 
inefficient. Moreover, Pol ι is unable to replicate through a CPD lesion but is proficient in 
bypassing N2-adducted guanines. Incorporation of a correct nucleotide opposite lesions is 
presumably achieved via formation of a protonated Hoogsteen pair with the templating base 
in syn and the incoming nucleotide in anti conformation.[101, 102] Opposite an AAF-dG, human 
Pol ι incorporates predominantly a correct dCTP, although it is unable to catalyze the 
extension from the lesion.[99] 
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3.4.5 Pol ζ 
 
The heterodimeric DNA Pol ζ consists of the Rev3 catalytic subunit and the Rev7 accessory 
subunit [103] and belongs to the B-family of polymerases, which includes the high-fidelity 
replicative polymerases δ, ε and α. Nonetheless, Pol ζ lacks, such as all TLS polymerases, the 
3′ → 5′ exonuclease activity. Pol ζ is in general highly inefficient in replicating through DNA 
lesions. It is mostly unable to incorporate nucleotides opposite the lesions. However, Pol ζ is 
capable of bypassing some DNA damages such as CPD lesions. In vitro, yeast Pol ζ is highly 
inefficient in incorporating nucleotides opposite an AAF-dG lesion and can only incorporate 
dGTP opposite the lesion to some extend. However, Pol ζ is capable of catalyzing the 
extension from the AAF-dG lesion, most efficiently if a dA or dC is opposite the AAF-dG 
lesion.[104] It was observed, that translesion synthesis of AAF-dG adducts by Pol ζ is further 
stimulated by Rev1 in yeast.[105] In yeast cells, Pol ζ is evidently required for error-prone 
translesion synthesis across from AAF-dG DNA adducts.[106, 107] Thus, the enzyme appears to 
be specialized in extending correctly paired and mismatched template-primer constructs 
resulting from correct or inaccurate base insertion by another TLS polymerase.[74, 108, 109] 
Therefore, Pol ζ is often entitled as the general extender taking over extension from a lesion 
which is (correctly) bypassed by another TLS polymerase.  
3.4.6 Rev1 
 
Rev1 acts together with Pol ζ in translesion synthesis. By itself, Rev1 is specific for dG 
templates and is restricted primarily to inserting dCTP opposite template dGs and certain 
DNA lesions such as abasic sites and adducted dG residues.[108, 110, 111] This specialized dCMP 
transferase activity is conserved from yeast to humans[112], but the catalytic activity of Rev1 
seems not to be required for the bypass of several lesions for which Rev1 is essential in vivo. 
Rev1 possesses a variety of protein-protein interaction modules and is able to interact with 
many other proteins, particularly other TLS polymerases.[109] 
In vitro, AAF-dG is a strong block for nucleotide incorporation by Rev1. Nevertheless, Rev1 
may contribute to the in vivo bypass of AAF-dG lesions together with Pol ζ.[104, 107]  
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3.5 Crystallographic snapshots of bulky DNA adduct blockage and bypass  
 
Although the biochemistry of lesion tolerance by TLS polymerases is well investigated, only 
limited structural data of TLS polymerases in complex with bulky adduct containing DNA are 
available to date. The following section provides an overview about the known crystal 
structures of high-fidelity and TLS polymerases in complex with bulky lesions containing 
DNA.  
Besides benzo[a]pyrene which generates adducts with dG and dA (section 3.2.2), 
benzo[c]phenanthrene (B[c]Phe) is another well studied polycyclic aromatic hydrocarbon, 
which forms covalent adducts with DNA after metabolic activation. The most frequently 
formed bulky adduct is the N2-guanine adduct [BPhe]-dG formed from (-)-1R,2S-epoxy-
3S,4R-dihydroxy-1,2,3,4-tetrahydrobenzo[c]-phenanthrene.[113] Crystal structures of [BP]-dG, 
[BP]-dA and [BPhe]-dG in complex with high-fidelity and TLS polymerases are available.[114-
117] The crystal structure of the 10S (+)-trans-anti-BP-N2-dG lesion ([BP]-dG) in complex 
with the high-fidelity polymerase Bst Pol I shows that the [BP]-dG still has some base paring 
capabilities with dC. Nevertheless, the adduct protrudes into the minor groove, which leads to 
severe distortion of the DNA duplex polymerase complex and blocks further replication.[118]  
The archaeal Y-family polymerase Dpo4 in contrast is capable of bypassing both the [BP]-dG 
and the 10R (+)-cis-anti-BP-N6-dA ([BP]-dA) lesion by flipping the lesion out into the minor 
and major groove, respectively (Figure 19, A).[114, 115] 
 
Figure 19. A) Crystal structure of the Y-family polymerase Dpo4 in complex with [BP]-dG lesion 
containing DNA. A –I frameshift mutation is observed. B) Crystal structure of Pol β in complex with a 
DNA duplex containing the [BPhe]-dG lesion. The phenanthrene ring stacks on top of the previously 
formed base pair occupying the binding pocket for the incoming nucleotide. The protein is shown as 
cartoon (grey) and the DNA as stick model (blue) with the lesions highlighted in pink.  
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The polymerase accomodates the huge template distortion using a sequence dependent 5' 
template slippage/misalignment mechanism. This results either in a base substitution mutation 
or, in case of template realignment, generates a -I frameshift mutation (Figure 19, A).[114, 115] 
A similar template misalignment/slippage mechanism depending on the sequence context 
seems to allow Dpo4 to bypass also the 1,N2-etheno(ε)guanine adduct.[119] 
Furthermore, the human DNA polymerase β involved in gap filling during BER, was found to 
bypass the [BPhe]-dG lesion.[116] However, this proceeds inefficiently and error-prone. The 
structure of Pol β in complex with [BPhe]-dG containing template revealed the mechanism of 
this erroneous bypass: The stacking of the phenanthrene ring on the previous correctly formed 
base pair occupies the binding pocket for the incoming nucleotide holding the polymerase in 
an open conformation (Figure 19, B). Thus, correct nucleotide insertion is prevented. Due to 
the established stacking interactions with the phenanthrene ring, purine (dA) incorporation is 
preferred opposite the lesion.[116]  
As discussed above, AF-dG is replicated by high-fidelity polymerases while AAF-dG is 
locked in syn-conformation due to the sterical restriction by its N8-acetyl group and therefore 
a strong block for all replicative polymerases. Crystal structures of the AAF-dG adduct in 
DNA in complex with the high fidelity polymerases T7 and Bst Pol I reveal that the adduct 
either prevents dNTP entry (T7, Figure 20, A)[120] or prevents the modified template from 
entering the preinsertion site (Bst Pol I)[121]. The crystal structure with T7 DNA polymerase 
shows that the AAF-dG template base is in syn conformation and the adduct inserts in a 
hydrophobic pocket of the fingers’ subdomain locking the fingers in an open 
conformation.[120] In Bst Pol I polymerase, the AAF-dG does not enter the active site and is 
therefore partially disordered and not visible in the electron density. The preinsertion site is 
empty and no incorporation of an incoming dNTP can be observed.[121] Thus, replication past 
AAF is blocked in both cases.  
In contrast, AF-dG adopts anti-conformation with the fluorene residue projecting into the 
major groove in the active site of Bst Pol I. Thus correct dCTP incorporation can take place 
(Figure 20, B).[121] For T7 polymerase, electron density for the AF-dG is absent. However, the 
active site is empty and AF-dG does not bind in the active site.[120] Moreover, there is no 
evidence that the AF-dG is bound in a hydrophobic pocket similar to AAF-dG and no bound 
nucleotide can be observed. Nevertheless, bypass of the AF-dG is most likely achieved by the 
polymerase. A recent crystal structure of archaeal Y-family polymerase Dpo4 in complex 
with AF-dG containing DNA shows the AF-dG in the process of being bypassed 
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(Figure 20, C).[122] AF-dG adopts anti conformation which allows correct Watson-Crick base 
pairing with the 3'-terminal primer dC and positions the AF moiety in the major groove 
(Figure 20, C). Further extension from this complex is observed.  
 
Figure 20. Crystal structures of AF-dG and AAF-dG lesions inside different polymerases. A) The high-
fidelity bacteriophage T7 polymerase in complex with AAF-dG containing DNA; The AAF-dG adopts 
syn-conformation, preventing dNTP entry and holding the polymerase open. B) The high-fidelity 
polymerase Bst Pol I in complex with AF-dG containing DNA; The AF-dG base pairs with dC. C) The 
archaeal low-fidelity polymerase Dpo4 accomodating an AF-dG lesion within its active site, the AF-dG 
base pairs with dC. The protein is shown as semi-transparent surface representation (grey), with the 
DNA as stick model (blue) and the lesions highlighted in pink. 
In summary, the crystal structures of Ellenberger, Beese and Patel displaying the non-
acetylated AF-dG lesion inside different polymerases proof that the lesion is indeed bound in 
anti conformation allowing Watson-Crick base pairing with an incoming dCTP.[51, 120, 122] 
However, the mechanism that allows low-fidelity polymerases such as Pol η to replicate past 
acetylated AAF-dG lesions is still unknown. Biochemical studies demonstrate that Pol η 
bypasses the lesion correctly.[56-58, 91] Nonetheless, there is no crystal structure of a Y-family 
polymerase in complex with the AAF-dG lesion available so far. Computational modeling 
studies of the Y-family polymerase Dpo4 suggest that rotation of the lesion into the anti 
conformation is required for the bypass to allow base pairing.[123] Due to the strong syn 
preference of the adducted base, this rotation is difficult to accomplish, which may force Pol η 
or other TLS polymerases to find a different mechanism for accurate lesion bypass. The 
bypass of acetylated bulky DNA lesions by Pol η is subject of this thesis work.  
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3.6 Repair of bulky DNA adducts 
 
Bulky DNA adduct lesions are mostly removed by the nucleotide excision repair pathway 
(NER), which is one of the major DNA repair pathways in eukaryotic cells, able to remove a 
variety of DNA damages.[124-126] To date, only limited structural insight into lesion 
recognition and removal by the NER machinery is available. Defects in the NER system lead 
to severe diseases such as xeroderma pigmentosum (XP), a hereditary disease characterized 
by extreme photosensitivity and a 2000-fold increased incidence of sunlight-induced skin 
cancer, or trichothiodystrophy (TTD).[127]  
Two ways of NER can be distinguished: Repair of lesions within the entire genome, referred 
to as global genome NER, and repair of transcription-blocking lesions during transcription, 
thus called transcription-coupled NER. Multiple proteins are involved in the NER pathway. 
First, the lesion is recognized, then DNA incision occurs on the 3' and 5' sides of the lesion 
and a short olionucleotide segment containing the lesion is removed. Thirdly, the gap is filled 
by DNA synthesis and ligation occurs using the undamaged strand as template.[128] Whereas 
the actual repair mechanism in NER is rather well investigated, damage recognition is still not 
understood. It is remarkable how a certain pool of proteins is able to recognize various DNA 
lesions.[129, 130] The detection of lesions leading to the assembly of the NER system is 
controversially discussed. The two essential human NER proteins XPA (xeroderma 
pigmentosum group A) and XPC (xeroderma pigmentosum group C) are believed to be 
primarily involved in damage recognition.[128] To date, there exist three models for the critical 
initial damage recognition step in NER with either the XPA, XPC, or both proteins acting 
randomly as the primary lesion sensor. The first model suggests, that XPC is responsible for 
the initial damage recognition step recognizing distorted DNA helix structures.[131] A crystal 
structure of a truncated version of the XPC yeast homologue Rad4 in complex with a CPD 
lesion shows how the protein binds to the DNA, surprisingly without contacting the lesion 
itself.[132] The second model proposes that XPA is the primary lesion sensor. This idea is 
supported by studies in which DNA repair is stimulated by pre-incubation of lesion containing 
DNA with a complex of XPA and the replication protein A (RPA).[133] The third model 
suggests a cooperative damage recognition by RPA, XPA, and XPC and final complex 
formation of the four proteins XPA, RPA, XPC and the xeroderma pigmentosum group C 
protein complex XPC-HR23B at the lesioned site.[134]  
XPA is suggested to be involved in recognition and removal of a large variety of structurally 
diverse bulky DNA lesions.[135-137] The protein is required for both global genome repair and 
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transcription-coupled repair, in the absence of XPA, no incision complex can form and no 
excision of damaged DNA damage occurs.[127, 138] The protein, which contains a zinc finger 
motif, is capable of binding specifically to damaged DNA in vitro recognizing aromatic units 
attached to DNA, which do not distort the helical structure of the DNA.[139, 140] Moreover, it 
interacts with RPA. The nucleic acid interaction domain of XPA has been identified and its 
structure was determined by NMR spectroscopy (Figure 21).[141, 142] 
 
Figure 21. NMR solution structure of the minimal DNA binding domain of XPA (residues 98–210).[141] 
A) Cartoon representation of the structural motifs of XPA, the Zn2+ is depicted as light blue sphere, B) 
Electrostatic potential on the solvent-accessible surface (displayed with WebLab Viewer). Blue 
corresponds to positive potential and red to negative potential.  
The minimal DNA binding domain (122 amino acids, residues 98-219) consists of an acidic 
subdomain containing the zinc finger motif and a C-terminal subdomain (residues 138-209) 
which forms a positively charged cleft on the protein surface which is presumably involved in 
DNA binding (Figure 21, B).[141, 143] Additionally, chemical shift perturbation experiments 
carried out in the presence of DNA or a short RPA peptide sequence revealed that the zinc 
finger motif is required for the interaction with RPA but not involved in DNA binding.[141]  
However, structural data of XPA-DNA complexes, or its yeast homologue Rad14, are still not 
available. Thus, the recognition of bulky DNA lesions by XPA proteins needs to be 
elucidated. 
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4 Aims of the project 
 
Heterocyclic aromatic amines produce bulky C8 guanine lesions in vivo, which interfere and 
disrupt DNA and RNA synthesis. These lesions are consequently strong replication blocks. In 
addition they give rise to point and frameshift mutations. The translesion synthesis DNA 
polymerase η is able to slowly bypass C8 bulky adduct lesions such as the widely studied 
2-aminofluorene-dG (AF-dG) and its acetylated analogue (AAF-dG) mainly in an error-free 
manner.[56-58, 91]  
Aim of this thesis work was to decipher the bypass mechanism of the AAF-dG lesion by 
translesion synthesis polymerases by crystallizing AAF-dG containing DNA in complex with 
the TLS polymerase η. For crystallographic and biochemical studies, bulky lesion containing 
DNA should be used. This requires the synthesis of the lesions, protection and activation as 
phosphoramidites and site-specifically insertion into oligonucleotides. AAF-dG could be 
obtained via a published procedure, derivatives with other aromatic units may possibly be 
synthesized in the same way. Figure 22 gives the structure of the lesions to be synthesized.  
 
Figure 22. Bulky C8-adducts which are planned to be synthesized and used for crystallization as well 
as biochemical studies in this thesis work.  
The mechanism of the AAF-dG bypass by Pol η could be investigated using biochemical 
methods such as primer extension studies to determine the base pairing partner of the AAF-
dG and to examine the sequence dependency of the bypass process by Pol η. Moreover, by 
using different bulky dG adducts, the influence of the aromatic unit on the replication ability 
of Pol η across these lesions should be investigated. 
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A second part of this thesis work includes the investigation of frameshift mutations by 
AAF-dG adducts. Frameshift mutations induce a shift of the genetic reading frame. If the shift 
involves one or two bases, the corresponding frameshift mutations cause the loss of the 
information content of the whole gene. The mechanisms that lead to frameshift mutations are 
not well understood but it is known that frameshifts are produced in consequence of the 
mutagenic effect of aromatic amines.[16, 53, 61-64] The occurrence of frameshift mutations is 
highly sequence specific. Probably, insights into the mechanism of frameshift mutations 
induced by AAF-dG could be obtained by placing the AAF-dG lesion in different 
oligonucleotide sequences and studying the bypass products of Pol η. Furthermore, the TLS 
polymerase κ is supposed to be cloned, expressed and purified in order to investigate the 
bypass of bulky adducts by this enzyme in comparison to Pol η.  
An additional project was to start crystallization experiments of AAF-dG containing DNA in 
complex with the yeast NER protein Rad14 and its human homologue XPA. It has been 
shown that Rad14 binds DNA containing bulky adducts such as AAF-dG. To date, only a 
solution structure of the minimal DNA binding domain of XPA is available but no structural 
data about the lesion recognition step. A crystal structure together with AAF-dG would give 
valuable insights into the mechanism of lesion recognition. 
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5 Synthesis of C8-deoxyguanosine adducts 
 
In order to investigate translesion synthesis and repair of bulky DNA adducts, 
oligonucleotides containing several bulky C8-adducts were prepared. In the past, 
oligonucleotides containing C8-arylamine and acetylarylamine adducts of dG have been 
synthesized using a post-synthetic modification strategy.[144, 145] Therefore, oligonucleotides 
were treated with the corresponding N-hydroxy or N-acetoxy arylamine derivates.[144] This 
reaction is severely limited in yield and scope and the utilized arylamine derivatives are 
extremely toxic (carcinogenic). In particular, a single site-specific modification cannot be 
introduced into oligonucleotides that contain multiple guanines, therefore the sequence 
context in which adducted dG can be introduced is severely restricted (Figure 23, A).  
Thus, the corresponding phosphoramidites, suitably protected for automated solid-phase DNA 
synthesis, were synthesized according to a reported strategy.[146-148] By using the 
phosphoramidite approach, site specific incorporation of the acetylarylamine adducts into 
oligonucleotides is possible and consequently, the influence of the sequence context around 
the lesion can be investigated. 
 
Figure 23. Preparation of AAF-dG containing oligonucleotides. A) Post-synthetic approach: Short DNA 
strands are reacted with N-hydroxy-AAF 8 or N-acetoxy-AAF 10. B) Synthesis of an AAF-dG 
nucleoside 14 via Buchwald-Hartwig coupling of 2-aminofluorene to a protected 8-bromo-2'-dG (8-Br-
dG) and site specific incorporation into oligonucleotides using solid-phase DNA synthesis.  
The synthetic strategy for these adducts is based on Buchwald-Hartwig coupling reaction of 
protected 8-bromo-2'-deoxyguanosine (Br-dG) derivates with aromatic amines (Figure 23, B). 
This method was first reported by Rizzo[146] and later applied by Schärer to a synthetic route 
for AAF-dG 14, suitably protected for automated solid-phase DNA synthesis.[147, 148]  
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The synthesis poses several challenges. First, a mild deprotection step after oligonucleotide 
synthesis, which does not affect the base labile N8-acetyl group of AAF-dG, is obligatory. 
Thus, a protecting group for the exocyclic N2 amino group of guanine which is cleavable 
under conditions maintaining the acetyl group, needs to be used. To this end, an 
isopropylphenoxyacetyl (iPrPac) protecting group was introduced at the N2 position.  
Moreover, acetylation of the N8 position needs to be selective in the presence of the NH at 
position N2. The iPrPac group is not sterically demanding enough and increases the aciditiy of 
the NH, in consequence, the reaction is preferred at this site. Thus, the transient, sterically 
more demanding dimethoxytrityl (DMT) protecting group was used for the N2 position of Br-
dG prior to introduction of the iPrPac protecting group. The DMT group allows efficient 
coupling of several amines and further acetylation at the N8-position without affecting the N2 
position.  
In this thesis, the aromatic amines aniline, 2-naphthylamine, 2-aminoanthracene, 
2-aminofluorene and 1-aminopyrene were coupled to the C8 position of Br-dG using the 
strategy of Rizzo[146] and Schärer[147] and the corresponding phosphoramidites of 14, 22-25, 
suitably protected for automated solid-phase DNA synthesis, were prepared (Figure 24).  
 
Figure 24. C8-dG adducts 8-(N-acetyl-amino-benzene)-2'-deoxyguanosine 22 (AAB-dG), 8-(N-acetyl-
2-amino-naphthalene)-2'-deoxyguanosine 23 (AAN-dG), 8-(N-acetyl-2-amino-fluorene)-2'-deoxy-
guanosine 14 (AAF-dG), 8-(N-acetyl-2-amino-anthracene)-2'-deoxyguanosine 24 (AAA-dG) and 8-(N-
acetyl-1-amino-pyrene)-2'-deoxyguanosine 25 (AAP-dG). Derivatives, suitably protected for solid-
phase DNA synthesis, were prepared. 
The main purpose of all syntheses presented in the following was to supply sufficient amounts 
of material for automated solid-phase DNA synthesis. Thus, as soon as this purpose was 
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accomplished no further optimization of the reaction conditions was performed. In Figure 25, 
the synthetic pathway to the acetylarylamine dG adducts is depicted.  
 
Figure 25. Synthetic pathway towards acetylarylamine dG adducts bearing an iPrPac protecting group 
at N2-position for solid-phase DNA synthesis. Reaction conditions are: a) NBS, water, acetonitrile (26 
→ 27); b) TBDMS-Cl, imidazole, DMF (27 → 28); c) Bn-OH, PPh3, DIAD, dioxane (28 → 29); d) 
DMT-Cl, pyridine (29 → 30); e) Pd2(dba)3, BINAP, toluene, NaOtBu, arylamines aniline / 2-
naphthylamine / 2-aminofluorene / 2-aminoanthracene or 1-aminopyrene (30 → 31-35); f) 1.) Ac2O, 
Et3N, DMAP, pyridine, 2.) 0.01 M HCl in MeOH (31-35 → 36-40); g) iPrPac-Cl, pyridine (36-40 → 41-
45); h) CH3COOH, TBAF, THF (41-45 → 46-50); i) Pd/C, cyclohexene, EtOH (46-50 → 51-55). 
 
The synthesis started by bromination of dG 26 with N-bromosuccinimide (NBS) at C8 
position and precipitation of the product in acetone as the sole purification step. Silylation of 
the 5' and 3' hydroxy groups with tert-butyldimethylsilyl chloride (TBDMS-Cl) resulted in 
compound 28. The O6 position was protected as a benzyl ether (29) under Mitsunobu 
conditions. The exocyclic N2 amino group was further protected with dimethoxytrityl chloride 
(DMT-Cl), which is stable under basic conditions and thus survives the subsequent 
Buchwald-Hartwig coupling reaction (30). In the Buchwald-Hartwig coupling reaction, the 
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arylamines aniline, 2-naphthylamine, 2-aminoanthracene, 2-aminofluorene or 1-aminopyrene 
were coupled to 30 using tris-(dibenzylideneacetone)-dipalladium (Pd2(dba)3) and rac-2,2'-
bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) as a catalyst, sodium tert-butoxide 
(NaOtBu) as a base, and toluene as a solvent. The reaction gave the adducted nucleosides 31-
35 (Figure 26).  
 
Figure 26. Buchwald-Hartwig coupling reaction of the protected Br-dG 30 with several arylamines 
(aniline, 2-naphthylamine, 2-aminoanthracene, 2-aminofluorene or 1-aminopyrene) provided the 
adducted nucleosides 31-35 (yields are shown next to the compound number). Reaction conditions 
are Pd2(dba)3, BINAP, toluene, NaOtBu, arylamines: aniline / 2-naphthylamine / 2-aminofluorene / 2-
aminoanthracene or 1-aminopyrene. 
Protection of both the N2 and O6 position is absolutely required for the successful coupling 
reactions in order to avoid side reactions.  Not only 2-acetylaminofluorene and 1-aminopyrene 
(literature known)[147] but also aniline, 2-aminonaphthalene and 2-aminoanthracene could be 
successfully coupled to 30 in reasonable yields (Figure 26). Direct coupling of 30 with 
2-acetylaminofluorene is difficult and does not work using the applied coupling 
conditions.[147] However, the acetylated arylamine dG adducts 36-40 were obtained by 
selective acetylation of the N8 position with acetic anhydride adding triethylamine and 4-
(dimethylamino)-pyridine (DMAP) in pyridine (Figure 27). 
 
Figure 27. Acetylation of the N8 position of the arylamine dG adducts 31-35 resulting in the 
nucleosides 36-40. Yields are given next to the compound number. Reaction conditions are 1.) Ac2O, 
Et3N, DMAP, pyridine, 2.) 0.01 M HCl in MeOH.  
The large, sterically demanding DMT group at N2 position prevents acetylation at 
this position. The product of the acetylation is rather acid- and base-sensitive, therefore, the 
DMT group had to be removed under extremely mild conditions using dilute HCl in methanol 
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without previous purification of the acetylation reaction product. This two-step reaction 
known for AF-dG[147] 33 was applied to the other bulky adducts 31, 32, 34 and 35 as well, 
giving the corresponding acetylated nucleosides 36, 37, 39 and 40 in good yields. The N2 
position was subsequently protected with isopropylphenoxyacetyl chloride (iPrPac-Cl, 
synthesized from (4-Isopropyl)-phenoxy acetic acid) in pyridine providing 41-45. 
The silyl protecting groups of 41-45 were finally removed using tetrabutylammonium fluoride 
(TBAF) buffered with acetic acid to maintain the base-sensitive N8 acetyl group. This gave 
the nucleosides 46-50. Removal of the benzyl protection group was carried out by 
hydrogenolysis using palladium on charcoal and cyclohexene as hydrogen donor yielding the 
adducted nucleoside building blocks ready for protection and activation for solid-phase DNA 
synthesis (51-55).  
Synthesis of the phosphoramidites 
The iPrPac-protected acetylarylamine-2'-deoxyguanosine adducts 51-55 were selectively 
DMT-protected at their 5' hydroxyl groups using dimethoxytrityl chloride (DMT-Cl) in 
pyridine (Figure 28, a).   
 
Figure 28. DMT-protection and synthesis of the phosphoramidites 61-65 for solid-phase DNA 
synthesis. Reaction conditions are a) DMT-Cl, pyridine and b) Bis-(diisopropylamino)-(2-cyanoethoxy)-
phosphine, DIAT, CH2Cl2. 
Last step of the synthesis was the introduction of the 3' phosphoramidite function. Therefore, 
56-60 were reacted with bis-(diisopropylamino)-(2-cyanoethoxy)-phosphine using 
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diisopropylammonium tetrazolide (DIAT) as activator to yield the acetylarylamine dG 
phosphoramidites 61-65 which could be used for solid-phase DNA synthesis (Figure 28). 
Table 1 gives an overview about the yields obtained for the synthetic routes to the various 
2'-deoxyguanosine phosphoramidites containing acetylated C8-adducts of aniline, 
2-naphthylamine, 2-aminoanthracene, 2-aminofluorene and 1-aminopyrene. 
synthetic step no. yield 
bromination 27 85 % 
TBDMS protection 28 91 % 
O6-benzyl protection 29 45 % 
DMT protection 30 99 % 
 
 
 benzene naphthalene fluorene anthracene pyrene 
 AAB-dG AAN-dG AAF-dG AAA-dG AAP-dG 
synthetic step no. yield no. yield no. yield no. yield no. yield
coupling 31 57 % 32 41 % 33 64 % 34 53 % 35 68 %
acetylation 36 38 % 37 57 % 38 69 % 39 54 % 40 80 %
iPrPac protection 41 86 % 42 91 % 43 92 % 44 84 % 45 99 %
OH deprotection 46 63 % 47 95 % 48 57 % 49 74 % 50 62 %
O6 deprotection 51 63 % 52 68 % 53 77 % 53 36 % 55 82 %
DMT protection 56 98 % 57 96 % 58 85 % 59 66 % 60 99 %
phosphitylation 61 90 % 62 87 % 63 90 % 64 75 % 65 75 %
 
Table 1. Yields obtained for the synthetic steps to the arylamine dG phosphoramidites.  
Even though the individual yield (Table 1) are quite acceptable, the overall yields are low and 
careful handling in each of the 11 steps is required. Critical transformations are still the 
Buchwald-Hartwig coupling and the acetylation step with yields of approximately 50%. 
Figure 29 summarizes the synthesized acetylarylamine-dG-phosphoramidites which are 
subsequently used for solid-phase DNA synthesis.  
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Figure 29. Synthesized acetylated arylamine-dG phosphoramidites further used for solid-phase DNA 
synthesis: 8-(N-acetyl-amino-benzene)-3′-O-(2′-cyanoethoxydiisopropyl-amino-phosphino)-(5'-O-
dimethoxytrityl)-N2-isopropylphenoxyacetyl-2'-deoxyguanosine 61, 8-(N-acetyl-2-amino-naphthalene)-
3′-O-(2′-cyanoethoxydiisopropyl-amino-phosphino)-(5'-O-dimethoxytrityl)-N2-isopropylphenoxyacetyl-
2'-deoxyguanosine 62, 8-(N-acetyl-2-amino-fluorene)-3′-O-(2′-cyanoethoxydiisopropyl-amino-
phosphino)-(5'-O-dimethoxytrityl)-N2-isopropylphenoxyacetyl-2'-deoxyguanosine 63, 8-(N-acetyl-2-
amino-anthracene)-3′-O-(2′-cyanoethoxydiisopropyl-amino-phosphino)-(5'-O-dimethoxytrityl)-N2-iso-
propylphenoxyacetyl-2'-deoxyguanosine 64 and 8-(N-acetyl-1-amino-pyrene)-3′-O-(2′-cyanoethoxy-
diisopropyl-amino-phosphino)-(5'-O-dimethoxytrityl)-N2-isopropylphenoxyacetyl-2'-deoxyguanosine 65. 
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6 Incorporation of C8-dG adducts into oligonucleotides 
6.1 Solid phase DNA synthesis 
 
The DNA oligonucleotides were synthesized on a PerSeptive Biosystems Expedite 8900 
Synthesizer and an Äkta Oligopilot 10 (GE) following standard phosphoramidite protocols for 
the solid phase oligonucleotide synthesis.[149, 150] The used amounts of the phosphoramidites 
of the bulky adducts were equal to those of the standard bases but coupling times were 
extended to 10 minutes. Ultramild protected phosphoramidites were used, which could be 
deprotected under mild conditions without cleaving the base-labile acetyl group of AAF-
dG.[148] These ultramild phosphoramidites contain an isopropylphenoxyacetyl (iPrPac) group 
at N2 position of dG, an acetyl group at N4 position of dC and a phenoxyacetyl group at N6 
position of dA (Figure 30, B). A special linker, the Q-linker (hydroquinone-O,O'-diacetate 
linker with CPG resin) was used, which can be cleaved faster and under milder conditions 
compared to the standard succinate linker (Figure 30, B). [148]  
 
Figure 30. Protecting groups used for the exocyclic amino functions of the nucleobases and linker 
employed to attach the DNA to the solid support for DNA synthesis. A) Standard protection groups. 
The N2 position of dG is protected with an isobutyryl, the N4 position of dC and the N6 position of dA 
with a benzoyl group. The first base is coupled via a succinate linkage to the solid support. 
B) Protection groups and linker for ultramild DNA synthesis. The N2 position of dG is protected with an 
isopropylphenoxyacetyl, the N4 position of dC with an acetyl and the N6 position of dA with a 
phenoxyacetyl group. Attachment to the solid support was achieved via a hydroquinone-O,O'-
diacetate linker (Q-linker). 
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In addition, a different, more bulky capping reagent had to be used compared to standard 
methods (acetic anhydride) to avoid exchange of the iPrPac protecting group on the dG by 
acetate from the typically employed acetic anhydride capping solution. For all syntheses, 
phenoxyacetic anhydride, synthesized from phenoxyacetic acid, was consequently used as the 
capping reagent.  
The AAF-dG as well as the other C8-dG adducts were stable under the conditions of the 
solid-phase DNA synthesis, including the deblocking step with dichloroacetic acid and the 
oxidation step with iodine in water/acetonitrile. 
The oligonucleotide synthesis was monitored online by measurement of the UV-Vis 
absorption of the reagents leaving the solid support cartridge. Since every consecutive 
coupling step finishes with the acidic cleavage of the 5'-DMT protecting group 
(“detritylation”), this process can be used to quantify coupling efficiencies by monitoring the 
cleavage of the 4,4'-dimethoxytrityl cation at a wavelength of 500 nm. For this work, various 
modified oligonucleotides carrying the acetylarylamine-dG adducts (Figure 29) were 
synthesized. Coupling of the acetylarylamine dG phosphoramidites was usually as efficient as 
the coupling of the standard ultramild phosphoramidites. A representative chart of the trityl-
values obtained during the synthesis of the oligonucleotide ODN 33 on the Expedite 8900 
DNA synthesizer is depicted in Figure 31.  
 
Figure 31. Trityl values monitored during DNA synthesis of ODN 33 on an Expedite 8900 DNA 
synthesizer. Position 6 marks the incorporation of the AAP-dG. Coupling of the modified 
phosphoramidite is nearly as efficient as the coupling of the standard ultramild phosphoramidites.  
Following the automated oligonucleotide synthesis, the DNA strands were cleaved from the 
solid support and all protecting groups were removed from the bases and the backbone. The 
standard method for both processes is the treatment of the solid-phase bound oligonucleotides 
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with aqueous ammonia for several hours. This method cannot be used for the acetylated 
arylamine containing oligonucleotides due to their labile N8-acetyl groups. Particularly mild 
deprotection conditions involving 10 % diisopropylamine and 0.25 M β-mercaptoethanol in 
methanol at 55°C for 20 hours were effective in removing the protecting groups from the 
oligonucleotides and in releasing them from the Q-solid support without cleaving the base-
labile acetyl group at N8 of the acetylarylamine dG adducts.[148] β-Mercaptoethanol was added 
to avoid oxidation of the acetylarylamine dG adducts during the long incubation at high 
temperatures.[151, 152]  
Not only the literature known AAF-dG could be successfully incorporated into 
oligonucleotides, but, in this way, also the other acetylarylamine adducts AAB-dG, AAN-dG, 
AAA-dG and AAP-dG were successfully inserted. A list of all DNA strands containing the 
bulky adducts synthesized for this thesis can be found in the experimental section (10.2.2, 
Table 3). 
 
6.2 Purification and characterization of the various C8-dG adduct 
containing oligonucleotides 
 
6.2.1 HPLC purification and characterization via MALDI-TOF mass spectrometry  
 
After deprotection and cleavage from the solid support, the oligonucleotide solutions were 
concentrated in vacuo, redissolved in ddH2O and the oligonucleotides were purified via 
preparative RP-HPL-chromatography. The preparative Waters HPLC system allows 
monitoring a second wavelength during purification. Thus, the oligonucleotides containing 
aromatic adducts could be easily detected at wavelengths between 300 and 350 nm depending 
on the aromatic unit attached. Thus separation from shorter truncated fragments was in this 
way facilitated. Moreover, due to the aromatic adducts, the retention time of the modified 
oligonucleotides was delayed by 5-10 minutes compared to unmodified oligonucleotides.  
Figure 32 shows an exemplary HPL-chromatogram of a crude, AAP-dG containing 
oligonucleotide directly after DNA synthesis, as well as examples of purified, the various 
bulky adduct containing oligonucleotides analyzed via analytical HPL-chromatography with a 
purity greater than 98 %. All oligonucleotides gave crude HPLC data similar to these 
reported.  
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Figure 32. HPL-chromatograms of the synthesized acetylarylamine containing oligonucleotides. 
A) Crude HPL-chromatogram of the AAP-dG containing ODN 32* directly after cleavage from the solid 
support and deprotection. Several shorter, truncated oligonucleotides are visible. B) ODN 32 after 
purification. The oligonucleotide can be detected at 260 and 349 nm due to the large aromatic system 
attached. C) HPL-chromatogram of the purified AAA-dG containing ODN 28. D) HPL-chromatogram of 
the purified AAF-dG containing ODN 16. E) HPL-chromatogram of the purified AAN-dG containing 
ODN 25. F) HPL-chromatogram of the purified AAB-dG containing ODN 22. 
The identity of the C8-adduct containing oligonucleotides was confirmed by MALDI-Tof 
mass spectrometry. In Figure 33, mass spectra of different oligonucleotides containing the 
various synthesized lesions (AAB-dG, AAN-dG, AAF-dG, AAA-dG and AAP-dG) are 
displayed as examples.   
                                                 
* The synthesized strands are summarized in the experimental section and continuously numbered from 1-33. 
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To obtain deacetylated AF-dG oligonucleotides needed for further biochemical studies, they 
were prepared from the corresponding AAF-dG containing oligonucleotides by simple 
deacetylation. To this end, the oligonucleotide was incubated in sodium hydroxide solution in 
the presence of β-mercaptoethanol. Total cleavage of the acetyl group was achieved after 
three hours at 37 °C. Afterwards, the oligonucleotides were again purified by reversed phase 
HPLC (Figure 33, B).  
 
 
Figure 33. MALDI-Tof mass spectra of purified bulky adduct containing oligonucleotides. A) ODN 17, 
m/zcalc = 5592.6; B) ODN 1 after cleavage of its acetyl group, m/zcalc = 6313.3; C) ODN 21, m/zcalc = 
6267.9; D) ODN 24, m/zcalc = 6317.7; E) ODN 29, m/zcalc = 4964.8; F) ODN 32, m/zcalc = 4987.3. 
 
6.2.2 Enzymatic digestion analysis 
 
Analysis of the prepared oligonucleotides by enzymatic digestion was performed to further 
prove the presence of the bulky adduct lesions and to ensure that the additional acetyl group 
found in mass spectrometry of the intact oligonucleotides was correctly located on the N8 of 
the adducted dG and not on a dC residue due to incomplete deprotection of an acetyl-dC. The 
modified oligonucleotides were incubated with a large excess of snake venom 
phosphodiesterase following incubation with calf intestine phosphatase. The resulting 
nucleosides were analyzed by HPLC-MS (Figure 34).  
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Figure 34. A) HPL-chromatogram of the enzymatic digest of the AAF-dG containing ODN 3 at 260 nm. 
B) ESI-MS spectrum of the peak eluting at a retention time of 41 min. The signal corresponds to the 
deacetylated AF-dG. C) HPL-chromatogram of the digest of ODN 3 at 305 nm. D) ESI-MS spectrum of 
the peak eluting at a retention time of 54 min. The signal corresponds to the AAF-dG nucleoside. 
 
Figure 35. A) HPL-chromatogram of the enzymatic digest of the AAA-dG containing ODN 29 at 260 
nm. B) ESI-MS spectrum of the peak eluting at a retention time of 41 min (AA-dG). C) HPL-
chromatogram of the digest of ODN 29 at 305 nm. D) ESI-MS spectrum of the peak eluting at a 
retention time of 58 min. The signal corresponds to the AAA-dG nucleoside. 
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Figure 36. A) HPL-chromatogram of the enzymatic digest of the AAP-dG containing ODN 32 at 260 
nm. B) ESI-MS spectrum of the peak eluting at a retention time of 43 min (AP-dG). C) HPL-
chromatogram of the digest of ODN 32 at 349 nm. D) ESI-MS spectrum of the peak eluting at a 
retention time of 59 min. The signal corresponds to the AAP-dG nucleoside. 
 
Figure 37. A) HPL-chromatogram of the enzymatic digest of the AAN-dG containing ODN 26 at 260 
nm. B) ESI-MS spectrum of the peak eluting at a retention time of 44 min. The signal corresponds to 
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the AAN-dG nucleoside. C) HPL-chromatogram of the digest of ODN 26 at 305 nm. D) ESI-MS 
spectrum of the peak eluting at a retention time of 45 min. The signal corresponds to the deacetylated 
AN-dG nucleoside. 
 
 
Figure 38. A) HPL-chromatogram of the enzymatic digest of the AAB-dG containing ODN 23 at 260 
nm. B) ESI-MS spectrum of the peak eluting at a retention time of 39 min. The signal corresponds to 
the AAB-dG nucleoside. C) HPL-chromatogram of the digest of ODN 23 at 305 nm. D) ESI-MS 
spectrum of the peak eluting at a retention time of 40 min. The signal corresponds to the deacetylated 
AB-dG nucleoside. 
The canonical bases dC, dT and dA as well as dI, which is the deamination product of dA, 
were detected in all HPLC-spectra. The nucleosides were assigned via their ESI mass spectra 
to their calculated molecular masses. Moreover, the peaks corresponding to the adducted dG’s 
were identified. Additionally, a second peak corresponding to the deacetylated adduct is 
visible for all adducts. The deacetylation of the adducted dG’s occurs during the enzymatic 
digest, which is performed at pH 8.5 and 37°C for several hours. The pH optimum for the 
snake venom phosphodiesterase is between pH 9.8-10.4.[153] A compromise had to be found 
between deacetylation of the adducted dG and maintaining the activity of the enzyme. 
However, the HPLC and mass spectra of the total oligonucleotides show only one peak 
corresponding to the acetylated adducts (Figure 33). Thus, deacetylation occurs only under 
the conditions used for the enzymatic digestion and the acetylated adducts are stable at 
physiological pH.  
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Furthermore, several small peaks are detected with retention times similar to the deacetylated 
and acetylated adducts. These peaks correspond to mass values which could be decomposition 
products of the deacetylated adducted dG’s. Kadlubar et al. found a degradation product in 
the alkaline enzymatic digests (without addition of an antioxidant) of DNA containing a C8-
naphthalene-dG adduct.[154] This was assumed to be an alternate ring-opened structure. 
Currently, there is not enough spectroscopic evidence to support this theory. Kriek et al. found 
that AF-dG decomposed under alkaline conditions into three new compounds which were 
assigned to the structures 67 – 68a, b (Figure 39).[155] All these structures are still 
speculative.[152] In the present thesis, no reduction agent such as β-mercapthoethanol was 
added to the digest solutions. Thus oxidative decomposition of the adducted dG’s may occur.  
 
Figure 39. Speculative degradation products of AF-dG: Ring-opened structures 66 and 67 and 
spirodiastereomers 68a and 68b.  
Particularly after enzymatic digestion of the AAN, AAP and AAB-dG containing 
oligonucleotides, additional small peaks were detected in the HPL-chromatograms at 260 nm. 
Analysis of these peaks gave mass values which are in agreement with ring-opened and spiro-
structures. An example of the data obtained for ODN 26 is shown below (Figure 40). 
 
Figure 40. A) HPL-chromatogram of the enzymatic digestion of the AAN-dG containing ODN 26 at 260 
nm. B) ESI-MS spectrum of the singal with a retention time of 34 min. Calculated m/z mass values of 
the ring-openend structure (analogous to 66) and the spiro-structure (analogous to 68 a and b) are 
426.1652 and 424.1496, respectively.  
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The assignment of the found mass values to the corresponding spiro-compounds is highly 
speculative. Nevertheless, due to the used digestion conditions, some degradation products of 
the modified nucleosides occur.   
In summary, the digestion analysis of the acetylarylamine-dG containing oligonucleotides 
proves that the modified phosphoramidites were successfully incorporated into 
oligonucleotides and that the acetyl groups found by mass spectrometry are located at the 
adducted dG’s and not at a dC within the DNA strand due to incomplete deprotection. 
However, due to the used basic digestion conditions and a lack of reduction agents in the 
digest solution, several decomposition products of the modified nucleosides were additionally 
found. These degradation products occurred only under digestion conditions and were not 
found in the HPLC and mass spectra of the synthesized oligonucleotides. The lesions are 
hence stable under physiological conditions and could be used for biochemical investigations. 
 
6.2.3 Melting point analysis  
 
In order to determine the thermal stability of DNA duplexes containing acetylarylamine dG 
lesions, melting point measurements were performed. The optical density of oligonucleotide 
solutions at a wavelength of 260 nm is different for single strands and double strands. Double 
strands have a lower extinction coefficient at 260 nm than the corresponding mixture of single 
strands because the absorption of the aromatic systems of the bases is reduced by the stacking 
interactions in the double helix. Heating of hybridized DNA duplexes results, above a certain 
temperature depending on the length, the oligonucleotide sequence and the buffer conditions, 
in dissociation of the duplexes into single strands. Thus, the height of the UV absorption 
maximum increases (hyperchromicity). The melting point (Tm) of an oligonucleotide duplex 
is defined as the transition point of the absorption at 260 nm plotted against the temperature. 
The sequence 5'-TCTCTCG*CTCATCCAC-3' containing either the AAF-dG, AF-dG or the 
AAP-dG adduct was annealed to the corresponding counter strand in tris buffer at pH 7.4. 
Several cycles of heating and cooling between 0 to 85 °C were performed and the average 
value was used for calculating of the melting points. In Figure 41, the measured melting 
curves of AAF-, AF- and AAP-dG containing DNA duplexes are displayed.  
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Figure 41. Graphical comparison of the melting curves of the sequence 5'-TCTCTCG*CTCATCCAC-3' 
containing different modified G*’s (either AAF-dG, AF-dG or AAP-dG). Melting points of the 
oligonucleotides are: AAF-dG = 49.8 °C (red curve), AAP-dG 51.4 °C (blue curve) and AF-dG 52.5 °C 
(green curve). The calculated melting point of the undamaged oligonucleotide is 55°C.  
The UV-based melting curve studies with AAF-dG, AF-dG and AAP-dG containing 
oligonucleotides show that all lesion containing oligonucleotides form stable duplexes with 
melting temperatures around 50 °C (Figure 41). The undamaged oligonucleotide duplex has a 
slightly higher melting temperature of 55 °C. Even the acetylated AAF-dG and AAP-dG 
lesions reduce the melting point of the duplex by only a small amount (around 4-5 °C) 
showing that the adducts cause only small overall structural perturbations of the duplex 
structure.  
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7 Bypass of bulky DNA adducts by Y-family DNA polymerases 
 
The Y-family DNA polymerases Pol η and Pol κ were analyzed with oligonucleotides 
containing the synthesized C8 bulky adducts described in section 5 and 6. Primer extension 
experiments as well as co-crystallization with Pol η were performed in order to give insights 
into the blockage/bypass mechanism of these adducts by Y-family polymerases.  
7.1 Translesion synthesis of bulky DNA adducts by Pol η 
7.1.1 Purification of yeast Pol η  
 
The S. cerevisiae Rad30 gene encodes the 632 residues of full length Pol η. A plasmid 
(pDEST007-polη1-513) containing the Rad30 gene coding for a shortened, but still active 
version of 513 amino acids, truncated at the C-terminus was cloned and transformed into 
E. coli Rosetta gami by Dr. Claudia Chioccini.[90] The missing C terminal residues of the 
yeast Pol η catalytic core are of regulatory use, but do not affect the catalytic properties of the 
DNA polymerase and its translesion synthesis properties. The expression and purification 
protocol was also established by Dr. Claudia Chioccini.[90] Pol η1-513, containing an 
N-terminal Strep-tag, was purified on two columns. First, a Strep-Tactin column was 
employed. Finally, a Heparin ion exchange column was used to remove residual DNA (yield: 
0.5 mg protein / L culture). In Figure 42, a SDS-gel of the purified Pol η as well as the UV 
chromatogram of the elution profile of the heparin column purification are displayed.  
 
Figure 42. Expression and purification of yeast Pol η. A) SDS-PAGE: 1: Cells before induction; 2: Cells 
after 4 h induction; 3: Cell pellet after lysis; 4: Crude cell lysate; 5: Pol η after Strep-tag purification; 
 
 
 
                                                7. Bypass of bulky DNA adducts by Y-family DNA polymerases  
 
41 
 
6: Pol η after heparin purification; 7: Protein marker. B) Chromatogram of the Heparin affinity 
purification. DNA and impurities are found in the flow-through. The red curve corresponds to the 
detection at 254 nm, the blue line shows the elution profile at 280 nm. The green line marks the NaCl-
gradient for elution of the protein (Pol η size: 58.1 kDa + 1.25 kDa Strep-tag, 513 amino acids). 
 
7.1.2 Mechanism of replication blocking and bypass of Pol η by AAF-dG adducts 
 
The translesion synthesis DNA polymerase η is able to replicate through C8 bulky adduct 
lesions such as AF-dG and its acetylated analogue (AAF-dG). Bypass occurs mainly in an 
error-free manner, but at a reduced rate.[56-58, 91] Replicative polymerases are in contrast fully 
blocked by the acetylated lesion 14 (see section 3.3), probably due to its restriction to the syn-
conformation (Figure 43).[52-54]  It is not understood so far, how Pol η is able to incorporate a 
dCTP opposite the lesion in order to bypass the AAF-dG lesion correctly despite the 
syn-conformation of the lesion. Co-crystallization of yeast Pol η in complex with DNA 
containing the two bulky adducts AAF-dG and AAA-dG as well as in vitro primer extension 
studies were performed in order to give insights into the bypass mechanism of Pol η.  
 
Figure 43. Syn-conformation of the 2-acetylaminofluorene-dG lesion (AAF-dG) 
 
7.1.2.1 In vitro bypass of AAF-dG and AAA-dG lesions by Pol η 
 
20mer DNA strands containing either the AAF-dG (ODN 2) or the AAA-dG (ODN 28) lesion 
at position 14 and, as a control, the undamaged DNA strand with identical sequence were 
annealed to shorter 5' fluorescence-labeled DNA counter strands (13mer primers). The DNA 
constructs were incubated with the purified yeast Pol η at concentrations ranging from 100-
300 nM in the presence of one or all four nucleotide triphosphates and the primer extension 
reactions were analyzed by gel electrophoresis (Figure 44). 
 
 
 
 
                                                7. Bypass of bulky DNA adducts by Y-family DNA polymerases  
 
42 
 
 
Figure 44. Translesion synthesis through different bulky dG DNA adducts catalyzed by Pol η. The 
primer extension reactions were carried out with fluorescence labeled primers and the extension 
products were resolved on a denaturing PAA-gel. A) Incorporation of individual nucleotides and of all 
four nucleotides with AAF-dG containing oligonucleotides and lesion-free oligonucleotides (200 nM Pol 
η, 1 μM template DNA, 200 µM of each dideoxynucleotide or all four dNTPs; 1, 6 = ddATP, 2, 7 = 
ddTTP, 3, 8 = ddGTP, 4, 9 = ddCTP, 5, 10 = all four dNTPs). B) Incorporation of individual nucleotides 
and all four nucleotides with AAA-dG containing oligonucleotides (1 = ddATP, 2 = ddTTP, 3 = ddGTP, 
4 = ddCTP, 5 = all four dNTPs). 
The enzyme fully extends undamaged template DNA (Figure 44 A, lane 10). In the presence 
of AAF-dG and AAA-dG, bypass is indeed possible, although with strongly reduced 
efficiency (Figure 44 A, lane 5 and Figure 44 B, lane 5). In both cases fully extended primer 
strands are however clearly observed, showing that Pol η is able to read through both lesions. 
To determine the base pairing partner of the adducted guanine during bypass, the primer 
extension experiments were performed adding 2',3'-dideoxynucleotides individually to the 
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reaction mixture. As depicted in Figure 44 A and B (lanes 4), Pol η incorporates, correctly 
and with high specificity, a dC opposite the AAF-dG and AAA-dG lesions despite the 
presence of the aromatic unit attached to C8. No incorporation of other nucleotides is 
observed opposite both lesions.   
 
7.1.2.2  Structures of AAF and AAA-dG containing oligonucleotides in complex with 
Pol η 
 
To elucidate the mechanism of the observed faithful replication across the AAF/AAA-dG 
adducts by Pol η, primer-template constructs of AAF-dG and AAA-dG were crystallized with 
Pol η from S. cerevisiae adding dCTP. Nucleotide insertion through the enzyme was 
prevented by using a primer strand ending with a dideoxy nucleotide, which pairs with the 
nucleobase located directly 3' of the lesion (for details, see section 10.5). The following 
primer-template construct was used: 
5'-TCTCTCG*CTCATCCAC-3'   G* = AAF-dG (ODN 3) 
  3'-      ddGAGTAGGTG-5'                    G* = AAA-dG (ODN 29) 
           
 
Ditetrahedral-bipyramidal shaped crystals were obtained of both lesion-polymerase 
complexes and diffracted X-rays to about 2.7Å spacing (Figure 45).  
 
Figure 45. Crystals obtained with AAF-dG (A) and AAA-dG (B) containing oligonucleotides in complex 
with Pol η from S. cerevisiae (residues 1-513). 
The structures were solved by molecular replacement. For details on data collection and 
structure refinement see section 10.6 and appendix 11.1. As previously observed for the 
enzyme, there are two molecules in the asymmetric unit cell of both crystals[90, 156, 157] 
showing the enzyme-DNA complexes in two different states (A and B, Figure 47). An overall 
structure of the protein and the DNA duplex in complex A is depicted in Figure 46. In the 
crystal structure, the AAF and AAA moieties of the AAF-dG lesion are well defined in both 
complexes in the electron density (Figure 47).  
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Figure 46. Crystal structure of S. cerevisiae Pol η with the AAF-dG oligonucleotide in complex A. The 
overall folding topology is depicted with the enzyme as cartoon representation, the DNA as stick model 
(gold) and the AAF-dG adduct in orange. The different domains typical for Y-family DNA polymerases 
are highlighted by special colors. 
 
Figure 47. Difference-omit electron density map (Fobs-DFcalc) of the AAF-dG (A, B) and the AAA-dG (C, 
D) lesion with the surrounding protein residues. Figures A and C show the AAF-dG and the AAA-dG, 
respectively in complex A, Figures B and D both lesions in complex B. The aromatic C8-adduct of the 
fluorene as well as the anthracene are found at structural equivalent positions in respect to the active 
site of the protein. 
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In the two complexes A, the aromatic amine units stack on top of the Watson-Crick base pair 
formed by the primer ddC and the -1 dG. For both lesions, the bulky aromatic units therefore 
fully block the active site for the incoming dCTP (Figure 47 A, C and Figure 48 A). In 
complex B the situation is surprisingly different (Figure 47 B, D and Figure 48 B). First of all, 
a relatively small movement of the DNA template strand compared to complex A is observed. 
In both structures, the aromatic C8-adduct of the fluorene as well as the anthracene are found 
at structural equivalent positions in respect to the active site of the protein (Figure 47). 
However, the primer DNA strand is rotated in complex B relative to the aromatic moiety by 
about 6 Å. Due to this strand rotation, the location of the primer end is strongly different in 
both complexes A and B. This primer rotation brings the dG part of both lesions despite their 
prevalent syn-conformation closer into the active site, destacking the aromatic unit. In 
consequence of the primer motion, the dG-lesion packs above the Watson-Crick base pair 
formed by the primer end and the template strand. The primer strand displacement results in a 
partial opening of the active site, for the putative dCTP to bind (Figure 47 B, D and Figure 48 
B). However, no bound dCTP could be observed in the crystal structures.  
 
Figure 48. Stick model of the DNA in both complexes A and B containing the AAF-dG lesion A) In 
complex A, the fluorene moiety of the AAF-dG adduct stacks on the previous Watson-Crick base pair, 
blocking the active site for the incoming nucleotide. B) In contrast, the DNA in complex B is rotated in 
respect to the aromatic unit, with the adducted dG moved towards templating position, partially freeing 
the active site. Whereas in complex A the AAF and AAA unit stack on top of the base pair, this 
stacking interaction is fully sacrificed in complex B. 
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Figure 49. Overlay of the AAF-dG and AAA-dG containing DNA duplexes in complex A and B. The 
AAF-dG strands are depicted in green (complex A) and light green (complex B). The AAA-dG are 
shown in blue (complex A) and light blue (complex B).  
In summary, a small primer movement is detected in going from complex A to complex B, 
which opens up the active site for the incoming dCTP. A rather small further movement of the 
DNA along this trajectory would result in a situation in which the triphosphate can finally 
bind and nucleotide incorporation can occur. 
 
7.1.2.3 Model of the bulky adduct bypass 
 
In order to visualize how Pol η copies though the AAF/AAA-dG lesions, the complex was 
modeled with the bound dCTP (Figure 51). To this end, the primer was shortened by one base 
and the dC-triphosphate was inserted. In all so far obtained crystal structure of Pol η with a 
bound triphosphate, the position of the triphosphate is invariant (Figure 50).[88, 90, 157] Thus, the 
dCTP was placed at exactly the same position relatively to the protein where it is positioned 
in the known Pol η structures. Figure 50 shows a structural superposition of known yeast Pol 
η structures, the close-up view of the active site with the incoming dCTP is depicted in Figure 
50 C.  
Minor changes of the overall protein conformation were discovered, when the presented bulky 
adduct structures and structures of Pol η in complex with the cisplatin adducts[90, 157] were 
compared with a recent structure of Pol η reading through a CPD lesion (Figure 50 A, B).[88] 
The crystallographic results of this thesis work as well as of the cisplatin lesion structures 
were obtained with the wild type Pol η enzyme, which crystallizes with an open PAD domain. 
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The CPD structure however was obtained with a mutated Pol η. Here, particular crystal 
contacts were removed by site directed mutagenesis resulting in a further closing of the PAD 
domain. This however does not change the situation in the active site, particularly not of the 
base paring motifs and the positioning of the incoming dCTP (Figure 50 C).  
 
Figure 50. Structural superposition of known yeast Pol η structures. The proteins were least-square 
fitted using the main-chain atoms of residues number 1-230, which were chosen as reference frame. 
A) Closing of the PAD domain and slight rotation of the DNA helix in the Pol η structure in complex 
with the CPD lesion (PDB code 3MFI, red) compared to the AAF (this thesis work, golden). In the 90° 
rotated view the finger domain (residues 1-122) was removed for clarity. The polypeptide chain is 
shown as ribbon and the DNA as cartoon representation. B) Superposition of all known yeast Pol η - 
DNA complex structures: the cisplatin GG adduct (PDB codes 2R8J and 2R8K, green and blue); the 
cisplatin-GTG adduct (PDB code 2WTF, grey); and CPD lesion (PDB code 3MHI, red), AAF (PDB 
code 2XGP, gold). C) Close-up in the active site with the same color scheme as in B. The respect 
triphosphates are drawn as stick model and the ions as spheres. For clarification, the DNA is not 
shown. The superposed structures are Pol η bound to lesion containing DNA: the cisplatin GG adduct 
(PDB codes 2R8J and 2R8K, green and blue); the cisplatin-GTG adduct (PDB code 2WTF, grey); and 
CPD lesion (PDB code 3MHI, red). In all structures with a bound triphosphate, the ions in the active 
site are in structural similar positions, regardless if there are catalytic competent magnesium (Pol η - 
CPD) or calcium ions (all other Pol η - DNA complex structures). Despite closing of the PAD domain, 
no structural changes occur in the active site. 
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After shortening of the primer by one base, the triphosphate fits perfectly into the active site. 
The AAF-dG lesion was then moved into the -I position. In this way, Pol η moving one base 
pair forward could be simulated (Figure 51 C). After these manipulations, the mechanism of 
the difficult bypass step can be visualized. 
 
Figure 51. Model for AAF-dG bypass by Pol η. A) In complex A, the fluorene moiety of the AAF-dG 
adduct stacks on the previous Watson-Crick base pair, blocking the active site for the incoming 
nucleotide. B) In contrast, the DNA in complex B is rotated in respect to the aromatic unit, with the 
adducted dG moved towards the templating position, partially freeing the active site. C) Hypothetical 
model of the AAF bypass by Pol η. The dG : dC basepair 3’ of the lesion in the AAF-dG-Pol η complex 
B was replaced by the AAF-dG adduct and the dCTP triphosphate. The dCTP was placed in the active 
site according to the structure of Pol η in complex with the cisplatin GG lesion (PDB code 2R8J). Thus 
the active site for the incoming dCTP opens, which forms one critical hydrogen bond to the adducted 
nucleobase in syn conformation. 
 In the proposed model, the extension of the template rotation as described above is sufficient 
to fully open the active site for the incoming dCTP. The dCTP placed in the active is able to 
form one hydrogen bond with the dG of the lesion. Thus, the crystal structure (Figure 51 A 
and B) in combination with the model (Figure 51 C) allows to decipher the basis for faithful 
bypass of acetylated bulky adduct lesions. Here, the acetylated bulky adduct lesions do not 
have to rotate into the anti-conformation to enable Watson-Crick base pairing. Instead, the 
DNA primer strand rotates, which allows Pol η to decode the bulky dG adduct with dCTP. 
One critical hydrogen bond is established between the N4 of the triphosphate and the O6 of the 
dG part of the lesion (Figure 51 C and 52). A similar single H-bond based decoding was also 
observed to allow Pol η to bypass the cisplatin GG lesion.[90]  
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Figure 52. Close-up view of the bypass model for AAF/AAA-dG lesions by Pol η. A critical hydrogen 
bond is established between the N4 of the dCTP and the O6 of the dG part of the AAA-dG lesion. 
 
7.1.2.4 Further biochemical investigation of the bypass model 
 
The bypass hypothesis proposes, that Pol η keeps the bulky adduct of the lesion at the same 
position, but rotates the primer strand around the lesion in order to bring the dG of the lesion 
into a templating position. The major energetic penalty of this rotational process is the 
required destacking of the aromatic bulky adduct unit and the last formed Watson-Crick base 
pair between the primer and the template strand. In complex A, the fluorene and anthracene 
units stack almost perfectly on top of the base pair (Figure 47, A and C). This stacking 
interaction is fully sacrificed in complex B (Figure 47, B and D). Biochemical support for the 
mechanistic proposal could therefore be obtained by measuring the translesion synthesis 
process depending on the size of the aromatic unit, which determines the amount of the 
stacking interaction. The required destacking forces should increase with increasing size of 
the flat aromatic adduct, thus slowing down the bypass process. Thus, primer extensions were 
also performed with the small benzene-, the larger naphthyl- or the largest pyrene-dG adduct 
(see sections 5 and 6). The results are depicted in Figure 53 and Figure 54 (lanes 1-5). The 
experiment shows that TLS efficiency is strongly reduced if the size of the aromatic adduct is 
increased. Whereas bypass is surprisingly efficient for the small benzene unit, bypass is 
almost impossible when the benzene was replaced by a large pyrene unit.  
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Figure 53. Translesion synthesis of different bulky dG DNA adducts in the same sequence context 
catalyzed by Pol η. The primer extension reactions were carried out with fluorescence labelled primers 
and extension products resolved on a denaturing PAA-gel. Reaction conditions are: 300 nM Pol η, 1 
µM template DNA, 200 μM dNTPs each, 1 = AAB-dG, 2 = AAN-dG, 3 = AAF-dG , 4 = AAA-dG , 5 = 
AAP-dG, 6 = undamaged template strand, m = marker. 
 
Figure 54. Primer extension studies with different bulky dG DNA adducts and lower Pol η 
concentrations (150 nM) compared to the experiments presented in Figure 53. 1 = AAB-dG, 2 = AAN-
dG, 3 = AAF-dG, 4 = AAA-dG, 5 = AAP-dG, 6 = undamaged template strand, m = marker. 
To further support the proposed TLS mechanism, additional experiments with zebularine 
triphosphate (dZTP) were performed (Figure 55). Since the bypass process was found to rely 
on the formation of one hydrogen bond between the incoming dCTP and the dG part of the 
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lesion, lesion bypass should be reduced with dZTP where this H-bond cannot form. In 
agreement with the postulated mechanism, dZTP indeed cannot be incorporated by Pol η 
opposite the lesion (Figure 55, lane 5).  
 
Figure 55. Left: Primer extension reaction with 2’-Deoxyzebularine-5’-Triphosphate (dZTP) and 
AAF-dG containing oligonucleotides (100 nM Pol η, 1 μM template DNA, 200 µM of each 
deoxynucleotide of all four dNTPs and dZTP; 1 = dATP, 2 = dTTP, 3 = dGTP, 4 = dCTP, 5 = dZTP); 
Right: Primer extension reaction with undamaged template DNA, 6 = dCTP, 7 = dZTP (200 nM Pol η) 
In a control experiment with undamaged template DNA, dZTP incorporation opposite dG is 
observed, albeit with reduced efficiency compared to a dCTP (Figure 55, lane 7). 
 
7.1.2.5 Discussion 
 
The acetylated C8-AAF-dG and the non-acetylated C8-AF-dG adducts have distinct 
mutagenic properties. The AF-dG lesion strongly reduces the efficiency of replicative bypass, 
but read through by high fidelity polymerases is accomplished because these lesions can 
rotate around the glycosidic bond into the anti-conformation.[51, 120] Thus, the AF-dG unit can 
correctly pair with an incoming dCTP in the active site by forming a Watson-Crick base 
pair.[158, 159] The acetylated bulky adducts in contrast, are not bypassed by high fidelity 
polymerases because these lesions are fixed in the syn-conformation.[52-54] Faithful bypass of 
the acetylated lesions in vivo is achieved by low-fidelity TLS polymerases, with Pol η playing 
a major role.[56, 57, 60] Two crystal structures of DNA containing the two different acetylated 
bulky adduct lesions AAF-dG and AAA-dG in complex with Pol η were obtained in this 
thesis work. Both structures show the primer-template constructs in two different positions 
(complex A: Figure 56 A and B, complex B: Figure 56, C and D). Complex A features the 
bulky adduct in the active site, blocking the dCTP from entering. In this complex, the bulky 
adduct fully stacks on top of the last primer-template base pair. Complex B in contrast shows 
the bulky adduct in the process of being bypassed.  
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Figure 56. Schematic representation of Pol η binding AAF-dG and AAA-dG containing DNA. In the 
complexes A, the aromatic moieties of AAF-dG (A) and AAA-dG (B) stack on top of the previous G-C 
base pair, adopting structural equivalent positions. In the complexes B, the enzyme rotates the DNA in 
respect to the fluorene moiety in order to free its active site for an incoming dCTP (AAF-dG (C) and 
AAA-dG (D)). The protein is shown as semi-transparent surface representation (grey) with the DNA as 
stick model (gold) and the lesion highlighted in orange. Active site residues are also depicted as stick 
model (blue). The catalytic calcium ions in the active site are displayed as red spheres. 
In complex B, the enzyme has rotated the DNA primer strand, while keeping the aromatic C8-
adduct at a structural equivalent position. This rotational motion partly unblocks the active 
site but a dCTP can still not enter, which explains why bypass of these lesions is so difficult 
even for Pol η. A modeling study, in which further movement along this trajectory was 
performed, shows how the active site might open to enable the nucleotide triphosphate 
binding in the active site (Figure 51 C). The model shows that a bound dCTP might be able to 
form one H-bond between the C4-NH2 group of the dCTP and the C6=O group of the 
AAF/AAA-dG. The starting point of the model is the fact that the triphosphate occupies in all 
known structures exactly the same position (Figure 50 C), which allows to simulate the dCTP 
bound structure when the primer and the template have moved one step further on the 
elongation pathway. The formed critical H-bond could provide the basis for Pol η to correctly 
insert a dC opposite the lesion. Purine triphosphates can not bind due to their larger size. The 
alternative pyrimidine base dTTP would fit sterically and can indeed be modeled into the 
active site, but dTTP would be unable to form the critical H-bond. The importance of this 
H-bond was proven with the artificial triphosphate dZTP lacking the C4-amino group. The 
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dZTP triphosphate is not inserted opposite the lesion, thus supporting the proposed bypass 
model.  
Further support comes from a chemical biology study, in which the size of the aromatic 
adduct was systematically changed, thereby modulating the stacking interactions between the 
lesion and the last primer template base pair. The experiments show that smaller sized adducts 
which establish smaller π-stacking forces are more efficiently bypassed, even though the 
energy potential for the syn-anti rotation around the glycosidic bond is unchanged.[55] Bypass 
of the large pyrene unit is in consequence hindered because of the large size of the stacking 
interaction.[160, 161] In summary, efficient destacking of the aromatic unit on top of the primer 
template base pair is a key prerequisite for the efficient bypass reaction by the low fidelity 
polymerase Pol η. 
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7.1.3  Crystallization experiments with other bulky adducts 
 
Bypass of the large pyrene adduct is almost impossible for Pol η. The smaller benzene and 
naphthalene adducts are replicated more easily. Crystal structures of oligonucleotides 
containing these adducts in complex with Pol η could give further insight into the bypass 
process, especially in the blockage by the AAP-dG adduct. Thus, additional crystallization 
experiments were performed with AAN-dG, AAB-dG and AAP-dG containing 
oligonucleotides in complex with Pol η using the same DNA sequence as before (section 
7.1.2.2).  For the AAN-dG and AAB-dG adducts, only crystals of the apo-enzyme exhibiting 
the typical, rhombic shape were obtained (Figure  57 A). AAP-dG crystals had a similar 
morphology as the AAF-dG crystals (Figure  57 B).  
 
 
Figure  57. Crystals obtained with bulky adduct containing oligonucleotides in complex with Pol η from 
S. cerevisiae (residues 1-513). A) The crystals obtained with addition of AAB-dG DNA (ODN 23) 
contained no DNA. B) AAP-dG (ODN 32) crystals diffracted X-rays to 2.7 Å spacing and contained 
DNA. 
The AAP-dG crystals diffracted X-rays to about 2.7 Å spacing and the structure was 
provisionally solved by molecular replacement. Again, two Pol η molecules were found in the 
asymmetric unit cell of the crystals. The protein is well defined in electron density. 
Unfortunately, the lesion is flexible and does not enter the active site of the enzyme, thus the 
AAP-dG is not defined in the electron density. The observation that the AAP-dG is unable to 
access the polymerases active site in the crystal may also explain why bypass of the lesion is 
so difficult for the enzyme. Figure 58 shows a close-up view of the active site of the enzyme. 
The C:G base pair 3' to the lesion can still form but is slightly out of plane. There is no 
electron density found for either the guanine, the deoxyribose or the pyrene unit.  
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Figure 58. Provisional crystal structure of AAP-dG containing DNA in complex with Pol η. The modeled 
position of the AAP-dG (golden stick model) is marked by a pick arrow. The G:C base pair 3' to the 
lesion is highlighted by a blue arrow.  
 
 
 
 
                                                7. Bypass of bulky DNA adducts by Y-family DNA polymerases  
 
56 
 
7.1.4 Mechanism of acetylaminofluorene-dG induced frameshifting 
7.1.4.1   Primer extension studies in combination with mass spectrometry 
measurements give insights into the occurrence of frameshift mutations 
 
Frameshift mutations induce a shift of the genetic reading frame, which can be fatal for the 
cell. If the shift involves one or two bases, the corresponding frameshift mutations cause the 
loss of the information content of the whole gene. The mechanisms that lead to frameshift 
mutations are not well understood but, as discussed in section 3.3, frameshifts are produced in 
consequence of the mutagenic effect of aromatic amines. Bypass of the acetylated AAF-dG 
lesion is often accompanied by a frameshift event. If the lesion is located in special repetitive 
sequences such as the NarI sequence, it induces a –I or –II frameshift mutation.[16, 53, 61-64] 
This process involves a primer-template misalignment by one or two bases during replication 
and it is believed that the misaligned primer-template duplex is stabilized by the AAF (see 
section 3.3).[21, 62, 65-68] In order to study the mechanisms of the various frameshift processes 
several oligonucleotides containing the AAF-dG lesion in different sequence contexts were 
synthesized (ODN 1, 2, 13-15 and 18-20). Primer extension studies with Pol η were 
performed and the NarI base sequence was systematically changed to study which part of the 
sequence is needed to induce the frameshift reaction.  
For the primer extension reaction, fluorescent labeled primers, ending one nucleotide 3' of the 
lesion or with a dC directly opposite the lesion, were annealed to the corresponding template 
strand. Primer extension was carried out using 300 nM Pol η and 200 µM of each nucleoside 
triphosphate at 30°C for 5 min. The primer extension assay products were investigated by gel 
electrophoresis and also directly by MALDI-Tof mass spectrometry. This allows gaining 
information not only about the lengths of the synthesized primers but also about the base 
composition of the primer product. For the mass spectrometry analysis, the DNA of the 
primer extension reactions containing 30 pmol of the primer/template construct was extracted 
by phenol/chloroform extraction. The aqueous phase was concentrated and desalted using a  
ZipTipC18 (Millipore). 
Figure 59 contains the complete gel of the primer extension reaction performed with the 
various AAF-dG containing oligonucleotides.  
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Figure 59. Primer extension reaction catalyzed by Pol η with the AAF-dG in various sequences and 
complementary primers ending 3’ before the AAF-dG lesion at 5 min incubation time. Reaction 
conditions are 300 nM Pol η, 1 μM template DNA, 200 μM deoxynucleotides. Individual lanes of both 
gels are depicted in Figure 59. 
The results of the study are compiled in the Figure 60. For this, single lanes from the gel were 
individually discussed. If the AAF-dG lesion is placed in the NarI sequence (Figure 60, A) 
formation of only a small amount of the fully elongated primer is observed. Most of the 
product is a primer, which is two bases shorter in agreement with data from literature.[61] The 
MALDI-Tof mass spectrum provided for the truncated primer an m/z-value of 6021, which is 
in agreement with a -II-frameshift product, in which the AAF-dG lesion itself and one of the 
cytosines next to the lesion are not correctly translated (see appendix, section 11.2). If one 
changes the base sequence 5' to the AAF-dG lesion (Figure 60, B, C and D) a normal full 
length primer product is formed comparable to what is obtained in the absence of any lesion 
(Figure 60, J). Since in sequence B, the 5'-CGAAF-3' is replaced by 5'-TGAAF-3', misalignment 
of the primer end would involve formation of a 5'-TGAAF-3' bulge. This is apparently not 
occurring, instead full extension is observed. These results suggest, that it is specifically the 
dC base located 3' to the AAF-dG lesion, which is responsible for the frameshifting process. 
In all these primer extension reactions we used a primer that ended directly in front of the 
AAF-dG lesion was used. The dC base in position -1, located 3' to the lesion, is consequently 
the last template base that is correctly base paired with a dG base in the primer. The obtained 
primer extension results allow therefore postulating directly a mechanism for the –II-
frameshift process which is shown in Figure 61, A. Pol η correctly inserts a dC into the primer 
opposite the AAF-dG lesion despite the syn-conformation of the lesion. Then, however, 
primer slippage occurs, which is accompanied by an extrusion of the 3'dC and the AAF-dG 
lesion. The primer slips over this dinucleotide sequence and misaligns with the -CG- sequence 
present in the template in 5' direction relative to the AAF-dG lesion. This misaligned primer is 
subsequently elongated, which manifests the –II frameshift product. 
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Figure 61. A) Schematic description of the slippage process leading to a –II frameshift, B) to a –III 
frameshift and C) to a –I frameshift. 
Thus, a dC-base in 3' direction to the AAF-dG lesion and a CG sequence 5' to the AAF-dG 
lesion are needed for the frameshift process. This idea was examined with a template 
sequence in which we replaced the dC base at position -2 relative to the AAF-dG by a dT. The 
result is depicted in Figure 60, E. This dC to dT change did not affect formation of the –II 
frameshift showing that indeed only the dC in –I position is involved in the frameshift 
process. Even more informative is experiment F shown in Figure 60. Here all dC bases in 
close vicinity of the lesion were replaced by dG. This gives a tightly closed and stable duplex 
in which primer-template misalignment should be energetically costly. Now, slippage and 
misalignment is indeed limited to just one base. It is presumably the lesion itself, which is 
bulged out to provide the basis for a –I frameshift (Figure 61, C). Astonishing is the high yield 
by which this -I frameshift is formed. On the gel shown in Figure 60, F it is the only formed 
reaction product. MALDI-Tof analysis* shows the presence of only two oligonucleotides in 
the assay solution (Figure 62, A). Next to the primer strand with a m/z = 4431, the only other 
oligonucleotide detected has a value of m/z = 6231, which is the correct molecular weight for 
the –I frameshifted primer.  
In a further experiment (Figure 60, G), the sequence 5' to the AAF-dG lesion was changed so 
that misalignment of the primer can only occur if in total three bases are extruded. Now, next 
to full length extended primer, an additional band is detectable on the gel, which is formed by 
an extended primer indeed three bases too short. Analysis of the primer extension reaction by 
MALDI-Tof mass spectrometry shows in fact formation of the full length primer with m/z = 
6639 (Figure 62, B). All other signals, however, are derived from primers with feature the –III 
                                                 
* MALDI-Tof spectra of all primer extension reactions can be found in the appendix (section 11.2) 
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frameshift (Figure 62, B). Consequently, Pol η indeed first extends the primer with a dC base 
inserted opposite the lesion. After this, a substantial fraction of the primer misaligns to pair 
with the alternative dG in the template two bases further away (Figure 61, B). This large 
misalignment process, which is in full agreement with the formulated frameshift mechanism, 
is surprisingly efficient. 
 
Figure 62. A) MALDI-Tof mass spectrum of experiment F. The –I frameshift is detected at m/zcalc = 
6236.7. B) MALDI-Tof of experiment G. Next to full extension at m/zcalc = 6639.6, the –III frameshift is 
detected at m/zcalc = 5734.7 together with truncated –III frameshift products. 
The results show that the template-primer stability in close proximity to the lesion is a key 
parameter which determines the kind of frameshift established. Formation of a –III frameshift 
is limited to sequences in which the AAF-dG lesion is located in weakly paired A:T 
sequences. If the lesion is embedded in G:C sequences, only a –I or –II frameshift is observed. 
This idea is further supported by experiment H in Figure 60. When the dC 3' to the lesion is 
replaced by a dT, slippage and misalignment is not possible any more. Now, the AAF-dG 
lesion establishes a replication block even for the low fidelity polymerase Pol η. It seems that 
for primer elongation to occur through the lesion, a stable primer-template duplex with a GC 
base pair below the lesion is required.  
The experiments show that acetylated C8 bulky adduct lesions such as AAF-dG can, when 
they are bypassed by Pol η, induce –I, -II, and –III frameshift mutations depending on the 
base sequence around the lesion. The critical event is in all cases the insertion of a correct dC 
base opposite the bulky adduct. This seems to require a G:C base pair 3' to the lesion, possibly 
to ensure proper alignment of the primer opposite the lesion in order to enable attacking of the 
triphosphate. If the G:C base pair is replaced by an A:T base pair, replication past the lesion is 
not longer possible. In this case, the AAF-dG lesion establishes a replication block. After 
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insertion of the dC base opposite the lesion, the primer starts to probe the base sequence 
behind (5') the lesion. If a complementary sequence is available, the primer end will misalign, 
bulging the lesion itself and if necessary up to two additional bases out. In the majority of 
cases and in particular in the NarI sequence, the dinucleotide 3'- dC-AAFdG -5' is bulged out. 
In G:C rich sequences, in which bulging out of bases is energetically more costly, the bulging 
is limited to a single base inducing a –I frameshift.  
To further prove that correct dCTP incorporation opposite the lesion is indeed always 
preceding mutagenic extension slippage, a 14mer primer instead of the 13mer was employed, 
containing additionally the correct initial dC incorporated opposite the AAF-dG. This primer 
was annealed to the NarI sequence and extended under the same conditions. Again, the -II 
frameshift can be clearly detected (Figure 60, I and 63, A and E), thus confirming that the -II 
frameshift originates after correct 13mer primer extension with a dC, followed by slippage 
and realignment of the primer template construct. Moreover, using the proper 14mer primers 
in all the other primer extension reactions, the –I and the –III frameshifts as well as the 
replication blocking events could be reproduced, showing that correct pairing of the lesion 
with dC precedes all frameshifting events (Figure 63).  
 
Figure 63. Primer extension reaction catalyzed by Pol η with the AAF-dG in various sequences and 
complementary primers ending with a dC opposite the AAF-dG lesion at 5 min incubation time. 
Reaction conditions are 300 nM Pol η, 1 μM template DNA, 200 μM deoxynucleotides. The -II 
frameshift is clearly visible (lanes E and A), in lane J, the correct extension of the 14mer primer 
annealed to an undamaged template is shown. Sequence H leads to a total block of the polymerase, 
no extension of the primer takes place. Sequence E shows a different mobility compared to the other 
14mer primer sequences. Gel electrophoresis and mass spectrometry analysis confirmed the purity of 
the primer strand E. Formation of secondary structures might lead to a different mobility of this 
oligonucleotide. The experiment demonstrates that the various frameshift events (-I, -II, -III) and 
blockage of the polymerase (sequence H) also occur if an elongated primer with a dC opposite the 
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lesion is used. This supports the proposed model of the AAF-dG bypass in which dCTP incorporation 
opposite the AAF-dG precedes mutagenic or error-free extension from the lesion. 
 The general scheme that emerges from the study is that frameshift formation is triggered by a 
special instability of the AAF-dG:dC base pair. Once formed, extension of the dC-ending 
primer seems to be so difficult that it is easier for the enzyme to slip the primer end forward 
until the primer dC end misaligns with a complementary dG base upstream on the template 
strand. If the formed bulged out structure is stable enough, elongation occurs and the 
frameshift is manifested. The instability of the AAF-dG:dC base pair and not a particular 
stabilizing effect of the aromatic adduct seems to determine the frameshift process.  
 
7.1.4.2 Towards crystallization of the –II frameshift 
 
In order to get a better insight into the formation of the -II frameshift caused by AAF-dG in a 
repetitive sequence context, oligonucleotides were designed for the co-crystallization of the 
two (and one) nucleotide bulge with Pol η.  The AAF-dG containing DNA primer/template 
constructs used for crystallization are summarized in Table 2. 
ODN primer/template construct dNTP/ddNTP crystals diffraction 
ODN 8 5'-CTCTGGCG*CCTCACAC-3' 3'-          ddCG -  - GAGTGTG-5'  dCTP small crystals 8 Å 
ODN 8 5'-CTCTGGCG*CCTCACAC-3' 3'-            dCG -  - GAGTGTG-5'  ddCTP 
large crystals,  
tetrahedron-shaped 
2.9 Å, DNA 
disordered 
ODN 8 5'-CTCTGGCG*CCTCACAC-3' 3'-       ddCCG -  - GAGTGTG-5'       dATP no crystals  
ODN 8 5'-CTCTGGCG*CCTCACAC-3' 3'-         dCCG -  - GAGTGTG-5'       ddATP 
large crystals, 
tetrahedron-shaped 
3.4 Å, DNA 
disordered 
ODN 10 5'-CTCTGGCG*CCTCACC-3' 3'-         ddCG -  - GAGTGG-5'   dCTP no crystals  
ODN 10 5'-CTCTGGCG*CCTCACC-3' 3'-            dCG -  - GAGTGG-5'  ddCTP large crystals 
2.9 Å, DNA 
disordered 
ODN 12 5'-CTCTGGCG*CCTCACACC-3' 3'-         ddCG -  - GAGTGTGG-5'   dCTP no crystals  
ODN 9 5'-GACGTCTCG*CTCATCC-3' 3'-                 dG - GAGTAGG-5'   ddATP crystals 4.5 Å 
ODN 11 5'-GACGTCTCG*CTCATCAC-3' 3'-                 dG - GAGTAGTG-5'    ddATP deformed crystals  
Table 2. AAF-dG containing oligonucleotides used for co-crystallization with Pol η. Results of the 
crystallization experiments as well as resolution of the diffraction data are presented.  
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The primer used for crystallization possessed either a 2'-deoxy base or a 2',3'-dideoxy base at 
the 3' end. For deoxy primer, a 2',3'-dideoxynucleoside triphosphate was used for 
crystallization. Incorporation of the incoming nucleotide was therefore possible, but 
afterwards, addition of further nucleotides was prevented due to the lacking 3'-OH group. For 
dideoxy primer, standard deoxy nucleoside triphosphates were utilized. Thus, no 
incorporation of the incoming nucleotide could take place. Crystallization conditions were 
similar to the conditions used for the crystallization experiments in section 7.1.2 (10–20% 
(w/v) PEG 3350, 150–200 mM CaCl2, 5 mM MgSO4, 1 mM dNTP).  
 
Figure 64. Crystals obtained with several oligonucleotides containing the AAF-dG lesion in the NarI 
frameshift sequence. A) ODN 8 with 9mer dideoxyprimer and dCTP (lane 1 in Table 2). B) ODN 8 with 
9mer deoxyprimer and ddCTP (lane 2 in Table 2). C) ODN 10 with 8mer deoxyprimer and ddCTP 
(lane 6 in Table 2). D) ODN 9 with 8mer deoxyprimer and ddATP (lane 8 in Table 2). 
Table 2 summarizes the results obtained with the crystallization experiments of the various 
AAF-dG containing oligonucleotides with the NarI sequence or a sequence allowing 
formation of a 1 nucleotide bulge. Only small, poorly diffracting crystals could be obtained, 
when a dideoxy primer was used. Crystallization with deoxy primer and ddNTPs resulted in 
bigger, mostly sufficiently diffracting crystals. In all cases however, electron density for the 
DNA was hardly visible. Often, only electron density for the phosphate backbone could be 
seen, the nucleobases were disordered. Several explanations are possible. Either, the deoxy 
primer produce a mixture of DNA-polymerase complexes. Some complexes contain 
incorporated nucleotides and some might not contain incorporated nucleotides, which leads to 
the poor electron density for the DNA. Or, the bulge formed in the extended frameshift 
sequences ODN 8 and 10 can be bound by the protein in different positions, interchanging the 
relative positions of the nucleobases but not of the phosphate backbone.  
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7.2 Bypass of bulky DNA adducts by Pol κ 
 
It was previously shown that Pol κ is able to bypass the AAF-dG lesion in vitro and in vivo in 
an error-free as well as in an error-prone manner by incorporating dTTP with the same ratio 
as the correct dCTP opposite the lesion.[20, 95, 96, 97] Moreover, Pol κ is, in addition to Pol η, 
involved in the generation of frameshift errors, particularly -I frameshift mutations.[94] The 
contribution of Pol κ to the generation of frameshift mutations during bypass of bulky adducts 
is not fully understood so far.[96] The bypass of several bulky DNA adducts by Pol κ,  the 
investigation of frameshift errors occurring during Pol κ mediated lesion bypass, and first 
crystallization experiments with Pol κ and AAF-dG containing oligonucleotides are described 
in the following section.  
 
7.2.1 Cloning, expression and purification of human Pol κ 
 
Two truncated Pol κ constructs, coding for the residues 50-530 and 1-530, were generated by 
PCR amplification of the human Pol κ gene (full gene coding for the residues 1-870). Each of 
the constructs was cloned in two steps into expression vectors using StarGate® cloning 
technology from IBA. The constructs were confirmed by sequence analysis, and expressed as 
C-terminal Strep-tag proteins in E. coli BL21(DE3)pLysS cells. The longer Pol κ construct 
(residues 1-530, Pol κL), truncated only at the C-terminus, should exhibit full polymerase 
activity according to the Pol κ construct prepared by Uljon et al.[93] The shorter construct 
(residues 50-530, Pol κS), truncated at both N- and C-terminus, does not possess complete 
polymerase activity (comparable to a known Pol κ version of residues 68-526), but this 
version crystallizes more easily.[162]  Expression was performed in standard LB medium, 
however, the protein yield obtained for both Pol κ versions was not sufficient for further 
crystallization studies. Therefore, an autoinduction medium from Novagen was tested for the 
expression of Pol κL. Autoinduction media allow regulated protein expression from lac 
promotors in E. coli without monitoring the culture or adding inducers during cell growth.  
The medium contains a mixture of carbon sources including lactose. Initially, glucose is 
metabolized by the E. coli cells. When the glucose is depleted, uptake of lactose occurs which 
induces protein expression. With this method, high cell densities are obtained and, in this 
case, much higher yields of Pol κ were obtained.  
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Both Pol κ versions (Pol κS and Pol κL) were purified with the help of two columns. First, a 
Strep-Tactin column was employed followed by a Heparin ion exchange column to remove 
residual DNA. The yield using standard LB medium was around 0.2 mg protein per litre of E. 
coli expression culture. As mentioned before, the use of the autoinduction medium led to 
much higher yields of around 30 mg protein per litre of E. coli culture. In Figure 65, SDS-gels 
of both purified Pol κ versions as well as UV chromatograms of the heparin column 
purification procedures are displayed. 
 
Figure 65. Purification of human Pol κ.  
A) SDS-PAGE of Pol κs: 1: Protein marker; 2: Flow-through of the heparin affinity column; 3: 3 µg Pol 
κs after heparin affinity purification; 4: 1 µg Pol κs after heparin affinity purification. (Pol κs size: 55.01 
kDa + 1.25 kDa Strep-tag, 481 amino acids) B) SDS-PAGE of Pol κL: 1: Protein marker; 2: 1 µg Pol κL 
after heparin affinity purification (Pol κL size: 60.6 kDa + 1.25 kDa Strep-tag, 530 amino acids) 
C) Chromatogram of the Heparin affinity purification of Pol κL. DNA and impurities are found in the 
flow-through. The red curve corresponds to the detection at 254 nm, the blue line shows the elution 
profile at 280 nm. The green line marks the NaCl-gradient for elution of the protein. 
 
7.2.2 Primer extension studies with Pol κ 
 
In order to compare the activity of both purified Pol κ versions, Pol κS and Pol κL, primer 
extensions with undamaged template DNA as well as with an AAF-dG lesion containing 
oligonucleotide were performed. ODN 1 and an undamaged template strand with the same 
sequence were annealed to a fluorescence labeled primer ending one nucleotide 3' to the 
lesion in Pol κ primer extension buffer (section 10.3.1). Primer extension was carried out with 
high concentrations of Pol κS or Pol κL (2 µM) and simultaneous addition of all four 
deoxynucleoside triphosphates at 37 °C for 30 min (Figure 66).  
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Figure 66. Translesion synthesis of AAF-dG containing oligonucleotides catalyzed by Pol κS and Pol κL 
(2 µM Pol κ, 1 μM template DNA, 200 μM of all four dNTPs). Lane 1: Extension of undamaged 
template DNA by Pol κS; Lane 2: Extension of and AAF-dG containing oligonucleotide (ODN 1) Pol κS; 
Lane 3: Extension of undamaged template DNA by Pol κL; Lane 4: Extension of and AAF-dG 
containing oligonucleotide (ODN 1) Pol κL. 
Pol κS, truncated at the N- and the C-terminus, is not even able to extend undamaged template 
DNA completely at the high enzyme concentrations used in this study (Figure 66, lane 1). 
Accordingly, AAF-dG damaged DNA presents a strong block for the N-terminal truncated 
Pol κ (lane 2). Pol κL fully extends undamaged template DNA (lane 3) and also the AAF-dG 
containing ODN 1 (lane 4). At these high polymerase concentrations, Pol κ is able to bypass 
the AAF-dG lesion. Additionally, shorter bands are visible, which might be lesion induced 
frameshifting product or not fully extended primers. For all following primer extension 
studies, Pol κL, truncated only at the C-terminus, was chosen to ensure the presence of active 
enzyme. To analyze the results further, single nucleotides were inserted in primer extension 
studies with AF-dG and AAF-dG containing oligonucleotides using 200 nM Pol κL at 37 °C 
for 30 min. The result of this experiment is displayed in Figure 67.  
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Figure 67. Incorporation of individual nucleotides with AF-dG, AAF-dG containing oligonucleotides and 
lesion-free oligonucleotides (200 nM Pol κ, 1 μM template DNA, 200 μM of each deoxynucleotide or all 
four dNTPs). A) Sequence used in this study (ODN 1); B) PAA-gel of the primer extension experiment;  
M: marker; Lanes 1, 6 and 11: all four dNTPs; Lanes 2, 7 and 12: dATP; Lanes 3, 8 and 13: dTTP; 
Lanes 4, 9 and 14: dGTP; Lanes 5, 10 and 15: dCTP. AF-dG containing DNA was used in lanes 6-10 
and AAF-dG containing templates in lanes 11-15.  
First of all, the relatively low fidelity of Pol κ on undamaged template DNA is obvious 
(Figure 67, lanes 2-5). Misincorporation of dA, dT and dG opposite a dG in the template 
strand occurs, if there is no other nucleotide present. For AF-dG and AAF-dG containing 
oligonucleotides, dC is well incorporated opposite the lesion. However, dA and dG are also 
inserted opposite the lesions with high efficiency. Misincorporation of dT opposite the AF-dG 
occurs to some extent as well. At these polymerase concentrations (200 nM), Pol κ is not able 
to bypass the AF-dG and AAF-dG lesions. Thus, Pol κ is able to insert nucleotides opposite 
both lesions and also to extent from the AAF-dG at higher enzyme concentrations (Figure 66). 
The polymerase does not possess the high selectivity for the incorporation of dCTP opposite 
the AAF-dG lesion found using Pol η.  
Pol κ was now tested with a variety of bulky adduct lesions. For this, 500 nM Pol κ were used 
at 37 °C and 30 min reaction time (Figure 68).   
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Figure 68. Translesion synthesis of different bulky dG DNA adducts catalyzed by Pol κL. The primer 
extension reactions were carried out with fluorescence labeled primers and extension products were 
resolved on a denaturing PAA-gel. A) and B) Sequence contexts used for the primer extension 
studies. C) PAA-gel of the bypass reaction of various bulky adducts. Reaction conditions are: 500 nM 
Pol κ, 1 μM template DNA, 200 μM dNTPs each. The different sequences A and B are marked with a 
(red) and b (green). 1a: AAB-dG (ODN 21), 2: AAN-dG (ODN 24), 3a: AF-dG (deacetylated ODN 1), 
4a: AAF-dG (ODN 1), 4b: AAF-dG (ODN 2), 5a: AAA-dG (ODN 27), 5b: AAA-dG (ODN 28), 6a: AAP-
dG (ODN 30), 6b: AAP-dG (ODN 31) 7a: Undamaged template strand (A), m = marker. 
Pol κ is able to bypass all bulky lesions except the huge pyrene dG adduct (Figure 68). TLS 
efficiency is reduced if the size of the aromatic adduct is increased. Whereas bypass is 
surprisingly efficient for the small benzene and naphthalene units, bypass is nearly impossible 
when the benzene was replaced by the large pyrene unit. Moreover, during bypass of AAF-dG 
and AAF-dG in the NarI frameshift sequence (marked with “a” in Figure 68), additional 
shorter extension products are observed, possibly due to the occurrence of frameshifts. 
However, no clear –II frameshift product can be found as in the case of Pol η bypassing AAF-
dG or AAA-dG the NarI sequence. Instead, truncated products from incorporation of one to 
six nucleotides were observed. Possibly, Pol κ does bypass lesions in such repetitive 
sequences by a frameshift mechanism, but the generated frameshift mutations are not as 
sequence specific as in the case of Pol η. The extension of the primer stopped in all cases one 
nucleotide before full extension (19 nt). Only for undamaged template DNA, some fully 
extended product could be found. This observation was made before in in vitro bypass studies 
of DNA lesions by Pol κ.[96] In vitro, complete extension of primers is difficult for Pol κ and 
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only achieved at high enzyme concentrations. Mostly, Pol κ dissociates from the template 
DNA without incorporating the last nucleotide.   
In summary, Pol κ is, like Pol η, able to bypass the C8 bulky DNA adducts synthesized in this 
thesis work. However, bypass seems to be more error-prone. The incorporation of nucleotides 
opposite the AAF-dG lesion is less selective.  
 
7.2.3 Preliminary crystallization screens with C8-dG containing oligonuclotides 
and the low fidelity polymerase κ 
 
In order to clarify the bypass mechanism of bulky DNA adducts, first crystallization 
experiments with Pol κ and AAF-dG containing oligonucleotides were performed. Pol κL was   
chosen for these experiments, because this Pol κ version is able to bypass the lesion whereas 
the shorter version (Pol κS) is blocked (see section 7.2.2). Crystallization of the polymerase 
containing the complete N-terminal part would be significant because the  encirclement of the 
DNA by its unique “N-clasp” at the N-terminus could further be studied.[162] Thus, Pol κL was 
incubated with double stranded DNA containing the template with the AAF-dG lesion 
annealed to primer with a 2’,3’-dideoxybase at the 3' end in a 1 to 2 molar ratio in 
crystallization buffer for co-crystallization. First, a screening with a 16mer AAF-dG strand 
(ODN 3), 5 mg/ml Pol κ and addition of dCTP was performed using commercial available 
screening kits from Qiagen. A second screening was performed with a 18mer AAF-dG strand 
(ODN 17), higher enzyme concentrations (11 mg/ml) and again addition of dCTP using 
commercial available screening kits from Hampton. This work was done at the Oxford 
Protein Production Facility in Oxford, UK. The DNA sequence containing the AAF-dG 
(ODN 17) was designed according to the sequence used for crystallization of undamaged 
DNA in complex with Pol κ.[162]  Additionally, a manual screening using the same DNA 
sequence was carried out in 24 well format using conditions previously published for the Pol 
κ in complex with undamaged DNA.[162] No diffracting crystals could be obtained so far.  
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8 Co-crystallization of AAF-dG containing oligonucleotides with the 
NER proteins Rad14 from yeast and its human homologue XPA 
 
In addition to translesion synthesis, bulky DNA adduct lesions are usually repaired by the 
nucleotide excision repair pathway (NER).[124-126] The mechanism how the repair system is 
able to recognize a variety of lesions is unclear and, as discussed in section 3.6, several 
models are proposed for the initial lesion recognition step. It has been shown that the NER 
protein Rad14 from yeast and its human homologue XPA bind DNA containing bulky DNA 
adducts such as AAF-dG.[139] To date, only a solution structure of the minimal DNA binding 
domain of XPA is available, but no structural data of the lesion recognition. In order to shed 
light on the mechanism of lesion recognition by these NER proteins, co-crystallization 
experiments of Rad14 and XPA with AAF-dG containing oligonucleotides were performed.  
 
8.1 Purification of Rad14 and XPA 
 
A plasmid containing the DNA sequence coding for the DNA binding domain of yeast Rad14 
from S. cerevisiae (residues 185-306) was cloned and transformed into E. coli BL21 in frame 
with a C-terminal Strep-tag by Dr. Ralf Strasser. A plasmid containing the DNA binding 
domain of the human XPA protein (residues 98-219) was prepared analogous by Sandra 
Koch. The expression and purification protocol was also established by Dr. Ralf Strasser.[139]  
Initially, both proteins were purified using a Strep-Tactin column, which was followed by ion 
exchange chromatography using a MonoQ anion exchange column (GE) for Rad14 and a 
Heparin affinity column for XPA. In order to solve the phase problem inherent to 
macromolecular crystallography, selenomethionine labeled protein was also prepared. To this 
end, the plasmids were transformed into a methionine auxotrophic E. coli strain and 
expression was carried out in a selenomethionine-containing medium. Purification of the 
proteins was performed analogous to the non-labeled proteins with degassed buffers and in 
the presence of DTT as reduction agent. In Figure 69, SDS-gels of the purified 
selenomethionine labeled Rad14 and XPA proteins as well as the UV chromatograms of their 
final purification steps are displayed.  
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Figure 69. Purification of selenomethionine labeled yeast Rad14 and human XPA 
A) SDS-PAGE of Rad14 (14.2 kDa + 1.25 kDa Strep-tag): 1: Protein marker; 2: Rad14 after Strep-tag 
purification; 3: Flow through of the MonoQ anion exchange column; 4: Second peak of the MonoQ 
anion exchange purification at 19 mL elution volume (see UV-chromatogram in B) The additional band 
at around 90 kDa might be a multimeric complex of the protein. 5: Rad14 after MonoQ anion exchange 
purification (at 15 mL elution volume, see UV-chromatogram in B) B) Chromatogram of the MonoQ 
anion exchange purification of Rad14. The red curve corresponds to absorption at 254 nm (DNA 
contamination), the blue line at 280 nm. The green line marks the NaCl-gradient for elution of the 
protein.  
C) SDS-PAGE of XPA (14.6 kDa + 1.25 kDa Strep-tag): 6: XPA after Strep-tag purification; 7: Flow 
through of the heparin affinity column; 8: XPA after heparin affinity purification D) Chromatogram of the 
Heparin affinity purification of XPA. The red curve corresponds to absorption at 254 nm, the blue line 
at 280 nm. The green line marks the NaCl-gradient for elution of the protein. 
 
8.2 Crystallization of Rad14/XPA in complex with an AAF-dG containing 
DNA duplex 
 
Initial crystallization experiments with the DNA binding domain of Rad14 were made 
together with Dr. Ralf Strasser. The first Rad14 crystals in complex with AAF-dG containing 
DNA were obtained with 2.8- 3.3 M ammonium sulfate in 0.08 – 0.11 M Tris pH 8 buffer. 
They diffracted X-rays to 7 Å spacing.[139]  
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Screening for new crystallization conditions was performed as described in section 10.5. 
Therefore, ODN 16 containing an AAF-dG lesion (5'-GCTCTACGAAFTCATCAC-3') was 
annealed to its counter strand and incubated with the either the purified Rad14 or XPA 
protein. Initial high-throughput crystallization screening with the unlabeled proteins was 
carried out using commercial available screening buffers from Qiagen and robotics. For 
Rad14, an initial hit was obtained with a sodium cacodylate buffer at pH 6.5 and calcium 
acetate/PEG 8000. These conditions were manually optimized by varying the protein 
concentration, concentration of the components of the crystallization buffer and drop size in 
24 well formats resulting in larger, but thin crystal plates (Figure 70, A).  
For XPA, an initial hit was obtained with PEG 3350 / MgSO4 (Figure 70 A). Conditions were 
also refined in 24 well formats, however only very small crystals were obtained (Figure 70 B) 
which could not be measured. The two crystals shown in Figure 70 A were frozen in artificial 
mother liquor containing ethylene glycol as cryoprotectant but did not diffract X-rays at a 
synchrotron radiation source (PX I, Swiss Light Source (SLS), Switzerland).  
 
Figure 70. Crystallization of Rad14 and XPA in complex with AAF-dG containing DNA. A) Crystals 
obtained in high-troughput screening experiment with XPA in complex with AAF-dG containing DNA 
(drop size 100 nL + 100 nL). B) Crystals obtained with XPA and AAF-dG containing DNA after 
optimization of the initial screening conditions (1 µL + 1 µL drop size). C) Crystals obtained with Rad14 
and AAF-dG containing DNA after optimization of the initial screening conditions. 
The Rad14/AAF-dG complex crystals (Figure 70 C) were transferred to a cryoprotectant of 
artificial mother liquor containing ethylene glycol prior to flash freezing. Data collection was 
carried out at the microfocus beamline ID23-2 at the European Synchrotron Radiation Facility 
(ESRF, France). Due to the plate like morphology of the crystals, very anisotropic diffraction 
was observed, ranging from 3 to 4.5 Å.  Indexing of the data revealed that the crystals belong 
to the orthorhombic space group C2221 with a unit cell of a=54.1 Å, b=154.2 Å, c= 99.3 Å, 
α=β=γ=90°. By collecting data over the whole area of the crystal, a complete data set with a 
resolution of 3.2 Å was obtained.  
 
 
 
                 8. Co-crystallization of AAF-dG containing oligonucleotides with Rad14 and XPA  
 
73 
 
8.3 Phase determination for structure solution of the Rad14 crystals 
 
In order to determine the structure of the Rad14/AAF-dG complex, two different approaches 
were chosen to obtain experimental phase information by carrying out a SAD experiment.  
Thus, on the one side, all three dT’s in the counter strand were replaced by 5-Bromo-
deoxyuridine (5-Br-dU) instead of dT. One the other side, selenomethionine labeled Rad14 
was used for crystallization together with the same DNA duplex used for production of the 
native crystals. Crystals were obtained with conditions similar to conditions used for the 
native Rad14 crystals. However, the crystals were again plate-shaped and even slightly 
smaller in size compared to the native crystals (Figure 71). 
 
Figure 71. Crystals of selenomethionine labeled Rad14 in complex with AAF-dG containing DNA. 
A) and B) Crystals obtained with selenomethionine labeled Rad14 at conditions similar to the 
conditions used for the native crystals (drop size 1 µL + 1 µL). C) Crystals obtained with 
selenomethionine labeled Rad14 and AAF-dG containing DNA in a new crystallization screening 
testing different buffer conditions (drop size 100 nL + 100 nL). 
The 5-Br-dU containing crystals diffracted X-rays to 3.5 Å spacing but no complete data set 
could be obtained due to radiation damage during the measurement. High beam intensities 
had to be used to get sufficient diffraction, which caused severe damages to the crystal. The 
space group was found to be identical to the native crystals. Nevertheless, an X-ray 
fluorescence scan at the Br-edge confirmed successful co-crystallization of Rad14 with the 
DNA duplex. 
Selenomethionine-labeled Rad14 crystals were again plate-shaped and varied in size 
depending on the screening conditions. Unfortunately the crystals continuously grew properly 
into two dimensions, but not in the third dimension (Figure 71, A and B). Micro- and macro-
seeding was performed in order to get thicker crystals but the crystal shape did not improve 
significantly.  
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Figure 72. Diffraction images of A) a native Rad14 crystal and B) a selenomethionine labeled Rad14 
crystal in complex with an AAF-dG containing DNA duplex taken at the microfocus beamline ID23-2 at 
the ESRF (France) and the PXI beam line at the SLS (Switzerland). In both images, high anisotropy of 
the crystals can be observed. 
A further problem arose from the cacodylate buffer used in the crystallization setup of the 
selenomethionine labeled Rad14/AAF-dG complex. Arsenic in the buffer solution has a 
theoretical absorption edge of 11.87 eV. This absorption edge is very close to the Se-edge 
with a theoretical value of 12.66 eV, thus interfering with the measurement. Therefore, a 
buffer screening at constant calcium acetate and PEG 8000 concentrations was performed and 
Rad14 crystals with Tris buffer at pH 7 could be obtained (Figure 71, C). These conditions 
were again optimized in 24 well formats. Slightly larger and thicker crystal plates were 
obtained compared to the initial crystals.  
The peak and inflection points of the anomalous scatterers were determined by an X-ray 
fluorescence scan around the respect resonance edge (Figure 73 and Figure 74).  
 
Figure 73. X-ray fluorescence scan near the bromine K - absorption edge of the 5-Br-dU containing 
Rad14 crystals. The inflection point is at 13472 eV with the anomalous scattering factors f' = 8.78 and 
f'' = 1.98. The peak is at 13483 eV with f' = 6.33 and f'' = 4.36.  
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Figure 74.  X-ray fluorescence scan near the selenium K - absorption edge of the selenomethionine 
labeled Rad14 crystals. The inflection point is at 12654 eV with the anomalous scattering factors f' = 
9.89 and f'' = 3.71. The peak is at 12655 eV with f' = 8.00 and f'' = 5.92. 
Several data sets were taken at the Se absorption edge showing that the protein crystallized in 
a different space group. The crystals were monoclinic. Again the derivatized complex crystals 
diffracted anisotropically and were very sensitive to radiation damage (Figure 72). Due to the 
lack of redundancy, radiation damage and the anomalous signal only extending to 4.5 - 5 Å in 
5-Br-dU and selenomethionine containing Rad14 crystals, structure solution so far remains 
elusive.   
8.4 Discussion 
 
The mechanism of lesion recognition in the NER pathway is still not well understood. It has 
been shown that the yeast Rad14 and its human homologue XPA bind specifically to DNA 
strands containing bulky adducts.[139] Here, the minimal DNA binding domains were 
overexpressed, purified and crystallized in complex with AAF-dG containing DNA. 
Diffracting crystals of Rad14 could be obtained and some phase information was derived 
from SAD experiments using complex crystals with 5-Br-dU containing DNA or 
selenomethionine labeled protein. Nevertheless, due to the anisotropic nature of the 
diffraction and the sensitivity to radiation damage, structure solution remained elusive. Thus, 
further screening by varying the DNA strands is necessary to obtain better quality crystals and 
so to be able to solve the structures of these so important proteins in order to shed light on 
their mechanism of action.  
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9 Conclusion and outlook 
 
Aromatic amines are known to be strong carcinogens forming DNA adducts after metabolic 
activation. Preferred reaction sides are the amino groups of adenine and guanine and 
particularly the C8-position of guanine. [16, 17] The latter reaction gives rise to the so called C8-
bulky adduct lesions, which interfere with the replication process leading to mutations. Two 
types of aromatic amine lesions are known. The non-acetylated lesions reduce the replication 
efficiency, but are in general faithfully bypassed by high fidelity polymerases.[51, 120] In 
contrast, the N8-acetylated derivatives block replicative polymerases but can be bypassed with 
special low-fidelity polymerases.[52-54] The low fidelity Y-family polymerase η plays a 
major role in the replication through acetylated aromatic amine lesion such as AAF-dG 
in vivo.[56, 57, 60]  
In this thesis work, lesions derived from aminofluorene (AAF-dG) and aminoanthracene 
(AAA-dG) served as model compounds to investigate the mechanism of the error-free bypass 
by Pol η. Crystal structures of Pol η in complex with oligonucleotides containing either the 
AAF-dG or the AAA-dG lesion show why the polymerase is blocked if it encounters the 
lesion but they also allow to construct a model that explains how Pol η finally achieves the 
bypass (section 7.1.2). Based on the crystal structure, correct bypass is achieved by the 
enzyme through rotation of the DNA around the bulky moiety while keeping the damaged dG 
in syn-conformation. Thus, TLS is accomplished without rotation of the lesion into the anti-
conformation as previously thought.[123] In this situation, correct dCTP incorporation opposite 
the lesion can be envisioned by formation of one hydrogen bond between the dCTP and the 
lesion (Figure 75).  
 
Figure 75. Model of the AAA-dG bypass by Pol η. The dG:dC basepair 3' of the lesion in the AAA-dG-
Pol η complex B was replaced by the AAA-dG adduct and the dCTP triphosphate. The dCTP was 
placed in the active site according to the structure of Pol η in complex with the cisplatin GG lesion 
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(PDB code 2R8J). Thus the active site for the incoming dCTP opens, which forms one critical 
hydrogen bond to the adducted nucleobase in syn conformation. 
The model was further supported by biochemical studies using synthetic zebularine 
triphosphate which is not incorporated opposite the AAF-dG lesion due to the lacking ability 
to form the critical hydrogen bond. Moreover, TLS efficiency of Pol η depends critically on 
the size of the bulky adduct forming the lesion.  
Future work could include additional crystallization screening of Pol η in complex with 
various AAF-dG oligonucleotides of different length. Perhaps, dCTP incorporation could then 
be observed crystallographically and the model of the bypass could be confirmed. Recently, it 
was proposed that the crystallization ability of Pol η – DNA adducts is improved by site-
directed mutagenesis of amino acid residues involved in crystal contacts.[88] In this crystal 
structure, the PAD domain of the protein closes, however, no structural changes occur in the 
active site. Crystallization with this mutated Pol η could result in more stable protein-DNA 
complexes, thus facilitating crystal growth.  
Another part of this thesis work involved the investigation of frameshift mutations. Bulky 
adduct DNA lesions such as AAF-dG lesion induce frameshift mutations if they are placed in 
special gene sequences.[16, 53, 61-64] With the help of synthetic AAF-dG lesions inserted into 
different repetitive frameshift prone sequences, the molecular basis of the frameshifting event 
was determined (section 7.1.4). It could be shown that frameshifting requires DNA 
polymerase induced primer-slippage followed by primer misalignment and extension of the 
misaligned primer-template complex. The mechanisms of -I, -II and –III frameshifts were 
deciphered. An example (-III frameshift) is shown in Figure 76. 
 
Figure 76. Slippage process leading to a –III frameshift during bypass of the AAF-dG lesion by Pol η. 
The polymerase first extends the primer with a dC base inserted opposite the lesion. After this, a 
substantial fraction of the primer misaligns to pair with the alternative dG in the template two bases 
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further away. MALDI-Tof mass spectrometry analysis proved the formation of a bulge consisting of 
three bases. 
However, crystallization of Pol η in complex with an AAF-dG containing, misaligned 
primer/template construct forming a bulge was not successful so far (section 7.1.4.2). 
Possibly, crystallization tendency will be improved when the mutated Pol η mentioned above 
is used. 
Moreover, the catalytic core of human Pol κ was cloned, overexpressed and purified for 
primer extension studies in this thesis work (section 7.2). It could be shown, that Pol κ is, like 
Pol η, able to bypass the synthesized C8 bulky DNA adducts. However, bypass seems to be 
more error-prone for Pol κ, the incorporation of nucleotides opposite the AAF-dG lesion is 
not selective. First crystallization screenings were performed with Pol κ in complex with an 
AAF-dG oligonucleotide. No diffracting crystals were obtained so far. Further experiments 
could involve screening with AAF-dG oligonucleotides with different lengths. Moreover, 
other truncated Pol κ versions could be prepared, for example from residues 19 to 526. This 
enzyme was recently used for crystallization in complex with 8-oxo-dG containing DNA.[163] 
Possibly, shortening of the flexible N-terminus could also facilitate crystallization with AAF-
dG containing oligonucleotides.  
This thesis work also includes crystallization of the yeast NER protein Rad14 and its human 
homologue XPA together with AAF-dG containing oligonucleotides (section 8). The 
mechanism of lesion recognition in the NER pathway is still not well understood. It has been 
shown that the Rad14 and XPA bind specifically to DNA strands containing bulky 
adducts.[139] In this thesis, the minimal DNA binding domains were overexpressed, purified 
and crystallized in complex with AAF-dG containing DNA. Diffracting crystals of Rad14 
could be obtained and some phase information was derived from SAD experiments using 
complex crystals with 5-Br-dU containing DNA or selenomethionine labeled protein. 
However, structure solution was not successful so far due to anisotropic diffraction and 
radiation damage. Future work could involve further screening varying the DNA strands to 
obtain better quality crystals and so to be able to solve the structures. 
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10 Experimental  
 
10.1 General chemical materials an methods 
 
Chemicals and solvents were used as commercial available in the qualities puriss., p.a. or 
purum and purchased from the companies Fluka, Acros, Aldrich, ABCR or Sigma. Bidestilled 
water was produced by a Milli-Q Plus unit (Millipore). Dry solvents (< 50 ppm H2O) were 
purchased from Fluka, Acros or Aldrich, solvents for extraction and chromatography had 
technical grade and were distilled before usage. All reactions employing dry solvents were 
performed under inert atmosphere (N2). Technical grade solvents were distilled prior to use 
for column chromatography using a Laborota 4001-efficient rotary evaporator (Heidolph) 
which was equipped with a Vario PC2001 membrane pump (Vacuubrand). A RZ-4 oil pump 
(Vacuubrand) was used for further drying of substances (final vacuum 10-2-10-3 mbar).  
Small amounts of aqueous and buffer containing solutions were removed by a SpeedVac Plus 
SC110A and SpeedVac SPD 111V (Savant) or a RVC 2-25 and RVC 2-33 IR (Christ) all 
equipped with a CT 62-50-cooling trap (Christ). An Alpha 2-4 plus lyophille (Christ) was 
used for the lyophillisation of aqueous solutions. Molecular sieve was washed with water 
prior to use, pre-dried in a cabinet-drier and further dried under high vacuum in a sand bath 
(350 °C) for 12 h.  
 
Column chromatography was performed with silica gel 60 from Merck.  
 
Thin layer chromatography (TLC) was performed with aluminum plates (silica gel 60 F254, 
10 × 5 cm). Substances were visualized by illumination with UV-light (λ = 254 nm, 365 nm) 
or by staining with subsequent heating. The staining was performed using anisaldehyde 
solution (2.2 g anisaldehyde, 2.0 mL conc. H2SO4, in 100 mL acetic acid). 
 
HPL-Chromatography was performed on a Merck-Hitachi system or on a Waters system. In 
detail, the systems contain the following units: Merckanalytical: L-7400 UV detector, L-7480 
fluorescence detector, L-7100 pump;  Merckpreparative: L-7150 pump, Rheodyne P/N 77 25i 
injection valve, L-7420 UV-Vis, ERC-3415 solvent degasser; Watersanalytical: alliance 2695 
Separation Module with PDA 2996 or 996 Diode Array detector and fluorescence detector 
2475); Waterspreparative: 1525 HPLC Pump, 2487 Dual Wavelength UV Detector. CC 250/4 
Nucleosil 120-3 C18- and VP 250/4 Nucleodur 100-3 C18 ec-columns (Macherey-Nagel) 
were used for analytical reversed-phase separations. VP 250/10 Nucleodur 100-5 C18 ec- und 
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VP 250/10 Nucleosil 100-7 C18-columns were used for preparative separations. For 
enzymatic digests, a MS Uptisphere 3HDO #15MS (150 x 2.0 mm) column from  Interchim 
was used.  
 
Mass spectrometry data for ESI-MS were collected on a Finnigan LTQ FTICR (Thermo 
Finnigan, Bremen) and on a Thermo Finnigan LTQ Orbitrap XL (Thermo Scientific). 
MALDI-Tof was performed on a Bruker Autoflex II spectrometer with 6-aza-2-thiothymine 
(ATT) or 3-hydroxypicolinic acid (HPA) as matrix (see section 10.3.5, Solutions) and a MTP 
AnchorChipTM var/384 (Bruker) as target. Salt-containing samples were desalted by dialysis 
on MF-Millipore™ membrane filters (pore size 0.025 µm) or by Zip-Tips C18 (Millipore). 
 
HPLC-MS High resolution mass spectra of digested oligonucleotides (section 10.2.6) were 
recorded on a Finnigan LTQ FTICR and on a Thermo Finnigan LTQ Orbitrap XL.  
Resolution was set to 100000 at m/z = 400. The mass range was set to 2000 mass units. A 
voltage of 3 kV and a temperature of 300°C were applied to the spray capillary. The HPLC 
system was operated with a flow of 150 µl/min. Detailed information to the columns and 
buffers used can be found in section 10.1 and 10.3.1. The mass values of the detected ions in 
correlation to their ion charge are indicated as m/z and the relative signal intensities are stated 
in percent referring to the maximum signal.  
 
Melting points were measured with a Büchi Melting Point B-540. 
 
Infrared spectroscopy was performed on a Perkin Elmer Spectrum BX FT-IR-System. The 
detection ranged from 400 to 4000 cm-1. The following abbreviations were used for the 
characterization of the bands: s (strong), m (medium), w (weak), br (broad). 
 
NMR spectra were recorded on the following spectrometers: Varian Oxford 200, Bruker AC 
300, Varian XL 400 and Bruker AMX 600. The chemical shifts (δ) are given in ppm. Coupling 
constants (J) are given in Hz, correspond to the observed frequency differences and were not 
corrected in non first order situations.  
 
Extinction coefficients of the oligonucleotides at 260 nm were calculated by addition of the 
extinction coefficients of the individual nucleobases. These are dA 15.0 L/mmol⋅cm, dC 7.1 
L/mmol⋅cm, dG 12.0 L/mmol⋅cm and dT 8.4 L/mmol⋅cm. For the bulky dG adducts, the dG 
value was used.  
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10.2  Oligonucleotide synthesis and characterization 
 
10.2.1  Automated DNA synthesis 
 
DNA oligonucleotides were synthesized on a PerSeptive Biosystems Expedite 8900 
Synthesizer and an Äkta Oligopilot 10 (GE) using ultramild bases and reagents and following 
standard phosphoramidite protocols (10 equivalents of phosphoramidite (0.1 M), 4 min 
recycling time and 1-2 μmol scale synthesis). The phosphoramidite amounts for the bulky 
adduct dG lesions were equal to those of the standard bases but coupling times were elongated 
to 10 minutes. Ultramild protected phosphoramidites were used with the following protecting 
groups:  
dC: N-acetyl (Ac-dC) 
dA: N-Phenoxyacetyl (Pac-dA) 
dG: N-isopropylphenoxyacetyl (iPrPac-dG) 
dT: no protection group necessary 
 
The ultramild Q-CPG-linker (controlled pore glass, preloaded with Ac-dG or iPrPAC-dG) as 
solid support was purchased from Glen Research. Phosphoramidites and the activator were 
solved in acetonitrile from Riedel de Haen (H2O < 10 ppm). All other reagents were prepared 
using HPLC grade acetonitrile from Roth. The reagents were dried over 3 Å molecular sieve 
for 12 h prior to synthesis. The following solutions were used for deblocking, capping and 
oxidation:  
Deblocking: 3 % dichloroacetic acid in toluene 
Cap A: 0.5 M phenoxyacetic anhydride‡ in MeCN/2,6-lutidine 9:1 
Cap B: 20 % N-methylimidazole in MeCN 
Oxidation: 0.025 M iodine in 2,6-lutidine/MeCN/ddH2O 6:65:30 
Activator: 0.25 M 5-benzylthiotetrazole (BTT) in MeCN 
 
In most cases, the terminal 5'-DMT group was removed after the synthesis. Only for long 
DNA strands (30mer oligonucleotides), the 5'-DMT group was kept to facilitate HPLC 
purification.  
 
 
                                                 
‡ for synthesis see section 10.7.13 
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Deprotection of the oligonucleotides and cleavage from the solid support were carried out 
under mild alkaline conditions adding β-mercapthoethanol to prevent the AAF-dG from being 
oxidized.[148, 151] In detail, deprotection was achieved with 10 % diisopropylamine and 0.25 M 
β-mercapthoethanol in methanol at 55 °C for 12 h. The solvents were removed in a SpeedVac 
concentrator and the resulting pellet was dissolved in ddH2O. The sample was shortly 
centrifuged and the supernatant was transferred to a fresh tube. Subsequent filtration through 
a 0.2 μm filter removed residual CPG before to HPLC purification.  
Lesion free oligonucleotides as well as 3’ddC or 5-Br-dU containing oligonucleotides were 
purchased RP-HPLC purified and lyophilized from Metabion (Martinsried). 
 
 
10.2.2 Purification of bulky adduct containing oligonucleotides 
 
Analytics and purification were performed on Merck and Waters HPLC systems using 
reversed-phase Nucleosil or Nucleodur C18 columns (Macherey-Nagel, section 10.1). As 
buffer system, 0.1 M triethylammonium acetate in ddH2O (buffer A) and 0.1 M 
triethylammonium acetate in 80 % MeCN (buffer B) were used. A gradient of 0-40 % buffer 
B over 45 min was used for separation of synthesized 15 to 30mer bulky adduct containing 
oligonucleotides. The preparative Waters HPLC system allowed monitoring a second 
wavelength during purification. The aromatic adduct containing oligonucleotides were 
detected at wavelengths between 300 and 350 nm depending on the aromatic unit attached. 
The HPLC fractions were lyophilized and analyzed by MALDI-Tof and analytical HPL-
chromatography. The fractions containing the pure oligonucleotide were dissolved in 1 ml 
ddH2O, desalted on Waters Sep-Pak® C18 cartridges and lyophilized again. If the terminal 
5'-DMT-group was kept for easier HPLC purification, the DMT group was cleaved with TFA 
during the desalting process on the Sep-Pak®. Therefore, a 1.5 % TFA solution was flushed 
through the column with the bound oligonucleotides for 30 s and was afterward directly 
neutralized with HPLC buffer A. Then, the standard Sep-Pak® protocol was continued. The 
oligonucleotides were stored lyophilized at -20 °C prior to usage.  
An overview about the synthesized oligonucleotides containing different bulky DNA lesions 
is found in Table 3.  
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ODN description lesion sequence length m/zcalc m/zfound
1 AAF-PE1 AAF 5’-CGT GGC G*CC ATC GCG AGG TC-3’ 20mer 6356.3 6351.0 
2 AAF-PE2 AAF 5’-CGT GAT G*CC ATC GCG AGG TC-3’ 20mer 6355.3 6350.9 
3 AAF-C1 AAF 5’-TCT CTC G*CT CAT CCAC-3’ 16mer 4949.4 4949.8 
4 AAF-C2 AAF 5’-TCT TCT CG*C TCA CCAC-3’ 16mer 4949.4 4949.2 
5 Liv1 AAF  5’-CCT CG*G CGC CTC-3’ 12mer 3777.6 3780.8 
6 Liv2 AAF 5’-TCT CTA G*AC CTC-3’ 12mer 3775.6 3776.0 
7 Liv3 AAF 5’-GTG ATT CCG GCA G*GC GTG CGA CCT 
GGC TAC-3’ 
30mer 9456.6 9451.8 
8 FS1 AAF 5’-CTC TGG CG*C CTC ACA C-3’ 16mer 4999.3 5001.0 
9 AS1 AAF 5’-GAC GTC TCG* CTC ATC C-3’ 16mer 5014.3 5015.8 
10 FS15mer AAF 5’-CTC TGG CG*C CTC ACC-3’ 15mer 4686.1 4686.1 
11 AS17mer AAF 5’-GAC GTC TCG* CTC ATC AC-3’ 17mer 5327.5 5327.5 
12 FS17mer AAF 5’-CTC TGG CG*C CTC ACA CC-3’ 17mer 5288.4 5287.4 
13 Mod2 AAF 5’-CGT GGT G*CC ATC GCG AGG TC-3’ 20mer 6371.1 6674.6 
14 Mod1 AAF 5’-CGT GGC G*TC ATC GCG AGG TC-3’ 20mer 6371.1 6373.3 
15 Mod3 AAF 5’-CGT GAC G*CC ATC GCG AGG TC-3’ 20mer 6340.1 6342.5 
16 ella1 AAF 5’-GCT CTA CG*T CAT CAC-3’ 15mer 4709.1 4707.4 
17 ella2 AAF 5’-CCT AG*GAGT CCT TCC CCC-3’ 18mer 5592.6 5589.7 
18 G_runs AAF  5’-CGT GGG G*GG ATC GCG AGG TC-3’ 20mer 6476.1 6474.3 
19 XCT AAF 5’-CGT GGC G*CT ATC GCG AGG TC-3’ 20mer 6371.1 6371.9 
20 C_runs AAF 5’-CGT CCC G*CC ATC GCG AGG TC-3’ 20mer 6276.0 6271.4 
21 AAB-PE1 AAB 5’-CGT GGC G*CC ATC GCG AGG TC-3’ 20mer 6267.9 6267.8 
22 AAB-PE2 AAB 5’-CGT GAT G*CC ATC GCG AGG TC-3’ 20mer 6268.9 6266.1 
23 AAB-C1 AAB 5’-TCT CTC G*CT CAT CCAC-3’ 16mer 4861.0 4860.5 
24 AAN-PE1 AAN 5’-CGT GGC G*CC ATC GCG AGG TC-3’ 20mer 6317.7 6316.4 
25 AAN-PE2 AAN 5’-CGT GAT G*CC ATC GCG AGG TC-3’ 20mer 6318.7 6317.6 
26 AAN-C1 AAN 5’-TCT CTC G*CT CAT CCAC-3’ 16mer 4911.1 4908.9 
27 AAA-PE1 AAA 5’-CGT GGC G*CC ATC GCG AGG TC-3’ 20mer 6368.1 6367.7 
28 AAA-PE2 AAA 5’-CGT GAT G*CC ATC GCG AGG TC-3’ 20mer 6367.1 6366.5 
29 AAA-C1 AAA 5’-TCT CTC G*CT CAT CCAC-3’ 16mer 4964.8 4964.9 
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30 AAP-PE1 AAP 5’-CGT GGC G*CC ATC GCG AGG TC-3’ 20mer 6391.9 6391.3 
31 AAP-PE2 AAP 5’-CGT GAT G*CC ATC GCG AGG TC-3’ 20mer 6390.9 6390.5 
32 AAP-C1 AAP 5’-TCT CTC G*CT CAT CCAC-3’ 16mer 4987.3 4984.3 
33 AAP-C15G AAP 5’-TCT CTC G*GT CAC CAC-3’ 15mer 4968.7 4723.6 
Table 3. Sequence and MALDI-Tof mass values of the synthesized oligonucleotides.  
AAB, AAN, AAF, AAA and AAP represent the corresponding C8-dG lesions: AAB-dG = N-(2’-
deoxyguanosin-8-yl)-acetylaminobenzol, AAN-dG = N-(2’-deoxyguanosin-8-yl)-2-acetyl-amino-
naphthalene, AAF-dG: N-(2’ -deoxyguanosin-8-yl)-2-acetylaminofluorene, AAA-dG = N-(2’-deoxy-
guanosin-8-yl)-2-acetylaminoanthracene, AAP-dG: N-(2’-deoxyguanosin-8-yl)-1-acetylaminopyrene. 
The strands can be found in the laboratory journal with the label of the column “description”. 
 
10.2.3  Preparation of AF-dG containing oligonucleotides 
 
AF-dG containing oligonucleotides were prepared by incubating AAF-dG containing 
oligonucleotides with 1 M NaOH solution containing 0.25 M β-mercaptoethanol for 3 h at 
37 °C according to a published procedure[151] followed by HPLC purification. 
 
10.2.4  DNA Quantification 
 
DNA concentration was determined using a Nanodrop UV-spectrometer ND-1000 (Peqlab). 
The concentration of nucleic acids was calculated as follows: 
1.0 A260-unit = 50 ng · µL-1 dsDNA = 33 ng · µL-1 ssDNA = 40 ng · µL-1 RNA 
For chemically synthesized oligonucleotides, the DNA concentration was calculated using the 
corresponding extinction coefficient for the oligonucleotide measured and its A260 absorption. 
In detail, 1.5 µL of the sample was pipetted directly onto the pedestal without previous 
dilution. The 260/280 nm ratio should be between 1.8 and 2.0 for uncontaminated DNA 
preparations.  
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10.2.5  Melting point measurements 
 
Melting profiles were measured on a Cary 100 UV-Vis and Jasco V-650 spectrophotometer 
using quartz glass cuvettes with 1 cm path length. Samples were prepared as shown in 
Table 4.  
1 µM (lesion containing) oligonucleotide 
1 µM complementary strand  
150 mM NaCl  
10 mM Tris pH 7.4  
935 µL ddH2O (total volume 1 mL) 
Table 4. Pipetting scheme for melting point measurements of DNA duplexes 
The samples were covered with 2 mm of dimethylpolysiloxane and tightly plugged. The 
measurements were repeated several times with independent sample preparations. First, the 
oligonucleotides were hybridized by slowly cooling the samples down from 85 °C to 0 °C. 
The melting profiles started with a denaturing run (0 °C to 85 °C) with a slope of 0.5 °C/min. 
At least two denaturing and two renaturing ramps were performed and averaged for 
evaluation of the melting point. (TM = zero-crossing of second derivative of the 450 nm-
background corrected change in hyperchromicity at 260 nm). For analysis of the data, the 
program Origin (Microcal) was used.  
 
10.2.6  Enzymatic DNA digestion 
 
To characterize DNA strands containing a bulky DNA lesion, the oligonucleotides were 
enzymatically digested and the digest products were analyzed via HPLC-MS. 1 nmol of DNA 
was dissolved in 50 µl 1x digest buffer (20 mM Tris, 10 mM MgCl2, 0.1M NaCl, pH 8.5). 5 
µl (0.1 U/µl) snake venom phosphodiesterase were added and the solution was incubated at 
37°C for 3 h. Addition of 0.5 µl (10 U/µl) calf intestine phosphatase and further incubation at 
37°C for 15 min completed digestion. The sample was centrifuged (Eppendorf MiniSpin 
centrifuge, 13400 rpm, 20 min). The supernatant was removed and ddH2O was added to a 
final volume of 100 µl. 45 µl were analyzed via HPLC using a digest HPLC buffer (2 mM 
ammonium acetate in ddH2O (buffer A) and 2 mM ammonium acetate in 80 % MeCN (buffer 
B)) and a MS Uptisphere 3HDO (Interchim) column with a flow of 0.2 mL/min. Furthermore, 
50 µl of the digest were analyzed via HPLC-MS (section 10.1).  
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10.3  Biochemical materials 
10.3.1  Buffers 
 
If not further declared, all buffers, solutions and media were prepared with ddH2O obtained 
from the Millipore System. Adjustment of the pH-value was done by addition of NaOH(aq) or 
HCl(aq).  
Strep-tag buffers A and B: 
Buffer A: 100 mM Tris, 150 mM NaCl, 1mM EDTA; pH 7.5 
Buffer B: 0.5 mg/ml D-Desthiobiotin in buffer A 
(+ 10 mM DTT for SeMet labeled proteins) 
 
Heparin buffers A1 and B1 (Pol η): 
50 mM Tris, 1 mM EDTA, 5 mM DTT and 5% (v/v) glycerol; pH 7.5 
Buffer A: 100 mM NaCl 
Buffer B: 800 mM NaCl 
 
Heparin buffers A2 and B2 (XPA): 
25 mM Tris-HCl, 1 mM DTT, 10 µM ZnCl2, 10 % glycerol, pH 7.5 
Buffer A: 50 mM NaCl 
Buffer B: 1 M NaCl 
(+ 10 mM DTT for SeMet labeled proteins) 
 
MonoQ buffer 
50 mM Tris, 5 mM β-mercapthoethanol, 10 µM ZnCl2, 10 % glycerol, pH 7.5 
Buffer A: 100 mM NaCl 
Buffer B: 600 mM NaCl 
(+ 10 mM DTT for SeMet labeled proteins) 
 
Crystallization buffer for Pol η (1x): 
20 mM Tris, 50 mM KCl, 10 mM β–mercaptoethanol and 10% (v/v) glycerol; pH 7.5 
 
Crystallization buffer for Pol κ (1x): 
20 mM Tris, 50 mM KCl, 10 mM β–mercaptoethanol and 10% (v/v) glycerol; pH 7.5 
 
General primer extension buffer (1x): 
10 mM Tris, 50 mM NaCl, 10 mM MgCl2, 1 mM DTT, pH 7.9 
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Pol κ primer extension buffer (1x): 
25 mM Tris-HCl, 5 mM MgCl2, 0.05 mg/ml BSA, 1 mM DTT, 10 % glycerol, pH 7.5 
RP-HPLC buffers A and B: 
Buffer A: 0.1 M NHEt3OAc(aq) 
Buffer B: 0.1 M NHEt3OAc in 80% MeCN(aq) 
 
HPLC buffers A and B for enzymatic digest 
Buffer A: 2 mM NH4CHOO 
Buffer B: 2 mM NH4CHOO in 80% MeCN 
 
Agarose gel loading buffer: 
50% (v/v) glycerol, 0.2% (w/v) SDS, 0.05% (w/v) bromophenol blue, 0.05% (w/v) 
Xylencyanol FF in TAE- buffer 
 
2 x PAA-denaturing loading buffer: 
12% (v/v) Ficoll, 0.01% (w/v) Bromophenol blue, 0.02% (w/v) Xylencyanol FF, 7 M urea in 
TBE- buffer 
 
SDS-loading buffer: 
62.5 mM Tris, 4% (w/v) SDS, 20% (w/v) Glycerol, 5% (w/v) β-mercaptoethanol, pH 6.8 
 
SDS buffer (10x):   250 mM Tris, 1.92 M Glycerol, 1% (w/v) SDS 
 
TE- buffer:    10 mM Tris-HCl, 1 mM EDTA; pH 8.0 
 
TAE-running buffer (agarose gels): 40 mM Tris, 1 mM EDTA, pH 7.5 
 
TAE-Gelpuffer (agarose gels):  20 mM Tris, 0.5 mM EDTA, pH 7.5 
 
10 x TBE buffer:    89 mM Tris, 89 mM boric acid, 20 mM EDTA; pH 8.0 
 
resolving gel buffer (SDS-gels):  3.0 M Tris, pH 8.8 
 
stacking gel buffer (SDS-gels):  0.5 M Tris, pH 6.8 
 
digest buffer10x:    200 mM Tris-HCl, 100 mM MgCl2, 1M NaCl, pH 8 
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10.3.2  Equipment 
 
Equipment Supplier 
Äkta purifier chromatography system GE, Munich 
Agarose gel electrophoresis chamber Biorad, Munich 
Autoclave Vakulab S3000 Systec, Gießen 
Biofuge pico Heraeus, Hanau 
BioPhotometer 6131 Eppendorf, Hamburg 
Centrifuge 5810R Eppendorf, Hamburg 
French pressure cell press Thermo, Dreieich 
Gel imaging system LAS 3000 Raytest, Straubenhardt 
Incubator 1S Noctua, Wiesloch 
Incubator 44R New Brunswick, Wesseling-Berzdorf 
Mini Protean 3 Cell Biorad, Munich 
Multicaster Biorad, Munich 
Nanodrop UV-spectrometer ND-1000 Peqlab, Erlangen 
pH meter MP220 Mettler Toledo, Gießen 
Sorvall centrifuge, Evolution RC Kendro, Dreieich 
Thermomixer Comfort Eppendorf, Hamburg 
Gel chamber Protean II xi Cell Biorad, Munich 
IDA gelscanner Raytest, Straubenhardt 
Mastercycler Personal Eppendorf, Hamburg 
PCR Realplex  Eppendorf, Hamburg 
Deep freezer Vip Series –86 °C Sanyo, Bad Nenndorf 
Desktop centrifuge 5415R Eppendorf, Hamburg 
Carey UV-Spectrometer Bio100  Varian, Darmstadt 
High pressure homogenizer  Avestin, Mannheim 
Electrotransformator, Micropuls  Biorad, München 
Crystallization robot Hydra II  Thermo, Dreieich 
Vortexer VWR, Darmstadt 
Water bath Labora, Mannheim 
Lyophille Alpha 2-4 LD plus Christ, Osterode am Harz 
MALDI-TOF Autoflex II-Spectrometer Bruker Daltonics, Bremen 
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Expedite 8900 Nucleic Acid Synthesis System PerSeptive Biosystems, Framingham, MA, USA 
Äkta Oligopilot 10 GE, Munich 
HPLC System Waters, Eschborn 
Speedvac Cryostat CT 04-50 SR Christ, Osterode am Harz 
Speedvac RVC 2-33 IR Christ, Osterode am Harz 
Speedvac Plus Thermo Life Sciences, Dreieich 
Waters Millipore System Millipore, Schwalbach 
 
10.3.3  Bacterial strains 
 
Strain Genotype Supplier 
TOP10 
F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 recA1 araD139 
galU galK Δ(ara-leu)7697 rpsL (StrR) 
endA1 nupG 
Invitrogen, Karlsruhe 
 
BL21 (DE3) F- ompT hsdSB(rB- mB-) gal dcm (DE3) 
 
Novagene, Schwalbach 
 
BL21(DE3)pLysS F
-, ompT, hsdSB (rB- mB-), gal, dcm, (DE3), 
pLysS, (CamR) Novagene, Schwalbach 
B834 (DE3)pLysS F- ompT hsdSB(rB
- mB-) gal dcm met (DE3), 
pLysS, (CamR) 
 
Novagene, Schwalbach 
 
DH5α 
F- φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rk-, mk+) phoA 
supE44 λ- thi-1 gyrA96 relA1 
Invitrogen, Karlsruhe 
 
Rosetta™ (DE3) F-, ompT, hsdSB(rB
- mB-) gal, dcm, (DE3), 
pRARE, (CamR) 
 
Novagene, Schwalbach 
 
10.3.4  Media 
 
LB- Medium: 
1% (w/v) peptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl; pH 7.5 
 
SOC-Medium: 
0.5% (w/v) peptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl; pH 7.2 
after autoclaving: 5.0 mM MgCl2, 5.0 mM MgSO4   
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Medium-agar:  Medium with 1.5% (w/v) agar 
 
Autoinduction medium: Overnight Express™ Instant TB Medium (Novagen) 
 
LeMaster medium [164] (selenomethionine-containing): 
For the composition of the medium see Appendix 11.2 
 
10.3.5  Solutions 
 
MALDI matrices: 
HPA: 3-hydroxypicolinic acid (50 mg), 15-Crown-5 (10 μl), ammonium hydrogencitrate 
(10 mg) in ddH2O 
HPA Crown: 3-hydroxypicolinic acid (50 mg), 15-Crown-5 (10 μl), ammonium 
hydrogencitrate (10 mg) in ddH2O (1ml) 
ATT: 6-aza-2-thiothymine (10 mg) in 1 mL H2O 
 
Staining solution for SDS-gels: 
0.25% (v/v) Coomassie Brilliant Blue R 250, 10% (v/v) acetic acid, 40% (v/v) ethanol 
in ddH2O 
 
Destaining solution for SDS-gels: 
30% (v/v) ethanol, 10% (v/v) acetic acid in ddH2O 
 
Rotiphorese sequencing gel concentrate: 
25% (w/v) acrylamide, 1.32% (w/v) methylenbisacrylamide, 50% (w/v) urea 
 
Rotiphorese Gel 30: 
30% (w/v) acrylamide, 0.8% (w/v) methylenbisacrylamide 
 
10.3.6   Antibiotics and Inducers 
 
Anhydrotetracycline 2 mg/ml in DMF 
Carbenicillin 100 mg/ml in ddH2O 
Chloramphenicol 34 mg/ml in ethanol 
IPTG  238 mg/ml isopropyl-β-D-thiogalactopyranoside in ddH2O 
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10.3.7  Enzymes 
 
Snake venom phosphodiesterase I (Crotalus adamanteus venom) was obtained from USB 
corporation, calf intestine phosphatase (CIP), XbaI and HindIII from New England BioLabs. 
Klenow fragment exo- and exo+ was also obtained from New England BioLabs. 
 
10.4 Biochemical methods 
 
10.4.1  Agarose gel electrophoresis 
 
Plasmid DNA was analyzed on 0.8 or 1 % TAE agarose gels. These were run with a 
horizontal cell (Sub-Cell Bio-Rad) at 100 V. The DNA was stained with ethidium bromide. 
The bands were visualized using a Raytest IDA gelscanner. 
Gel buffer:  tris base (40 mM, pH 7.5), EDTA (1 mM), pH adjusted with sodium acetate 
Running buffer: tris base (20 mM, pH 7.5), EDTA (0.5 mM),  
 pH adjusted with sodium acetate 
staining: 1 mg/mL EtBr (0.1 μL EtBr/1 mL agarose gel) 
DNA-ladder: 1kB DNA ladder, New England BioLabs 
 
10.4.2  Polyacrylamide gel electrophoresis 
 
Denaturing PAGE 
Denaturing polyacrylamide gel electrophoresis (PAGE) was used for the analytical separation 
of short DNA fragments of the primer extension experiments (section 10.4.11). A 20% 
polyacrylamide gel was used in a Protean II xi Cell (Biorad) gel chamber allowing resolution 
of one base on the gel. The gels were run at 35 mA constant current with a maximum voltage 
of 800 V in 1 x TBE-buffer. The 20 % polyacrylamide gels were cast according to the table 
below and used directly after a polymerization time of 1 h.  
 
 
Rotiphorese 
sequencing gel 
concentrate 
8.3 M Urea 10x TBE 10% APS TEMED 
20% PAA-gel 32 mL 4 mL 4 mL 200 µL 20 µL 
Table 5. Composition of the 20 % denaturing polyacrylamide gels. 
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10 µL of a primer extension experiment mixed with 2x PAA-loading buffer (section 10.3.1) 
was loaded onto the gel. A self-made DNA ladder consisting of fluorescein-labeled DNA 
fragments of sizes ranging from 13 to 20 bases was used. The fluorescein-labeled DNA 
fragments were detected with a LAS-3000 gel imaging system (Raytest).  
 
SDS gel electrophoresis 
SDS gel electrophoresis was used to check the size and the purity of a protein after 
purification. 0.1 – 5 µg protein in 10 µL buffer (storage buffer depending on the protein) were 
mixed with 5 µL SDS-loading buffer.  The sample was centrifuged shortly with a Eppendorf 
Minispin centrifuge and subsequently heated to 95 °C for 10 min to destroy secondary and 
tertiary structures. The composition of the gels can be found in Table 6.  
 
 Rotiphorese Gel 30 ddH2O
Tris  
(1.5 M, 
pH 8.8)
Tris  
(0.5 M, 
pH 6.8)
10% SDS 10% APS TEMED
resolving gel 12%   8 mL 6.6 mL 5 mL - 200 µL 200 µL 20 µL
stacking gel    5% 1.3 mL 5.5 mL - 1 mL 80 µL 80 µL 8 µL
Table 6. Composition of the stacking and resolving gels for SDS gel electrophoresis 
 
The gels were cast in a Mini Protean 3 Cell (Biorad). The resolving gel was covered with a 
layer of isopropanol in order to obtain a straight edge on the top. After a polymerization time 
of 1 h, the stacking gel was cast on top of the resolving gel. If not directly used, the gels were 
stored at 4°C (covered in wet tissues). 10 µL sample volume and 4 µL protein standard 
(SeeBlue® Plus2 Pre-Stained Protein Standard, Invitrogen) were loaded onto the gel. Gels 
were run at 120 V for approximately 1 h and further stained with a Coomassie solution for 10 
min. Destaining was performed with a mixture of acetic acid and ethanol in water. Details of 
the composition of all buffers and solutions can be found in section 10.3.1 and 10.3.5. 
 
10.4.3  Polymerase chain reaction (PCR) 
 
The catalytic domain of the gene coding for the human DNA polymerase κ was amplified by 
PCR. A plasmid containing the complete Pol κ gene was purchased from Origene (USA). The 
following primer were used to amplify DNA regions coding for residues 50-530 and 1-530 of 
Pol κ. 
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Pol κS (50-530) 
Forward primer 5’-Pho-AAT GGG AAA TGA GCT CAA GAA AGA AAA GC-3’ 
Reverse primer 5’-Pho-TCC CAA TAA TGC TCC TTT GTT GGT GTT TC-3’ 
 
Pol κL (1-530) 
Forward primer 5’-Pho-AAT GGA TAG CAC AAA GGA GAA GTG TGA G-3’ 
Reverse primer 5’-Pho-TCC CCA TAA TGC TCC TTT GTT GGT GTT TG-3’ 
The PCR was performed using a temperature gradient and a constant DNA template 
concentration.  
Mastermix (11x):   44 µL  5x buffer (Phusion buffer) 
     11 µL  dNTP’s   (10 mM, each) 
     11 µL  Primer sense   (10 mM) 
     11 µL  Primer antisense  (10 mM) 
     6.6 µL DMSO  (100 %) 
     2.2 µL  Phusion  (2 U/µL) 
= 85.8 µL  
The 11 samples were prepared as described below and added onto a 96 well plate.  
         1 µL  cDNA template (10 ng/µL)  
     11.2 µL  ddH2O 
  7.8 µL  Mastermix  
   
PCR - program (performed on a PCR Realplex device, Eppendorf): 
     1.  98 °C   5 min 
     --------------------------------- 
     2. 98 °C   10 s 
     3. 53-55 °C  10 s temperature gradient  
       (sample 1-10) 
     4.  72 °C   1 min 
     5.  Goto 2.  30x 
     --------------------------------- 
     6.  72°C   7 min 
     7. 4°C   hold 
 
The PCR-products were analyzed on a 1% agarose gels, the corresponding bands were cut out 
from the gel and isolated with a MiniElute-Gel-Extraction-Kit (Quiagen).  
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10.4.4  Assembly of the expression vectors for Pol κ 
 
Entry reaction  
The PCR products of both Pol κ versions (chapter 10.4.3) were cloned into the pENTRY-IBA 
10 donor vector using StarGate® cloning technology (IBA) according to the protocol from 
IBA and were subsequently sequenced (performed by Dr. Melanie Maul).   
 
Transfer reaction 
After sequence confirmation, the Pol κ gene was subcloned into several acceptor vectors 
according to the StarGate® protocol. The following destination vectors containing different 
tags for protein purification were assembled:  
Pol κS (50-530) in pPSG-IBA3 (C-terminal Strep-tag II, T7 promotor) 
Pol κL (1-530) in pPSG-IBA3 (C-terminal Strep-tag II, T7 promotor) 
Pol κL (1-530) in pPSG-IBA3 (C-terminal Strep-tag II, T7 promotor) 
Pol κL (1-530) in pPSG-IBA33 (C-terminal 6x Histidine (His)-tag, T7 promotor) 
The resulting destination vectors were then transformed into the corresponding host cells 
(E. coli Top 10 or Rosetta) for further experiments (section 10.4.5). 
 
Verification of the transfer reaction by enzymatic restriction digestion 
100 ng plasmid DNA (pPSG-IBA3 and pPSG-IBA33 containing the Pol κ gene) were 
digested with the restriction enzymes XbaI and HindIII (New England BioLabs).  
Assay:  100 ng DNA 
1 µL 10 x NEB2 buffer (New England BioLabs) 
0.1 µL BSA (10 mg/ml) 
0.2 µL XbaI (20 U/µL 
0.2 µL HindIII (20 U/µL) 
filled  up to 10 µl with ddH2O 
 
The sample was incubated at 37 °C for 1.5 h and then analyzed via agarose gel 
electrophoresis.  
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10.4.5  Transformation of E. coli 
 
Electrocompetent E. coli 
An electroporation cuvette was cooled on ice prior to usage. 1 mL SOC- or LB-medium was 
heated to 37 °C. The competent cells (stored at -80 °C) were thawed on ice. 10 ng to 100 ng 
DNA was added (maximum volume 2 µL) and incubated for 1 min on ice. The sample was 
transferred into the electroporation cuvette. Afterwards, a voltage pulse of 2.5 V was applied 
to the cells, they were directly transferred into the preheated medium and incubated at 37 °C 
for 1 h (shaking). The cells were pelleted at 4000 rpm for 3 min in a desktop centrifuge 
5415 R (Eppendorf) and plated on LB agar containing the corresponding antibiotics. Cells 
were grown over night at 37 °C and stored at 4 °C.  
Chemically competent E. coli 
One aliquot chemically competent cells was thawed on ice and 10 ng to 100 ng DNA was 
added (maxium volume 2 µL). The sample was incubated on ice for 30 min and then heat 
shocked at 42 °C for 30 min. Next, the sample was incubated on ice for 2 min. 250 µL SOC-
medium was added and the cells were incubated at 37 °C for 1 h (shaking). The cells were 
pelleted at 4000 rpm for 3 min in a 5415 R desktop centrifuge (Eppendorf) and plated on LB 
agar containing the corresponding antibiotics. Cells were grown over night at 37 °C and 
stored at 4 °C.   
 
10.4.6  E. coli cultures 
 
E. coli cultures were stored as glycerol-stocks at -80 °C or on agar plates. Cells from agar 
plates were transferred to fresh plates every second or third week. Liquid cultures were grown 
in  a shaker incubator (New Brunswick) at 200 rpm and 37 °C.  
 
10.4.7  Isolation of plasmid DNA 
 
Plasmid-DNA was isolated with a QIAprep Spin Miniprep Kit from Qiagen. Plasmid 
contructs obtained from the StarGate® cloning (section 10.4.4) were amplified in E. coli 
Top10. Therefore, 5 mL LB-medium containing the corresponding antibiotics was inoculated 
with a clone and incubated at 37 °C and 200 rpm over night. The cells were pelleted at 4000 
rpm for 10 min in a 5415 R desktop centrifuge (Eppendorf). The QIAprep Spin Miniprep Kit 
protocol was then used to isolate the plasmid DNA. Isolated plasmid DNA was stored at 
-20 °C.  
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10.4.8  Induction of the protein expression 
 
Pol η 
Previously, the DNA sequence coding for residues 1-513 of the yeast DNA Polymerase η 
from Saccharomyces cerevisiae was PCR amplified (forward primer 5' GGG GAC AAG TTT 
GTA CAA AAA AGC AGG CTT CAT GTC AAA ATT TAC TTG GAA GGA G-3', reverse 
primer 5'-GGG GAC GAC TTT GTA CAA GAA AGC TGG GTC TCA TTT TTG TAA 
ATC TAT AAT ATC GAA ATT AG-3') and cloned in a two-step Gateway® reaction via the 
vector pDONR201 (Invitrogen) into the expression vector pDEST007, in frame with an N-
terminal Strep-Tag II (IBA) (performed by Dr. Claudia Chiocchini). The plasmid containing 
the Pol η gene was transformed into E. coli Rosetta.  
60 mL LB medium containing 100 μg/mL carbenicillin and 5 μg/mL chloramphenicol were 
inoculated with E. coli Rosetta cells containing the pDEST007-Pol η plasmid from the 
glycerol stock. Cells were grown overnight in 250 ml Erlenmeyer flasks at 250 rpm and 37°C.  
10 mL of this culture were added to 2 l Erlenmeyer flasks containing 1 L LB medium 
supplemented with 100 μg/mL carbenicillin and 5 μg/mL chloramphenicol. Cells were grown 
at 37 °C until an OD600=0.8 was reached. Expression was induced by adding 
anhydrotetracycline to a final concentration of 200 ng/ml and the incubation was continued at 
16 °C for 4–5 h. Cells were harvested by centrifugation in a Sorvall SLA-3000 rotor (10 min, 
8000 rpm) and, if not directly lysed, stored at -20 °C. 
 
Pol κ 
The plasmids pPSG-IBA3-Pol κL and pPSG-IBA3-Pol κS were transformed into E. coli 
BL21(DE3)pLysS.  
LB Medium: Human Pol κS and Pol κL were expressed according to the protocol described 
for Pol η differing only in the induction of the protein expression. The Pol κ gene is under 
control of the T7 promotor, therefore, IPTG to a final concentration of 1 mM was used for 
induction.  
Autoinduction medium: Human Pol κL (pPSG-IBA3-Pol κL) was also expressed using the 
Overnight Express™ Instant TB Medium from Novagen which resulted in much higher 
yields.  15 mL LB medium containing 100 μg/mL carbenicillin and 5 μg/mL chloramphenicol 
were inoculated with BL21 E. coli cells containing the pPSG-IBA3-Pol κlong plasmid at 37 °C 
and 225 rpm overnight. 10 mL of the overnight culture were added to 1 L of Overnight 
Express™ Instant TB medium containing 100 μg/mL carbenicillin and 5 μg/mL 
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chloramphenicol. The 1 L culture was split into 2 x 2 L Erlenmeyer flasks and incubated at 
37°C and 225 rpm. After 4 h, the temperature was reduced to 25 °C and incubated for further 
20 h. Cells were harvested by centrifugation in a Sorvall SLA-3000 rotor (10 min, 8000 rpm) 
and, if not directly lysed, stored at -20 °C. 
 
Rad14  
Previously, The DNA sequence coding for the DNA binding domain (residues 185-306) of 
the yeast Rad14 from Saccharomyces cerevisiae was PCR amplified (forward primer 5' Pho-
AAT GGC GCC GAA ATG TAT TGA ATG T-3’, reverse primer 5’-Pho-TCC CGT CTT 
TTT TCT CCT TCT GTG-3’) and cloned in a two-step StarGate® reaction via the vector 
pENTRY-IBA10 (IBA) into the expression vector pPSG-IBA3 (IBA), in frame with an 
C-terminal Strep-Tag II. The plasmid containing the Rad14 gene was transformed into E. coli 
BL21 (DE3). This work was performed by Dr. Ralf Strasser.[139] 
60 mL LB medium containing 100 μg/mL carbenicillin was inoculated with E. coli BL 21 
cells containing the pPSG-IBA3-Rad14 plasmid from a glycerol stock. Cells were grown 
overnight in 250 ml Erlenmeyer flasks at 250 rpm and 37°C.  
10 mL of this culture were added to 2 l Erlenmeyer flasks containing 1 L LB medium 
supplemented with 100 μg/mL carbenicillin. Cells were grown at 37 °C until an OD600=0.8 
was reached. Expression was induced by adding IPTG to a final concentration of 1 mM. 
Additionally, 10 µL ZnCl2(aq) (1M) were added and the incubation was continued at 28 °C for 
3 h. Cells were harvested by centrifugation in a Sorvall SLA-3000 rotor (10 min, 8000 rpm) 
and, if not directly lysed, stored at -20 °C. 
 
XPA 
Previously, The DNA sequence coding for the DNA binding domain (residues 98-219) of the 
human XPA protein was PCR amplified (forward primer 5'-AAT GGA ATT TGA TTA TGT 
AAT ATG CG-3'; reverse primer 5'-TCC CAA ATT TCT TCT GTT TCA TTT TTT CTC-3') 
and cloned in a two-step StarGate® reaction via the vector pENTRY-IBA10 (IBA) into the 
expression vector pPSG-IBA3 (IBA), in frame with an C-terminal Strep-Tag II. The plasmid 
containing the XPA gene was transformed into E. coli BL21 (DE3) pLysS. This work was 
performed by Sandra Koch. XPA was expressed according to the protocol described for 
Rad14. 
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Selenomethionine labeled Rad14 and XPA  
For crystallographic phase determination via selenomethionine labeling, the plasmid 
containing the gene for either the Rad14 or the XPA protein, was transformed into the 
methionine auxotrophic E.coli strain B834(DE3)pLysS. Expression was perfomed in 
selenomethionine-containing LeMaster medium (section 11.2). Therefore, 60 mL LB medium 
containing 100 μg/mL carbenicillin and 5 μg/mL chloramphenicol was inoculated with E. coli 
B834 cells containing the pPSG-IBA3-Rad14 or XPA plasmid. Cells were grown overnight in 
250 ml Erlenmeyer flasks at 250 rpm and 37°C. 5 mL of this culture were added to 2 l 
Erlenmeyer flasks containing 1 L LeMaster medium supplemented with 50mg/L 
DL-selenomethionine, 100 μg/mL carbenicillin and 5 μg/mL chloramphenicol. Cells were 
grown at 37 °C until an OD600=0.6 was reached. Due to the minimum medium, cells were 
grown for 8-10 h until the desired density was reached. Expression was induced by adding 
IPTG to a final concentration of 1 mM. Additionally, 10 µL ZnCl2(aq) (1M) were added and 
the incubation was continued at 20 °C overnight. Cells were harvested by centrifugation in a 
Sorvall SLA-3000 rotor (10 min, 8000 rpm) and, if not directly lysed, stored at -20 °C. 
  
10.4.9  Protein purification  
 
Pol η 
The cell pellet (section 10.4.8) was resuspended in cold Strep-tag buffer A with a cocktail of 
protease inhibitors (Roche) added, and lysed using a high pressure homogenizer (Avestin 
Europe GmbH). The cell lysate was cleared by centrifugation in a Sorvall SS-34 rotor at 
18000 rpm and 4°C for 30 min, filtered through a 0.2 μm filter and applied onto a Strep-
Tactin column (IBA, 5 ml column volume) at 4°C. The protein was eluted from the column 
with the Strep-tag buffer B containing 2.5 mM desthiobiotin (flow 1 ml/min). The fractions 
were pooled and concentrated in 50 mM Tris-HCl pH 7.6, 100 mM NaCl, 1 mM EDTA, 5 
mM DTT, 5% glycerol (Heparin buffer A1) and loaded onto a HiTrap Heparin column (GE 
Healthcare, 1 ml column volume). The protein was eluted with a linear gradient of the same 
buffer containing 800 mM NaCl (Heparin buffer B1, flow 1 ml/min). The buffer was 
exchanged to 20 mM Tris-HCl pH 7.6, 50 mM KCl, 10 mM β-mercaptoethanol, 10% glycerol 
(crystallization buffer for Pol η) using an Amicon Ultra centrifuge filter device (30,000 
MWCO) (Millipore) and an Eppendorf 5810R centrifuge. The enzyme was stored at a 
concentration of 10 mg/ml at -80 °C. 
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Pol κ  
The protocol used for the purification of Pol κ was similar to the protocol used for the Pol η 
purification. Both Pol κ versions, PolκS and PolκL were purified as C-terminally tagged Strep-
Tag II fusion proteins using a Streptactin affinity column (IBA) and applying the Pol η 
protocol. This was followed by a heparin affinity column (for details see Pol η purification). 
After purification, the enzyme was stored in 20 mM Tris-HCl pH 7.6, 50 mM KCl, 10 mM β-
mercaptoethanol, 10% glycerol at -80 °C. 
 
Rad14  
If selenomethionine-labeled Rad 14 was purified, 10 mM DTT was added to all buffers and 
all buffers were degassed prior to usage to prevent oxidation of selenomethionine.  
The cell pellet (section 10.4.8) was resuspended in cold Strep-tag buffer A with a cocktail of 
protease inhibitors (Roche) added, and lysed using a high pressure homogenizer (Avestin 
Europe GmbH). The cell lysate was cleared by centrifugation in a Sorvall SS-34 rotor at 
18000 rpm and 4°C for 30 min, filtered through a 0.2 μm filter and applied onto a Strep-
Tactin column (IBA, 5 ml column volume) at 4°C. The protein was eluted from the column 
with the Strep-tag buffer B containing 2.5 mM desthiobiotin (flow 1 ml/min). The fractions 
were pooled and concentrated in 50 mM Tris, 5 mM β-mercapthoethanol, 10 µM ZnCl2, 100 
mM NaCl, 10 % glycerol, pH 7.5 (MonoQ buffer A) and loaded onto a MonoQ 5/50GL 
column (GE Healthcare). The protein was eluted with a linear gradient of the same buffer 
containing 600 mM NaCl (MonoQ buffer B, flow 0.4 ml/min). The buffer was exchanged to 
50 mM Tris, 5 mM β-mercapthoethanol, 10 µM ZnCl2, 100 mM NaCl, 10 % glycerol, pH 7.5 
using an Amicon Ultra centrifuge filter device (10,000 MWCO) (Millipore) and an Eppendorf 
5810R centrifuge. The enzyme was stored at a concentration of 10 mg/ml at -80 °C. 
 
XPA 
If selenomethionine-labeled XPA was purified, 10 mM DTT was added to all buffers and all 
buffers were degassed prior to usage to prevent oxidation of selenomethionine.  
Cell lysis and Strep-tag purification was performed according to the protocol described for the 
Rad 14 purification. Subsequent to elution from the Strep-tag column, the fractions were 
pooled and concentrated in 25 mM Tris-HCl, 1 mM DTT, 50 mM NaCl, 10 µM ZnCl2, 10 % 
glycerol, pH 7.5 (Heparin buffer A2) and loaded onto a HiTrap Heparin column (GE 
Healthcare, 1 ml column volume). The protein was eluted with a linear gradient of the same 
buffer containing 1 M NaCl (Heparin buffer B2, flow 0.4 ml/min). The buffer was exchanged 
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to 25 mM Tris-HCl, 50 mM NaCl, 1 mM DTT, 10 µM ZnCl2, 10 % glycerol, pH 7.5 using an 
Amicon Ultra centrifuge filter device (10,000 MWCO) (Millipore) and an Eppendorf 5810R 
centrifuge. The enzyme was stored at a concentration of 10 mg/ml at -80 °C. 
 
10.4.10  Protein quantification 
 
Absorption at 280 nm (A280): In most cases, the protein concentration was measured by the 
absorption at 280 nm using the Nanodrop UV-spectrometer ND-1000 (Peqlab). Aromatic 
amino acids have their absorption maxima at this wavelength. Statistically, one absorption 
unit at 280 nm corresponds to a protein concentration of 1 mg/mL. The exact protein 
concentration was determined using the individual molar extinction coefficient of the protein 
(calculated from the amino acid sequence). For the consideration of nucleic acid 
contamination, the Warburg equation is used: 
protein concentration = (1.55 x A280) – (0.76 x A260) 
 
Bradford-Assay: The Bradford solution (Biorad) was diluted 1:5 with ddH2O. For 
determination of the reference value, 950 µL Bradford solution were mixed with 50 µL of the 
protein buffer. For the sample, 950 µL Bradford solution, 1-5 µL protein solution (depending 
on the concentration) and buffer were mixed to a total volume of 1 mL. Protein concentration 
was measured by the absorption at 595 nm using a BSA calibration curve.  
 
10.4.11  Primer extension studies 
 
A fluorescent labeled 13 or 14mer primer (Metabion, Germany) was annealed (95 °C for 4 
min followed by cooling down to 4 °C over a period of 45 min) to the unlabeled 20mer 
template DNA strand, either undamaged or containing the bulky DNA lesion in a 1:1.5 molar 
ratio in the Pol η reaction buffer (10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, 1 mM DTT, 
pH 7.9. For Pol κ, the following buffer was used: 25 mM Tris-HCl, 5 mM MgCl2, 0.05 mg/ml 
BSA, 1 mM DTT, 10 % glycerol, pH 7.5). The final concentration of the primer in the primer 
extension studies was 1 µM. Primer extensions studies using 50 – 300 nM Pol η or 
100-500 nM Pol κ were initiated by addition of one or all four nucleotides (final concentration 
200 µM) and incubated at 30 °C After 5 min, one half of the assay volume were transferred 
into a fresh tube and a solution sodium EDTA (100 mM, 1:1 volume ratio) was added to 
terminate these reactions. After 30 min, reactions of remaining samples were also terminated 
by addition of a solution sodium EDTA. The primer extension products were resolved on 22% 
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polyacrylamide-urea gels and visualized using a LAS-3000 imaging system (Raytest). Table 7 
describes the composition of a typical primer extension assay in detail: 
1 µL DNA (primer/template, 10 µM) 
1 µL dNTP/dNTPs (2 mM) 
1 µL 10x primer extension buffer (see 10.3.1)
x µL DNA polymerase 
y µL ddH2O (total volume 10 µL) 
Table 7. Pipetting scheme for primer extension assays  
 
10.4.12  Mass spectrometry analysis of the primer extension experiments 
 
Three primer extension assays (3x 10 µL, containing 1 µM template and extended primer 
DNA strands, see section 10.4.11) were combined. 20 µL ddH2O were added and the DNA 
was extracted from the crude primer extension products via phenol/chloroform (Roti-Phenol, 
Roth, Germany) extraction. Therefore, 50 µL phenol were added and mixed by vortexing. The 
aqueous phase was transferred to a fresh tube and extracted twice with 2 x 50 µL chloroform. 
The aqueous phase was concentrated to 10 µL (Speedvac) and desalted via ZipTipC18 
(Millipore). Therefore, the ZipTipC18 were equilibrated with 3 x 10 µL MeCN, washed with 3 
x 10 µL ddH2O and the sample was pumped through the ZipTipC18 5 times. The tip was then 
washed with 10 x 10 µL ddH2O and the DNA was eluted using 5 x 10 µL 50 % MeCN in 
ddH2O. The desalted samples were concentrated to 1 µL (Speedvac). 0.4 µL of the sample 
were mixed with 0.4 µL HPA matrix (section 10.3.5). Mass spectra were recorded on a 
Bruker Autoflex II (MALDI-Tof). 
 
10.5 Protein crystallization  
 
Pol η 
 For co-crystallization, Pol η (4.5 mg/ml) was incubated with double stranded DNA 
containing the template with the AAF-dG, AAA-dG or the AAP-dG lesion annealed to primer 
with a 2',3'-dideoxybase at the 3' end (5’-GTG GAT GAGdd) in a 1 to 4 molar ratio in 
crystallization buffer (20 mM Tris, 50 mM KCl, 10 mM β–mercaptoethanol and 10% (v/v) 
glycerol; pH 7.5). Crystals were grown by mixing an equal volume of protein-DNA complex 
with 11–15% (w/v) PEG 3350, 150–200 mM CaCl2, 5 mM MgSO4, 1 mM dCTP using the 
hanging-drop vapour diffusion method (drop size 1 µL + 1 µL). The crystallization plates 
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were incubated at 4 or 18 ºC and crystals appeared after 10 to 60 days. Crystals were frozen in 
artificial mother liquor containing 20% (v/v) butanediol and stored in liquid nitrogen until 
data collection. Table 8 describes the composition of a typical crystallization experiment:  
 
6 µL DNA (primer/template, 1 nmol/µL) 
1.25 µL dCTP (20 mM) 
0.5 µL MgSO4 (250 mM) 
x µL Pol η (4.5 mg/ml final concentration) 
y µL crystallization buffer (total volume 25 µL)
Table 8. Pipetting scheme for crystallization experiments with Pol η and bulky adduct containing DNA. 
 
Pol κ  
For co-crystallization, Pol κL (5 mg/ml) was incubated with double stranded DNA containing 
the template with the AAF-dG lesion annealed to primer with a 2',3'-dideoxybase at the 3' end 
in a 1 to 2 molar ratio in crystallization buffer (20 mM Tris, 50 mM KCl, 10 mM β–
mercaptoethanol and 10% (v/v) glycerol; pH 7.5) adding 5 mM MgSO4 and 1 mM dCTP. A 
crystallization screen was performed using the Hydra II crystallization robot (Thermo) with a 
drop size of 0.2 µL protein and 0.2 µL precipitant. The commercial available PEG I and PEG 
II Suites (Qiagen) were utilized. Additionally, a manual screening with 11 mg/ml Pol κlong and 
an AAF-dG containing DNA duplex (1:1.3 molar ratio) was carried out in 24 well format 
using 11-14 % PEG 5000, 200 mM NaCl and 0.19 -0.22 M ammonium acetate at pH 6.2 and 
6.5 (conditions previously published for the Pol κ in complex with undamaged DNA).[162]  
A second robot screen was done at the Oxford Protein Production Facility (OPPF, Oxford, 
UK). Pol κlong was used at a concentration of 11 m/ml in 20 mM Tris pH 7.5, 200 mM NaCl, 1 
mM dCTP and 5 mM MgSO4 (1:1.3 molar ratio protein/DNA). The following commercially 
available screening kits from Hampton Research were used: Hampton Crystal Screen 1 + 2, 
Hampton PEG/Ion Screen, Hampton Grid Screen PEG 6000, Hampton Grid Screen 
Ammonium Sulphate, Hampton Index. The plates were incubated at 4 °C for 12 month. No 
diffracting crystals could be obtained in all cases.  
 
Rad14 
For co-crystallization, Rad14 (4 - 6 mg/ml) was incubated with double stranded DNA 
containing the template with the AAF-dG and a counter strand in a 1 to 1.2 molar ratio in 
crystallization buffer (50 mM Tris, 5 mM β-mercapthoethanol, 10 µM ZnCl2, 100 mM NaCl, 
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10 mM DTT, 10 % glycerol, pH 7.5). First native Rad14 crystals in complex with AAF-dG 
containing DNA were obtained with 2.8- 3.3 M ammonium sulfate in 0.08 – 0.11 M Tris pH 8 
buffer (performed by Dr. Ralf Strasser).[139] These crystals diffracted X-rays only to 7 Å 
spacing. Therefore, a new crystallization screen was performed with a Phoenix nanodispenser 
robot (Art Robbins Instruments, drop size: 0.1 µL protein + 0.1 µL precipitant) in the group of 
E. Conti at the Max-Plank-Institute (Martinsried). The following commercial available 
screening kits (Qiagen) were used: Qiagen AmSO4 Kit, Qiagen Classics Kit, Qiagen JCSG+ 
Kit, Qiagen PEGs and CP-PEGS-Salt screen (Pegs salt II) Kit. After obtaining an initial hit 
with 0.2 M Calcium acetate, 0.1 M sodium cacodylate pH 6.5 and 18 % PEG 8000 at a 
protein concentration of 5.5 mg/ml and a 1 to 1.2 molar ration of protein to DNA (ODN 16) at 
4°C, the conditions of the initial hit were refined by varying the protein concentration, 
concentration of the components of the crystallization buffer and drop size in 24 well formats 
(hanging drop Crystalgen SuperClear™ Plates, Jena Biosciences).  For selenomethionine-
labeled Rad14 a concentration of 5 mg/ml and for crystallization with 5-Br-dU labeled DNA 
(Metabion), a concentration of 5.5 mg/ml was used. Crystals reached their maximum size 
after 1 week at 4 °C.   
After a buffer screening at constant calcium acetate and PEG 8000 concentrations, Rad14 
crystals with 0.1 M Tris pH 7 were obtained. Crystals were shock-frozen in cryoprotectant 
solution (see Table 9) and stored in liquid nitrogen (not longer than 1-2 weeks).  
100 µM Ca acetate (1 M) 
180 µL PEG 8000 (50 %) 
50 µL  Tris (1 M, pH 7) 
10 µL DTT (100 mM) 
125 µL ethylene glycol (25 %)
95 µL ddH2O 
Table 9. Composition of the cryoprotectant solution for Rad14 crystals.  
 
XPA 
For co-crystallization, XPA (12 mg/ml) was incubated with double stranded DNA containing 
the template with the AAF-dG (ODN 16) and a counter strand in a 1 to 1.2 molar ratio in 
crystallization buffer (25 mM Tris-HCl, 1 mM DTT, 10 µM ZnCl2, 50 mM NaCl, 10 % 
glycerol, pH 7.5). 
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First crystallization screening was performed with a Phoenix nanodispenser robot (Art 
Robbins Instruments, drop size: 0.1 µL protein + 0.1 µL precipitant) in the group of E. Conti 
at the Max-Plank-Institute (Martinsried). The following commercial available screening kits 
(Qiagen) were used: Qiagen AmSO4 Kit, Qiagen Classics Kit, Qiagen JCSG+ Kit, Qiagen 
PEGs and CP-PEGS-Salt screen (Pegs salt II) Kit. The plates were incubated at 18 °C. A 
second Qiagen Classics Kit plate was also incubated at 4 °C. After obtaining an initial hit 
with 20 % PEG 3350 and 0.2 M MgSO4 at 18 °C, conditions of the initial hit were refined in 
24 well formats. For selenomethionine-labeled XPA, a concentration of 8-10 mg/ml was used. 
No large crystals could be obtained. Two small native crystals, frozen in artificial mother 
liquor containing 20% (v/v) ethylene glycol and measured at the PXI beam line at the Swiss 
Light Source (SLS, Villigen, Switzerland), did not diffract X-rays.  
 
10.6  Collection and processing of X-ray diffraction data, phase   
determination and structure refinement 
 
Pol η crystals 
Diffraction data were measured at the PXI beam line at the Swiss Light Source (SLS), 
Villigen, Switzerland. The crystals diffracted X-rays to 2.7 Å spacing. Structure solution was 
performed by Dr. Sabine Schneider. The data were processed with the programs XDS and 
XSCALE[165] and the crystals belong to the same space group, with comparable unit cell 
constants as the apo enzyme[156] and co-crystals containing the cisplatin lesion[90, 157]. The 
structures were solved by molecular replacement (PHASER[166]) using the coordinates of the 
apo-enzyme as search model. In order to reduce model bias, the temperature factors were 
reset to the Wilson B-factor. Prior to model building in COOT[167] a simulated annealing omit 
map, removing the area around the lesion, was calculated with PHENIX.[168] Restrained 
refinement was carried out with PHENIX and REFMAC[169], excluding the same set of free 
reflections as for the previously reported Pol η-DNA complex structures.[90, 157] Data 
processing and refinement statistics are summarized in Table 10. Structural figures were 
prepared with PyMol (Delano Scientific). The atomic coordinates and structure factors (PDB 
codes 2XGP and 2XGQ) have been deposited in the PDB at the EBI Macromolecular 
Structure Database (http://www.ebi.ac.uk/pdbe). For details of the structure solution see 
section 11.1. 
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Rad14 crystals 
Diffraction data were measured at the PXI beam line at the Swiss Light Source (SLS), 
Villigen, Switzerland and the microfocus beamline ID23-2 at European Synchrotron 
Radiation Facility (ESRF), Grenoble, France.  
Single-wavelength anomalous dispersion (SAD) data at the selene and bromine absorption 
edge for either selenomethionine-labeled Rad14 co-crystals with an AAF-dG containing DNA 
duplex or Rad14 crystals in complex with 5-Br-dU and an AAF-dG containing DNA duplex 
were collected. The peak and the inflection points of the anomalous scatterers were 
determined by an X-ray fluorescence scan on each crystal. Labeled Rad14 crystals diffracted 
X-rays to 3.5 Å spacing but were highly anisotropic. Additionally, a data set of a native 
Rad14 crystal in complex with AAF-dG with a resolution of 3.3 Å was collected.  
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10.7 Synthesis of bulky DNA adducts 
 
10.7.1  8-Bromo-2'-deoxyguanosine 27 
 
 
2'-deoxyguanosine monohydrate (10.00 g, 35.06 mmol) was suspended in a mixture of 
acetonitrile (370 mL) and water (95 mL). N-bromosuccinimide (9.36 g, 52.59 mmol, 1.5 eq.) 
was added in three portions over 15 min. The yellow reaction mixture was stirred for 40 min 
at room temperature. The solvents were removed in vacuo and the precipitate was suspended 
in acetone (200 mL), stirred for 2 hours at room temperature and cooled overnight at -20°C. 
The precipitate was collected by filtration, extensively washed with 200 mL cold acetone and 
dried under vacuum to provide (10.26 g, 29.65 mmol, 85 %, lit.: 80 %) of a slightly yellow 
powder. 
Rf = 0.44 (CH2Cl2:MeOH 1:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 10.79 (s, 1H, N1-H), 6.48 (s, 2H, NH2), 6.13 (dd, 
2J = 7.8, 3J = 6.8 Hz, 1H, C1'-H), 5.29 – 5.21 (m, 1H, 5' OH), 4.85 (br d, 1H, 3' OH), 4.37 
(ddd, 3J = 2.8, 2.8, 5.9 Hz, 1H, C3'-H), 3.77 (ddd, 3J = 3.0, 5.6, 5.6 Hz, C4'-H), 3.65 – 3.55 (m, 
1H, C5'-Ha), 3.5 – 3.42 (m, 1H, C5'-Hb), 3.14 (ddd, 2J = 13.2, 3J = 6.4, 8.0 Hz, 1H, C2'-Ha), 
2.08 (m, 1H C2'-Hb). 
 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 155.89, 153.76, 152.43, 121.03, 117.92, 88.33, 
85.50, 71.46, 62.48, 36.86.  
 
IR ν (cm-1) 3354 (s), 3152 (s), 2952 (w), 2906 (w), 1677 (s), 1662 (s), 1605 (s), 1582 (s), 1514 
(w), 1459 (m), 1362 (m), 1290 (m), 1272 (m), 1254 (m), 1111 (w), 1080 (w), 1063 (m), 1024 
(m), 999 (m), 789 (w), 625 (w). 
 
HR-MS (ESI‾) m/z for [C10H11N5O479Br]‾ ([M-H])‾: calc.: 343.9994, found: 343.9996. 
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10.7.2  8-Bromo-3',5'-O-bis(tert-butyldimethylsilyl)-2'-deoxyguanosine 28 
 
 
 
8-bromo-2'-deoxyguanosine 27 (8.5 g, 24.50 mmol) and imidazole (7.96 g, 166.92 mmol) 
were suspended in DMF (55 ml) and treated with a 1 M solution of tert-butyldimethylsilyl 
chloride in THF (67 ml, 67 mmol). The reaction mixture was stirred for 5h at room 
temperature and the solvents were removed in vacuo. 270 mL water were added and extracted 
with EtOAc (2 x 400 mL). The organic layer was dried over MgSO4, concentrated in vacuo 
and purified by chromatography on silica gel (CH2Cl2:MeOH 20:1) to provide 12.81 g (22.30 
mmol, 91 %, lit. 98 %) of a slightly yellow powder. 
Rf = 0.43 (CH2Cl2:MeOH 10:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 10.83 (s, 1H, N1-H), 6.41 (s, 2H, NH2), 6.12 (dd, 
3J = 7.1, 7.1 Hz, 1H, C1'-H), 4.56 (ddd, 3J = 3.3, 3.3, 6.3 Hz, 1H, C3'-H), 3.72 (m, 2H, C5'-
Ha+Hb), 3.63 (m, 1H, C4'-H), 3.35 (ddd, 2J = 13.7, 3J = 6.7, 6.9 Hz, 1H, C2'-Ha), 2.12 (ddd, 3J 
= 3.6, 7.0, 2J  = 13.2, 1H, C2'-Hb), 0.87 (s, 9H, tBu-H), 0.80 (s, 9H, tBu-H), 0.09 (s, 6H, 2xSi-
CH3), -0.03 (s, 3H, Si-CH3), -0.05 (s, 3H, Si-CH3).  
 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 155.97, 153.80, 152.55, 121.10, 117.86, 87.57, 
85.17, 72.84, 63.27, 36.44, 26.24, 26.18, 26.14, 18.42, 18.40, 18.16, -4.25, -4.43, -4.71, -4.98, 
-5.00.  
 
IR ν (cm-1) 3399 (w), 3308 (m), 3244 (m), 3199 (m), 2952 (m), 2929 (m), 2857 (m), 1691 (s), 
1633 (m), 1608 (m), 1595 (s), 1557 (m), 1471 (w), 1463 (w), 1337 (w), 1285 (w), 1256 (w), 
1084 (m), 1038 (w), 834 (s), 777 (s), 665 (w).  
 
HR-MS (ESI‾) m/z for [C22H39N5O4Si279Br]‾ ([M-H])‾: calc.: 572.1724, found: 572.1721. 
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10.7.3  O6-Benzyl-8-bromo-3',5'-O-bis(tert-butyldimethylsilyl)-2'-deoxyguanosine 
29 
 
 
 
 
8-bromo-3',5'-O-bis(tert-butyldimethylsilyl)-2'-deoxyguanosine 28 (10.63 g, 18.50 mmol) and 
triphenylphosphine (7.30 g, 27.75 mmol, 1.5 eq.) were suspended in dioxane (220 ml).  
Benzylalcohol (2.94 mL, 27.75 mmol) and diisopropyl azodicarboxylate (4.38 mL, 27.75 
mmol) were added and the reaction mixture was stirred for 7 h at room temperature under 
argon. After concentration, the crude product was purified by chromatography on silica gel 
(iso-hexane:EtOAc 20:1) to provide 5.59 g (8.40 mmol, 45 %, lit. 78 %) of a white foam. 
Rf = 0.52 (iso-hexane:EtOAc 4:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 7.47 – 7.45 (m, 2H, Bz-H), 7.41 – 7.26 (m, 3H, 
Bz-H), 6.45 (s, 2H, NH2), 6.16 (dd, 3J = 6.9, 6.9 Hz, 1H, C1'-H), 5.45 (AB, 2J = 12.2, 2H, Bz-
CH2), 4.66 (ddd, 3J = 3.6, 3.7, 6.2 Hz, 1H, C3'-H), 3.75 (m, 2H, C5'-Ha+Hb), 3.61 (m, 1H, C4'-
H), 3.50 (m, 1H, C2'-Ha), 2.17 (ddd, 3J = 3.9, 7.0, 2J  = 13.1, 1H, C2'-Hb), 0.88 (s, 9H, tBu-H), 
0.77 (s, 1H, tBu-H), 0.10 (s, 6H, 2xSi-CH3), -0.07 (s, 3H, Si-CH3), -0.09 (s, 3H, Si-CH3). 
 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 159.67, 159.42, 155.09, 136.78, 128.84, 128.44, 
125.25, 114.87, 87.47, 85.43, 72.73, 66.79, 63.15, 36.17, 26.13, 17.85, -4.25, -4.27, -4.44, -
5.05, -5.08.  
 
IR ν (cm-1) 3506 (w), 3354 (br w), 2954 (s), 2929 (s), 2885 (m), 2856 (s), 1710 (br m), 1612 
(s), 1572 (s), 1520 (w), 1471 (m), 1455 (m), 1250 (s), 1217 (m), 1108 (s), 1028 (m), 833 (s), 
776 (s), 696 (m).  
 
HR-MS (ESI+) m/z for [C29H47N5O4Si279Br]+ ([M+H]+): calc.: 664.2350, found: 664.2348. 
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10.7.4  O6-Benzyl-8-bromo-3',5'-O-bis(tert-butyldimethylsilyl)-N2-dimethoxytrityl-
2'-deoxyguanosine 30 
 
 
 
 
 
O6-Benzyl-8-bromo-3',5'-O-bis(tert-butyldimethylsilyl)-2'-deoxyguanosine 30 (5.39 g, 8.10 
mmol) was dissolved in pyridine (85 ml). 4,4'-Dimethoxytrityl chloride (4.67 g, 13.78 mmol, 
1.7 eq.) was added and the reaction mixture was stirred overnight at room temperature. The 
reaction was quenched with methanol (2 mL), the solvents were evaporated in vacuo and the 
crude product was purified by chromatography on silica gel (iso-hexane:EtOAc 15:1, 1 % 
pyridine) to yield 7.77 g (8.03 mmol, 99 %, lit. 94 %) of the product as a white foam. 
Rf=0.58 (iso-hexanes:EtOAc 4:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 7.31 – 7.11 (m, 15H, Bz-5H + DMT-9H+N2-H), 
6.82 – 6.77 m, 4H, DMT-4H), , 6.04 (m, 1H, C1'-H), 4.72 (br s, 2H, Bz-CH2), 4.47 (m, 1H, 
C3'-H), 3.75 – 3.60 (m, 8H, 2xOMe + C5'-Ha+Hb), 3.52 (m, 2H, C4'-H + C2'-Ha), 2.06 (m, 1H, 
C2'-Hb), 0.85 (s, 9H, tBu-H), 0.75 (s, 9H, tBu-H), 0.08 (s, 6H, 2xSi-CH3), -0.08 (s, 3H, Si-
CH3), -0.13 (s, 3H, Si-CH3). 
 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 158.07, 158.06, 157.37, 154.40, 146.18, 138.10, 
138.07, 136.43, 130.12, 130.09 128.81, 128.51, 128.48, 128.02, 126.81, 115.30, 113.31, 
87.07, 85.87, 83.40, 80.91, 69.92, 67.34, 55.40, 35.47, 26.11, 26.08, 18.32, 18.20, 17.87, 
15.07, -4.27, -4.42, -5.03, -5.17. 
 
IR ν (cm-1) 3347 (w), 2953 (s), 2929 (s), 2856 (m), 2710 (w), 2552 (w), 1608 (s), 1584 (s), 
1509 (s), 1459 (m), 1442 (m), 1359 (m), 1249 (s), 1178 (m), 1078 (w), 1031 (m), 829 (s), 775 
(s), 699 (m). 
 
HR-MS (ESI+) m/z for [C50H63O6N5Si279Br]+ ([M+H]+): calc.: 964.3500, found: 964.3492. 
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10.7.5  Coupling of the protected deoxyguanosine with the aromatic unit 
10.7.5.1 8-(N-2-Amino-fluorene)-O6-benzyl-3',5'-O-bis(tert-butyldimethylsilyl)-N2-
dimethoxytrityl-2'-deoxyguanosine 33 
 
 
O6-Benzyl-8-bromo-3',5'-O-bis(tert-butyldimethylsilyl)-N2-dimethoxytrityl-2'-deoxyguano-
sine  30 (741 mg, 0.77 mmol), 2-aminofluorene 6 (259 mg, 1.38 mmol, 1.8 eq.), 
tris(dibenzylidenaceton)-dipalladium (Pd2(dba)3, 81 mg, 0.088 mmol, 10 mol%) and rac-2,2'-
Bis(diphenylphosphino)-1,1'-binaphtyl (BINAP, 147 mg, 0.236 mmol, 30 mol%) were 
degassed and flushed with argon in a flame dried and degassed apparatus. The entire reaction 
was carried out under argon atmosphere. Degassed toluene (7.5 mL) was added and the 
mixture was heated to 90ºC. After 40 min, a suspension of NaOtBu (136 mg, 1.38 mmol, 1.8 
eq.) in degassed toluene (7.5 mL) was added and the reaction mixture was stirred 1-2 h at 110 
ºC, until no more starting material 30 was detected by TLC. The reaction mixture was 
subsequently cooled, concentrated and purified by chromatography on aluminium oxide (n-
hexane:EtOAc 6:1) to provide 528 mg (0.50 mmol, 64 %, lit. 72%) of the product as a slightly 
yellow powder. Rf= 0.51 (n-hexane:EtOAc 3:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 8.85 (br s, 1H, N8-H), 7.82 (m, 1H, AF-C1-H), 
7.72 – 7.74 (m, 2H, AF-2H), 7.57 (m, 1H, AF-H), 7.55 (m, 1H, AF-H), 7.30-7.15 (m, 16 H, 
AF-2H + Bz-5H + DMT-9H), 6.78 (m, 4H, DMT-4H), 6.56 (s, 1H, N2-H), 6.20 (m, 1H, C1'-
H), 4.83 (s, 2H, Bz-CH2), 4.57 (m, 1H, C3'-H), 3.88 – 3.78 (m, 4H, AF-C9-2H + C5'-Ha+Hb), 
3.68 (s, 6H, 2xOMe), 3.60 (m, 1H, C4'-H), 3.29 (m, 1H, C2'-Ha), 2.00 (m, 1H, C2'-Hb), 0.85 (s, 
9H, tBu-H), 0.77 (s, 9H, tBu-H), 0.07 (s, 6H, 2xSi-CH3), -0.06 (s, 3H, Si-CH3), -0.07 (s, 3H, 
Si-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 157.96, 156.58, 155.77, 153.69, 147.28, 144.17, 
142.93, 141.67, 140.22, 137.14, 135.00, 130.19, 129.43, 129.00, 128.89, 128.77, 128.76, 
128.56, 128.53, 128.23, 127.92, 127.09, 126.64, 126.07, 125.32, 119.50, 117.4, 115.03, 
113.21, 112.34, 87.21, 83.50, 73.05, 69.84, 66.73, 63.10, 36.92, 36.28, 26.16, 26.07, 18.44, 
18.28, -4.25, -4.38, -5.03, -5.07. 
IR ν (cm-1) 3746 (w), 2650 (w), 2447 (br w), 3369 (w), 3058 (w), 2951 (s), 2928 (s), 2855 
(m), 1607 (s), 1590 (s), 1565 (m), 1507 (s), 1458 (s), 1418 (m), 1391 (m), 1359 (w), 1250 (s), 
1178 (m), 1108 (br m), 1079 (br m), 1032 (m), 831 (s), 777 (m), 699 (m). 
HR-MS (ESI+) m/z for [C63H75N6O6Si2]+ ([M+H]+): calc.:1067.5287, found: 1067.5291. 
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10.7.5.2 8-(N-Amino-benzene)-O6-benzyl-3',5'-O-bis(tert-butyldimethylsilyl)-N2-
dimethoxytrityl-2'-deoxyguanosine 31 
 
 
The coupling of aniline to the protected bromo-guanosine 30 was carried out according to the 
procedure described for the coupling with 2-aminofluorene (section 10.7.5.1). 
formulation  
         
1.54 g (1.59 mmol) 30  
0.30 g (0.48 mmol) BINAP 
0.17 g (0.16 mmol) Pd2(dba)3   
0.3 mL (2.87 mmol, 2 eq.) aniline  
0.27 g (2.85 mmol) NaOtBu in 18 mL toluene 
18 mL toluene  
        
 
yield: 880 mg, 0.90 mmol, 57 % 
Rf= 0.52 (n-hexane:EtOAc 3:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 8.78 (s, 1H, N8-H), 7.56 (d, 3J = 7.7, 2H, Phe-
H2,6), 7.33 – 7.09 (m, 16H, Phe-H3,5 + Bz-5H + DMT-9H), 6.81 (t, 3J = 7.4, 1H, Phe-H4), 6.78 
(m, 4H, DMT-4H), 6.52 (s, 1H, N2-H), 6.18 (m, 1H, C1'-H), 4.80 (s, 2H, Bz-CH2), 4.57 (m, 
1H, C3'-H), 3.80 – 3.73 (m, 2H, C5'-Ha + Hb), 3.67 (s, 6H, 2xOMe), 3.58 – 3.56 (m, 1H, C4'-
H), 3.29 (m, 1H, C2'-Ha), 2.43 (m, 1H, C2'-Hb), 0.85 (s, 9H, tBu-H), 0.76 (s, 9H, tBu-H), 0.07 
(s, 6H, 2xSi-CH3), -0.07 (s, 3H, Si-CH3), -0.09 (s, 3H, Si-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 157.94, 156.55, 155.72, 153.64, 147.34, 146.54, 
140.99, 137.11, 130.14, 129.00, 128.87, 128.76, 128.57, 128.31, 127.90, 126.63, 121.59, 
118.48, 113.20, 112.28, 87.18, 83.41, 73.02, 69.82, 66.72, 63.07, 55.38, 26.17, 26.14, 18.43, 
18.28, -4.24, -4.38, -5.04, -5.09. 
HR-MS (ESI‾) m/z for [C56H69N6O6Si2]‾ ([M-H]‾): calc.: 977.4817, found: 977.4890. 
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10.7.5.3 8-(N-2-Amino-naphthalene)-O6-benzyl-3',5'-O-bis(tert-butyldimethyl-
silyl)-N2-dimethoxytrityl-2'-deoxyguanosine 32 
 
 
The coupling of 2-napthylamine to the protected bromo-guanosine 30 was carried out 
according to the procedure described for the coupling with 2-aminofluorene (section 
10.7.5.1). 
formulation  
         
1.00 g (1.03 mmol) 30  
0.35 g (0.56 mmol) BINAP 
0.19 g (0.21 mmol) Pd2(dba)3   
0.27 g (1.86 mmol, 1.8 eq.) 2-napthylamine  
0.18 g (1.86 mmol, 1.8 eq.) NaOtBu in 12 mL toluene 
12 mL toluene  
        
 
yield: 431 mg, 0.42 mmol, 41 % 
Rf= 0.58 (n-hexane:EtOAc 3:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 9.02 (s, 1H, N8-H), 7.81 – 7.64 (m, 4H, Nap-
4H), 7.47 –  7.19 (m, 17 H, Nap-3H + Bz-5H + DMT-9H), 6.79 (m, 4H, DMT-4H), 6.57 (s, 
1H, N2-H), 6.22 (m, 1H, C1'-H), 4.84 (s, 2H, Bz-CH2), 4.59 (m, 1H, C3'-H), 3.77 (m, 2H, C5'-
Ha+Hb), 3.68 (s, 6H, 2xOMe), 3.59 (m, 1H, C1'-H), 3.46 (br m, 1H, C2'-Ha), 2.01 (m, 1H, C2'-
Hb), 0.84 (s, 9H, tBu-H), 0.76 (s, 9H, tBu-H), 0.07 (s, 3H, Si-CH3), 0.06 (s, 3H, Si-CH3) -0.07 
(s, 3H, Si-CH3), -0.09 (s, 3H, Si-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 157.96, 156.69, 155.87, 153.72, 147.26, 146.53, 
138.88, 138.44, 137.13, 134.06, 130.15, 129.24, 128.87, 128.75, 128.62, 128.45, 128.28, 
127.91, 127.86, 127.10, 126.71, 126.64, 124.09, 120.38, 113.20, 112.36, 87.23, 83.54, 73.07, 
69.85, 66.73, 63.09, 55.38, 36.22, 26.15, 26.14, 18.43, 18.27, -4.26, -4.39, -5.04, -5.08. 
IR ν (cm-1) 3367 (br m), 3059 (br m), 2952 (s), 2928 (s), 2896 (m), 2855 (m), 1605 (br s), 
1566 (s), 1505 (s), 1262 (m), 1419 (w), 1391 (m), 1359 (m), 1294 (w), 1249 (s), 1178 (m), 
1105 (br m), 1031 (m), 950 (br w), 831 (s), 778 (m), 698 (m). 
HR-MS (ESI‾) m/z for [C60H71N6O6Si2]‾ ([M-H]‾): calc.: 1027.4974, found: 1027.4937. 
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10.7.5.4  8-(N-2-Amino-anthracene)-O6-benzyl-3',5'-O-bis(tert-butyldimethylsilyl)-
N2-dimethoxytrityl-2'-deoxyguanosine 34 
 
 
The coupling of 2-aminoanthracene to the protected bromo-guanosine 30 was carried out 
according to the procedure described for the coupling with 2-aminofluorene (section 
10.7.5.1). 
formulation  
         
1.30 g (1.34 mmol) 30  
257 mg (0.41 mmol) BINAP 
142 mg (0.16 mmol) Pd2(dba)3   
0.40 g (2.07 mmol, 1.5 eq.) 2-aminoanthracene  
0.24 g (2.50 mmol, 1.8 eq.) NaOtBu in 16 mL toluene 
16 mL toluene  
        
 
yield: 773 mg, 0.72 mmol, 53 % 
Rf= 0.49 (n-hexane:EtOAc 3:1) 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 9.13 (s, 1H, N8-H), 8.41 (s, 1H, Ant-H9/10), 8.29 
(s, 1H, Ant-H10/9 ), 8.23 (d, J = 2.1, 1H, Ant-H1), 7.97 (m, 3H, Ant-H4,-H5,-H8), 7.66 (dd, J = 
9.2, 2.1, 1H, Ant-H3), 7.47 – 7. 34 (m, 2H, Ant-H6,-H7), 7.33 – 7.10 (m, 14H, Bz-5H + DMT-
9H), 6.83 – 6.76 (m, 4H, DMT-4H),  6.59 (br s, 1H, N2-H), 6.26 (br m, 1H, C1'-H), 4.87 (br s, 
2H, Bz-CH2), 4.60 (m, 1H, C3'-H), 3.85 – 3.74 (m, 2H, C5'-Ha + C4'-H), 3.69 (s, 6H, 2xOMe), 
3.64 – 3.59 (m, 1H, C5'-Hb),  3.49 (br m, 1H, C2'-Ha), 2.02 (m, 1H, C2'-Hb), 0.85 (s, 9H, tBu-
H), 0.77 (s, 9H, tBu-H), 0.08 (s, 3H, Si-CH3), 0.07 (s, 3H, Si-CH3), -0.05 (s, 3H, Si-CH3), -
0.08 (s, 3H, Si-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 157.97, 156.81, 155.93, 153.74, 147.10, 146.54, 
138.43, 138.23, 137.18, 132.40, 132.20, 130.36, 130.16, 129.04, 128.88, 128.77, 128.44, 
128.29, 128.00, 127.93, 127.59, 126.67, 126.20, 125.89, 124.91, 124.40, 121.78, 118.43, 
113.23, 112.44, 111.29,  87.26, 83.58, 73.08, 69.86, 66.72, 63.10, 55.40, 36.25, 26.16, 26.15, 
18.43, 18.28,  -4.25, -4.37, -5.03, -5.07. 
IR ν (cm-1) 3358 (br m), 3056 (w), 3031 (w), 2951 (s), 2928 (s), 2855 (m), 1599 (s), 1565 (s), 
1507 (s), 1291 (m), 1461 (s), 1414 (m), 1359 (m), 1295 (w), 1250 (s), 1220 (m), 1178 (m), 
1105 (br m), 1020 (m), 828 (s), 777 (m), 739 (m), 698 (m), 663 (w). 
HR-MS (ESI+) m/z for [C64H73N6O6Si2]+([M+H]+): calc.: 1079.5287, found: 1079.5285. 
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10.7.5.5 8-(N-1-Amino-pyrene)-O6-benzyl-3',5'-O-bis(tert-butyldimethylsilyl)-N2-
dimethoxytrityl-2'-deoxyguanosine 35 
 
 
 
 
The coupling of 1-aminopyrene to the protected bromo-guanosine 30 was carried out 
according to the procedure described for the coupling with 2-aminofluorene (section 
10.7.5.1). 
formulation  
         
2.10 g (2.17 mmol) 30  
416 mg (0.67 mmol) BINAP 
229 mg (0.25 mmol) Pd2(dba)3   
1.06 g (4.87 mmol, 2.2 eq.) 1-aminopyrene  
385 mg (4.00 mmol, 1.8 eq.) NaOtBu in 24 mL toluene 
24 mL toluene  
        
 
yield: 1.63 g, 1.48 mmol, 68 %, lit. 51 % 
Rf= 0.45 (n-hexane:EtOAc 3:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 9.05 (s, 1H, N8-H), 8.22 – 7.98 (m, 5H, Pyr-5H), 
7.78 (m, 1H, Pyr-1H), 7.43 (m, 1H, Pyr-1H), 7.28– 7.17 (m, 13H, Bz-3H + DMT-9H + Pyr-
H), 7.03 (m, 2H, Bz-2H), 6.80 – 6.76 (m, 4H, DMT-4H),  6.65 (br s, 1H, N2-H), 6.30 (br m, 
1H, C1'-H), 4.76 (br s, 2H, Bz-CH2), 4.56 (m, 1H, C3'-H), 3.84 (m, 2H, C5'-Ha + C4'-H), 3.68 
(s, 6H, 2xOMe), 3.68 – 3.63 (m, 1H, C5'-Hb),  3.39 (br m, 1H, C2'-Ha), 2.05 (m, 1H, C2'-Hb), 
0.80 (s, 9H, tBu-H), 0.68 (s, 9H, tBu-H), 0.06 (s, 3H, Si-CH3), 0.05 (s, 3H, Si-CH3), -0.13 (s, 
3H, Si-CH3), -0.17 (s, 3H, Si-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 157.93, 156.62, 155.79, 154.06, 149.54, 146.56, 
143.23, 138.46, 136.98, 135.15, 131.45, 131.08, 130.96, 130.17, 129.42, 128.99, 128.88, 
128.64, 128.42, 128.20, 127.89, 127.73, 127.15, 126.74, 126.60, 126.30, 126.08, 125.80, 
125.32, 125.15, 124.98, 124.52, 123.59, 122.55, 122.10, 113.18, 112.30, 87.36, 84.09, 73.06, 
69.76, 66.66, 63.15, 55.37, 26.08, 26.05, 18.37, 18.16, -4.31, -4.40, -5.12, -5.23. 
IR ν (cm-1) 3368 (br m), 3034 (m), 2951 (s), 2928 (s), 2855 (m), 1737 (m), 1297 (s), 1564 (m), 
1507 (s), 1486 (s), 1461 (m), 1413 (m), 1248 (s), 1178 (m), 1102 (m), 1032 (s), 951 (br w), 
830 (s), 776 (m), 698 (m), 677 (w). 
HR-MS (ESI+) m/z for [C66H75N6O6Si2]+ ([M-H]+): calc.:1103.5287, found: 1103.5283. 
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10.7.6   N-Acetylation at C8-position of the aromatic amine dG adducts 
10.7.6.1 8-(N-acetyl-2-amino-fluorene)-O6-benzyl-3',5'-O-bis(tert-butyldimethyl-
silyl)-2'-deoxyguanosine 38 
 
 
 
8-(N-2-amino-fluorene)-O6-benzyl-3',5'-O-bis(tert-butyldimethylsilyl)-N2-dimethoxytrityl-2'-
deoxyguanosine 33 (908 mg, 0.85 mmol) was dissolved in pyridine (17 mL) and triethylamine 
(588 μL, 4.3 mmol), 4-dimethylaminopyridine (50 mg, 0.43 mmol) and acetic anhydride (403 
μL, 4.3 mmol) were added. After stirring for 5 hours at room temperature, the solvents were 
removed in vacuo, the reaction mixture was diluted in EtOAc (150 mL) and extracted with 
water (3 x100 mL). The organic layer was dried over MgSO4, evaporated to dryness and 
treated with a 0.01 M solution of HCl in MeOH (4.5 mL, 45 μmol). The mixture was stirred 
overnight at room temperature, concentrated and purified by chromatography on silica gel (n-
hexane: EtOAc 6:1) to provide 474 mg (0.59 mmol, 69% overall, lit. 78 %) of the product as a 
slightly yellow powder. 
 
Rf = 0.21 (n-hexane:EtOAc 3:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 7.86 (m, 2H, AF-2H), 7.56 – 7.42 (m, 4H, AF-
4H), 7.40 – 7.24 (m, 6 H, AF-H + Bz-5H), 6.44 (s, 2H, N2-H2), 6.08 (m, 1H, C1'-H), 5.45 (s, 
2H, Bz-CH2), 4.61 (m, 1H, C3'-H), 3.88 – 3.72 (m, 4H, AF-C9-2H + C5'-Ha+Hb), 3.64 (m, 1H, 
C4'-H), 3.22 (m, 1H, C2'-Ha), 2.02 (s, 3H, N8-Ac), 1.85 (m, 1H, C2'-Hb), 0.84 (s, 9H, tBu-H), 
0.73 (s, 9H, tBu-H), 0.07 (s, 6H, 2xSi-CH3), -0.10 (s, 6H, Si-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 160.57, 159.98, 154.15, 153.91, 143.76, 140.55, 
138.37, 136.76, 129.17, 128.86, 128.61, 127.31, 125.58, 120.69, 113.27, 112.48, 87.71, 83.80, 
72.59, 67.48, 60.19, 36.88, 26.09, 26.05, 18.29, 18.05, -4.35, -4.41, -5.02, -5.07. 
IR ν (cm-1) 3406 (br m), 3035 (w), 2955 (s), 2928 (s), 2856 (m), 1696 (m), 1610 (s), 1589 (m), 
1508 (s), 1456 (m), 1428 (w), 1404 (w), 1361 (m), 1342 (m), 1293 (w), 1248 (br s), 1227 (br 
s), 1178 (m), 1100 (br w), 1078 (w), 829 (s), 775 (m), 735 (m), 698 (w), 667 (w).  
HR-MS (ESI+) m/z for [C44H59N6O5Si2]+ ([M+H]+): calc.: 807.4085, found 807.4071. 
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10.7.6.2 8-(N-acetyl-amino-benzene)-O6-benzyl-3',5'-O-bis(tert-butyldimethyl-
silyl)-2'-deoxyguanosine 36 
 
 
 
 
The acetylation at the C8 nitrogen of the aminobenzene-dG 31 was carried out according to 
the procedure described for the acetylation of 2-aminofluorene-dG (section 10.7.6.1). 
 
formulation  
         
0.88 g (0.90 mmol) 31  
420 µL (4.51 mmol) triethylamine 
60 mg (0.45 mmol) 4-dimethylaminopyridine 
420 µL (4.51 mmol) acetic anhydride 
17 mL pyridine  
        
4.00 mL 0.01 M methanolic HCl solution  
        
 
yield: 260 mg, 0.35 mmol, 38 % 
Rf= 0.33 (n-hexane:EtOAc 3:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 7.47 (m, 2H, Phe-H2,6), 7.39 – 7.20 (m, 8H, Phe-
H3,4,5 + Bz-5H), 6.45 (s, 2H, N2-H2), 6.02 (m, 1H, C1'-H), 5.45 (s, 2H, Bz-CH2), 4.62 (m, 1H, 
C3'-H), 3.80 – 3.72 (m, 2H, C5'-Ha+Hb), 3.64 (m, 1H, C4'-H), 3.21 (m, 1H, C2'-Ha), 1.98 (s, 3H, 
N8-Ac), 1.82 (m, 1H, C2'-Hb), 0.85 (s, 9H, tBu-H), 0.74 (s, 9H, tBu-H), 0.07 (s, 3H, Si-CH3), 
0.05 (s, 3H, Si-CH3), -0.09 (s, 3H, Si-CH3), -0.10 (s, 3H, Si-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 160.62, 159.91, 153.77, 136.75, 129.77, 129.13, 
128.86, 128.60, 112.44, 87.69, 83.75, 72.56, 67.47, 63.25, 57.88, 36.46, 26.10, 26.07, 23.20, 
18.31, 18.06, -4.31, -4.42, -5.00, -5.06. 
HR-MS (ESI+) m/z for [C37H55N6O5Si2]+ ([M+H]+): calc.: 719.3772, found: 719.3758. 
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10.7.6.3 8-(N-acetyl-2-amino-naphthalene)-O6-benzyl-3',5'-O-bis(tert-butyl-
dimethylsilyl)-2'-deoxyguanosine 37 
 
 
 
The acetylation at the C8 nitrogen of the aminonaphthalene-dG 32 was carried out according 
to the procedure described for the acetylation of 2-aminofluorene-dG (section 10.7.6.1). 
 
formulation  
         
0.43 g (0.42 mmol) 32  
220 µL (2.10 mmol) triethylamine 
30 mg (0.21 mmol) 4-dimethylaminopyridine 
200 µL (2.10 mmol) acetic anhydride 
8 mL pyridine  
        
1.90 mL 0.01 M methanolic HCl solution  
        
 
yield: 190 mg, 0.24 mmol, 57 % 
Rf= 0.27 (n-hexane:EtOAc 3:1) 
 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 8.02 – 7-81 (br m, 4H, Nap-4H),  7.58 – 7.27 
(m, 8 H, Nap-3H + Bz-5H), 6.45 (s, 2 H, N2H2), 6.04 (br m, 1H, C1'-H), 5.47 (br d, 2H, Bz-
CH2),  4.61 (br m, 1H, C3'-H), 3.83– 3.55 (m, 3H, C5'-2H + C4'-H),  3.22 (br m, 1H, C2'-Ha), 
2.05 (br s, 4H, N8-Ac + C2'-Hb), 0.82 (br s, 9H, tBu-H), 0.72 (s, 9H, tBu-H), 0.05 (br s, 6H, 
2Si-CH3),  -0.12 (br s, 6H, 2Si-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 159.75, 153.99, 136.61, 133.10, 129.14, 128.85, 
128.58, 128.24, 127.93, 127.00, 112.46, 87.63, 83.77, 79.61, 72.47, 67.53, 26.07, 18.28, -
4.34, -4.39, -5.04, -5.10. 
IR ν (cm-1) 3366 (br m), 2952 (m) 2928 (s), 2855 (s), 1933 (w), 1699 (m), 1611 (s), 1581 (s), 
1508 (w), 1469 (m), 1429 (m), 1367 (m), 1336 (m), 1281 (m), 1231 (s), 1108 (w), 1068 (m), 
1028 (w), 954 (br w), 834 (s), 776 (s), 746 (m), 695 (w), 669 (w). 
HR-MS (ESI+) m/z for [C41H57N6O5Si2]+ ([M+H]+): calc.: 769.3911, found: 769.3929. 
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10.7.6.4 8-(N-acetyl-2-amino-anthracene)-O6-benzyl-3',5'-O-bis(tert-butyl-
dimethylsilyl)-2'-deoxyguanosine 39 
 
 
 
The acetylation at the C8 nitrogen of the aminoanthracene-dG 34 was carried out according to 
the procedure described for the acetylation of 2-aminofluorene-dG (section 10.7.6.1). 
 
formulation  
         
0.77 g (0.75 mmol) 34  
530 µL (5.06 mmol) triethylamine 
45 mg (0.31 mmol) 4-dimethylaminopyridine 
360 µL (3.8 mmol) acetic anhydride 
15 mL pyridine  
        
3.90 mL 0.01 M methanolic HCl solution  
        
 
yield: 333 mg, 0.41 mmol, 54 % 
Rf= 0.28 (n-hexane:EtOAc 3:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 8.55 (s, 1H, Ant-H9/10), 8.50 (s, 1H, Ant-H10/9 ), 
8.11 – 7-81 (br m, 4H, Ant-4H),  7.57 – 7.26 (m, 8 H, Ant-3H + Bz-5H), 6.42 (s, 2 H, N2H2), 
6.08 (br m, 1H, C1'-H), 5.47 (br s, 2H, Bz-CH2),  4.59 (br m, 1H, C3'-H), 3.79– 3.56 (m, 3H, 
C5'-2H + C4'-H),  3.23 (br m, 1H, C2'-Ha), 2.08 (br s, 4H, N8-Ac + C2'-Hb), 0.81 (br s, 9H, tBu-
H), 0.69 (s, 9H, tBu-H), 0.03 (br s, 6H, 2Si-CH3),  -0.14 (br s, 6H, 2Si-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 160.50, 160.05, 153.89, 143.14, 137.21, 136.76, 
131.95, 131.91, 131.13, 130.06, 129.98, 129.72, 129.12, 128.85, 128.59, 128.53, 128.29, 
126.82, 126.51, 126.44, 126.28, 124.55, 124.33, 112.59, 87.70, 83.86, 79.60, 72.53, 67.53, 
63.22, 26.05, 23.20, 18.24, 18.01, -4.44, -5.07, -5.12. 
IR ν (cm-1) 3366 (w), 2926 (s), 2855 (s), 1977 (w), 1699 (m), 1611 (s), 1582 (s), 1471 (m), 
1419 (w), 1366 (m), 1338 (m), 1250 (s), 1066 (m), 1028 (w), 953 (w), 834 (s), 775 (s).  
HR-MS (ESI+) m/z for [C45H59N6O5Si2]+ ([M+H]+): calc.: 819.4085, found: 819.4090. 
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10.7.6.5 8-(N-acetyl-1-amino-pyrene)-O6-benzyl-3',5'-O-bis(tert-butyldimethyl-
silyl)-2'-deoxyguanosine 40 
 
 
 
 
The acetylation at the C8 nitrogen of the aminopyrene-dG 35 was carried out according to the 
procedure described for the acetylation of 2-aminofluorene-dG (section 10.7.6.1). 
 
formulation  
         
1.08 g (0.98 mmol) 35  
684 µL (6.53 mmol) triethylamine 
60 mg (0.42 mmol) 4-dimethylaminopyridine 
468 µL (4.91 mmol) acetic anhydride 
22 mL pyridine  
        
5.30 mL 0.01 M methanolic HCl solution  
        
 
yield: 660 mg, 0.78 mmol, 80 % 
Rf= 0.30 (n-hexane:EtOAc 3:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 8.35 – 8.08 (m, 5H, Pyr-5H), 7.92 (m, 1H, Pyr-
1H), 7.5 – 7.09 (m, 7H, Bz-5H, Pyr-2H), 6.37 (br s, 2H, N2-H2), 6.34 (m, 1H, C1'-H), 5.53 (br 
s, 2H, Bz-CH2), 4.59 (m, 1H, C3'-H), 3.92 – 3.85 (m, 2H, C5'-Ha + C4'-H), 3.81 – 3.72 (m, 1H, 
C5'-Hb), 3.41 (m, 1H, C2'-Ha), 2.25 (s, 3H, N8-Ac), 1.93 (m, 1H, C2'-Hb), 0.89 (s, 9H, tBu-H), 
0.74 (s, 9H, tBu-H), 0.13 (s, 6H, 2xSi-CH3), -0.06 (s, 3H, Si-CH3), -0.10 (s, 3H, Si-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 158.08, 136.73, 136.14, 131.01, 130.10, 128.82, 
128.04, 127.45, 126.37, 125.10, 123.92, 113.33, 87.91, 84.20, 72.81, 69.83, 67.33, 62.92, 
55.39, 26.06, 18.28, -4.36, -5.05. 
IR ν (cm-1) 3510 (br w), 3368 (br w), 3034 (w), 2951 (s), 2928 (s), 2884 (m), 2855 (s), 1735 
(w), 1694 (m), 1611 (s), 1582 (s), 1507 (m), 1462 (m), 1420 (w), 1367 (m), 1339 (m), 1248 (s), 
1179 (w), 1108 (m), 1067 (br m), 1029 (m), 833 (s), 775 (s), 696 (w). 
HR-MS (ESI+) m/z for [C47H59N6O5Si2]+ ([M+H]+): calc.: 843.4085, found: 843.4085. 
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10.7.7  Protection of the N2-position of the aromatic amine dG adducts 
10.7.7.1 8-(N-acetyl-2-amino-fluorene)-O6-benzyl-3',5'-O-bis(tert-butyldimethyl-
silyl)-N2-isopropylphenoxyacetyl-2'-deoxyguanosine 43 
 
 
8-(N-acetyl-2-amino-fluorene)-O6-benzyl-3',5'-O-bis(tert-butyldimethylsilyl)-2'-deoxyguano-
sine (519 mg, 0.64 mmol) 38 was dissolved in pyridine (25 mL). 4-Isopropylphenoxyacetyl 
chloride (575 mg, 2.74 mmol, for preparation see section 10.7.12) was added and the dark red 
reaction mixture was stirred overnight at room temperature. The solvent was subsequently 
removed in vacuo and the crude product was diluted in EtOAc (100 ml) and extracted with 
water (2 x 75 ml). The organic layer was dried over MgSO4, concentrated and purified by 
chromatography on silica gel (n-hexane:EtOAc 4:1) to provide 582 mg (0.91 mmol, 92%, lit. 
97 %) of the product as a slightly yellow powder. 
 
Rf = 0.13 (n-hexane:EtOAc 3:1) 
 
1H-NMR (600 MHz, DMSO-d6): δ (ppm) = 7.91– 7.87 (m, 2H, AF-2H), 7.56 – 7.51 (m, 4H, 
AF-4H), 7.37 – 7.29 (m, 6 H, AF-H + Bz-5H), 7.10 (d, 3J = 8.6, 2H, Pac-H2), 6.81 (d, 3J = 
8.6, 2H, Pac-H2), 6.22 (m, 1H, C1'-H), 5.59 (s, 2H, Bz-CH2), 4.84 (m, 3H, Pac-CH2, C3'-H), 
3.92 (s, 2H, AF-C9-H2), 3.77 –  3.70 (m, 3H, C5'-Ha+Hb + C4'-H), 3.23 (m, 1H, C2'-Ha), 2.79 
(sept, 3J = 6.9, 1 H, iPr-H), 2.06 (s, 3H, N8-Ac), 1.95 (m, 1H, C2'-Hb), 1.13 – 1.11 (m, 6H, 
2xiPr-CH3), 0.80 (s, 9H, tBu-H), 0.69 (s, 9H, tBu-H), -0.01 (br s, 6H, 2xSi-CH3), -0.18 (br s, 
6H, 2xSi-CH3). 
13C-NMR (151 MHz, DMSO-d6): δ (ppm) = 156.43, 143.81, 141.25, 136.26, 129.23, 128.94, 
128.81, 127.45, 127.32, 125.58, 116.31, 114.68, 88.17, 72.17, 68.52, 67.51, 36.89, 33.03, 
26.05, 24.52, 18.26, 17.93, -4.53, -4.63, -5.07, -5.14. 
IR ν (cm-1) 3650 (w), 3414 (br w), 3032 (w), 2953 (s), 2928 (s), 2891 (w), 2856 (m), 1696 (s), 
1610 (s), 1584 (s), 1508 (s), 1456 (s), 1426 (m), 1403 (w), 1342 (m), 1293 (w), 1249 (s), 1227 
(s), 1077 (m), 1030 (m), 954 (w), 910 (w), 832 (s), 775 (m), 734 (m), 698 (w), 668 (w). 
HR-MS (ESI+) m/z for [C55H71N6O7Si2]+ ([M+H]+): calc.: 983.4923, found: 983.4926. 
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10.7.7.2 8-(N-acetyl-amino-benzene)-O6-benzyl-3',5'-O-bis(tert-butyldimethyl-
silyl)-N2-isopropylphenoxyacetyl-2'-deoxyguanosine 41 
 
 
 
 
The protection of the N2-position of acetylaminobenzene-dG 38 was carried out according to 
the procedure described for the protection of acetylaminofluorene-dG (section 10.7.7.1). 
 
formulation  
         
0.26 g (0.35 mmol) 38  
310 µL (1.50 mmol) 4-Isopropylphenoxyacetyl chloride 
14 mL pyridine  
        
 
yield: 270 mg, 0.30 mmol, 86 % 
Rf = 0.15 (n-hexane:EtOAc 4:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 10.61 (s, 1H, N2-H), 7.51 – 7.32 (m, 10H, Phe-
5H + Bz-5H), 7.10 (d, 3J = 8.4, 2H, Pac-H2), 6.81 (d, 3J = 8.7, 2H, Pac-H2), 6.17 (m, 1H, C1'-
H), 5.57 (s, 2H, Bz-CH2), 4.84 (m, 3H, Pac-CH2, C3'-H), 3.80 –  3.65 (m, 3H, C5'-Ha+Hb + C4'-
H), 3.15 (m, 1H, C2'-Ha), 2.79 (sept, 3J = 7.3, 1 H, iPr-H), 2.10 (br m, 1H, C2'-Hb), 2.01 (s, 3H, 
N8-Ac), 1.14 (d, 3J = 7.2 Hz, 3H, iPr-CH3), 1.13 (d, 3J = 6.9 Hz, 3H, iPr-CH3), 0.80 (s, 9H, 
tBu-H), 0.69 (s, 9H, tBu-H), -0.01 (s, 3H, Si-CH3), -0.03 (s, 3H, Si-CH3), -0.16 (s, 3H, Si-
CH3), -0.17 (s, 3H, Si-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 167.02, 156.42, 152.16, 150.03, 141.23, 136.24, 
129.92, 129.24, 128.94, 128.83, 127.46, 127.41, 124.35, 116.26, 115.36, 114.64, 88.13, 84.01, 
72.12, 68.50, 67.44, 33.03, 26.06, 26.04, 24.67, 24.53, 18.29, 17.94, -4.52, -4.65, -5.06, -5.13. 
HR-MS (ESI‾) m/z for [C48H65N6O7Si2]‾ ([M-H]‾): calc.: 893.4453, found 893.4503. 
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10.7.7.3 8-(N-acetyl-2-amino-naphthalene)-O6-benzyl-3',5'-O-bis(tert-butyl-
dimethylsilyl)-N2-isopropylphenoxyacetyl-2'-deoxyguanosine 42 
 
 
 
The protection of the N2-position of acetylaminonaphthalene-dG 37 was carried out according 
to the procedure described for the protection of acetylaminofluorene-dG (section 10.7.7.1). 
 
formulation  
         
0.26 g (0.86 mmol) 37  
760 µL (3.50 mmol) 4-Isopropylphenoxyacetyl chloride 
35 mL pyridine  
        
 
yield: 740 mg, 0.79 mmol,  91 % 
Rf = 0.21 (n-hexane:EtOAc 4:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 10.61 (s, 1H, N2-H), 8.01 – 7.78 (m, 4H, Nap-
4H), 7.59 – 7.31 (m, 8 H, Nap-3H + Bz-5H), 7.13 – 7.06 (m, 2 H, Pac-H3,5),  6.84 – 6.77 (m, 2 
H, Pac-H2,6), 6.23 (br m, 1H, C1'-H), 5.58 (br s, 2H, Bz-CH2),  4.95 – 4.75 (br m, 3H, Pac-CH2 
+ C3'-H), 3.84 – 3.59 (m, 3H, C5'-2H + C4'-H),  3.16 (br m, 1H, C2'-Ha), 2.78 (sept, J = 6.9, 1H, 
iPr-H), 2.07 (br s, 4H, N8-Ac + C2'-Hb), 1.12 (d, J = 6.9, 6H, iPr-CH3), 0.79 (br s, 9H, tBu-H), 
0.67 (s, 9H, tBu-H), -0.03 (s, 6H, 2Si-CH3), -0.21 (br s, 6H, 2Si-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 13C NMR (101 MHz, dmso) δ = 167.03, 160.21, 
156.42, 152.23, 146.18, 141.23, 136.24, 133.37, 129.25, 128.94, 128.83, 128.34, 128.05, 
127.46, 127.23, 116.34, 114.65, 88.16, 84.11, 72.10, 68.52, 67.46, 63.74, 33.03, 26.03, 24.53, 
23.10, 18.25, 17.93, -4.55, -4.66, -5.10, -5.17. 
IR ν (cm-1) 3746 (w), 3671 (w), 3406 (w), 3058 (w), 2954 (s), 2927 (s), 2884 (m), 2856 (s), 
1669 (s), 1612 (s), 1589 (s), 1508 (s), 1462 (s), 1358 (s), 1340 (s), 1282 (w), 1248 (br m), 
1225 (s), 1178 (w), 1075 (m), 961 (w), 910 (w), 835 (s), 776 (s), 746 (m), 696 (w), 668 (w). 
HR-MS (ESI+) m/z for [C52H69N6O7Si2]+ ([M+H]+): calc.: 945.4766, found 945.4736. 
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10.7.7.4 8-(N-acetyl-2-amino-anthracene)-O6-benzyl-3',5'-O-bis(tert-
butyldimethyl-silyl)-N2-isopropylphenoxyacetyl-2'-deoxyguanosine 44 
 
 
 
The protection of the N2-position of acetylaminoanthracene-dG 39 was carried out according 
to the procedure described for the protection of acetylaminofluorene-dG (section 10.7.7.1). 
 
formulation  
         
0.60 g (0.73 mmol) 39  
645 µL (2.97 mmol) 4-Isopropylphenoxyacetyl chloride 
27 mL pyridine  
        
 
yield: 596 mg, 0.61 mmol,  84% 
Rf = 0.17 (n-hexane:EtOAc 3:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 10.57 (s, 1H, N2-H), 8.57 (s, 1H, Ant-H9/10), 8.51 
(s, 1H, Ant-H10/9 ), 8.13 – 7.96 (m, 4H, Ant-4H), 7.58 – 7.29 (m, 8 H, Ant-3H + Bz-5H), 7.13 
– 7.06 (m, 2 H, Pac-H3,5),  6.84 – 6.77 (m, 2 H, Pac-H2,6), 6.24 (br m, 1H, C1'-H), 5.59 (br s, 
2H, Bz-CH2),  4.90 – 4.73 (br m, 3H, Pac-CH2 + C3'-H), 3.85 – 3.59 (m, 3H, C5'-2H + C4'-H),  
3.18 (br m, 1H, C2'-Ha), 2.78 (sept, J = 6.9, 1H, iPr-H), 2.12 (br s, 4H, N8-Ac + C2'-Hb), 1.12 
(d, J = 6.9, 6H, iPr-CH3), 0.77 (br s, 9H, tBu-H), 0.64 (br s, 9H, tBu-H), 0.08 (s, 3H, Si-CH3), 
0.07 (s, 6H, Si-CH3), -0.04 (br s, 3H, Si-CH3), -0.22 (br s, 3H, Si-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 167.02, 160.27, 156.42, 152.31, 151.86, 146.16, 
141.27, 137.02, 136.26, 132.01, 131.97, 131.11, 130.13, 129.23, 128.94, 128.81, 128.54, 
128.31, 127.45, 126.93, 126.73, 126.60, 126.50, 126.40, 125.30, 125.14, 124.99, 124.70, 
116.40, 115.37, 114.69, 88.19, 84.17, 72.15, 68.55, 67.54, 63.72, 33.01, 26.24, 26.01, 24.50, 
23.20, 18.22, 17.91, -4.56, -4.65, -5.12, -5.18. 
IR ν (cm-1) 3752 (w), 3412 (m), 3032 (w), 2954 (s), 2928 (s), 2887 (w), 2885 (m), 1701 (br s), 
1609 (s), 1589 (s), 1508 (s), 1461 (s), 1426 (s), 1342 (s), 1284 (w), 1249 (br m), 1224 (s), 
1074 (br s), 1029 (m), 958 (w), 833 (s), 776 (s), 696 (w) 671 (w). 
HR-MS (ESI‾) m/z for [C56H69N6O7Si2]‾ ([M-H]‾): calc.: 993.4766  found 993.4752.  
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10.7.7.5 8-(N-acetyl-1-amino-pyrene)-O6-benzyl-3',5'-O-bis(tert-butyldimethyl-
silyl)-N2-isopropylphenoxyacetyl-2'-deoxyguanosine 45 
 
 
 
 
The protection of the N2-position of acetylaminopyrene-dG 40 was carried out according to 
the procedure described for the protection of acetylaminofluorene-dG (section 10.7.7.1). 
 
formulation  
         
0.78 g (0.92 mmol) 40  
830 µL (3.82 mmol) 4-Isopropylphenoxyacetyl chloride 
34 mL pyridine  
        
 
yield: 991 mg, 0.97 mmol,  99% 
Rf = 0.15 (n-hexane:EtOAc 3:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = = 8.37 – 8.07 (m, 5H, Pyr-5H), 7.59 – 7.14 (m, 
8H, Bz-5H, Pyr-3H), 7.10 (d, 3J = 8.6, 2H, Pac-H2), 6.80 (d, 3J = 8.4, 2H, Pac-H2), 6.51 (m, 
1H, C1'-H), 5.51 (br s, 2H, Bz-CH2), 4.95 (m, 1H, C3'-H), 4.83 (m, 2H, Pac-CH2), 3.80 –  3.84 
(m, 3H, C5'-Ha+Hb + C4'-H), 3.57 (m, 1H, C2'-Ha), 2.78 (sept, 3J = 6.8, 1 H, iPr-H), 2.26 (br s, 
3H, N8-Ac) 1.88 (m, 1H, C2'-Hb), 1.13 (m, 6H, 2xiPr-CH3), 0.81 (s, 9H, tBu-H), 0.71 (s, 9H, 
tBu-H), 0.08 (s, 3H, Si-CH3), 0.07 (s, 3H, Si-CH3), -0.14 (s, 3H, Si-CH3), -0.17 (s, 3H, Si-
CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 156.42, 149.98, 141.21, 136.18, 130.99, 129.23, 
128.87, 127.45, 124.95, 124.14, 115.21, 114.64, 113.32, 71.93, 68.53, 67.45, 55.39, 33.03, 
26.07, 24.53, 18.30, 17.84, -4.64, -5.11. 
IR ν (cm-1) 3669 (w), 3410 (m), 3037 (m), 2955 (s), 2928 (s), 2887 (m), 2856 (s), 1695 (s), 
1610 (s), 1586 (s), 1508 (s), 1461 (s), 1426 (s), 1343 (s), 1285 (m), 1224 (br s), 1178 (m), 
1076 (m) 1030 (w), 967 (w), 907 (w), 833 (s), 776 (m), 696 (w), 681 (w), 637 (w).  
HR-MS (ESI‾) m/z for [C58H69N6O7Si2]‾ ([M-H]‾): calc.: 1017.4766, found: 1017.4746. 
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10.7.8  Deprotection of the hydroxyl groups of the aromatic amine dG adducts 
10.7.8.1 8-(N-acetyl-2-amino-fluorene)-O6-benzyl-N2-isopropylphenoxyacetyl-2'-
deoxyguanosine 48 
 
 
 
8-(N-acetyl-2-amino-fluorene)-O6-benzyl-3',5'-O-bis(tert-butyldimethylsilyl)-N2-isopropyl-
phenoxyacetyl-2'-deoxyguanosine (1.09 g, 1.11 mmol) 43 was dissolved in THF (26 ml) and 
cooled under argon atmosphere to 0 ºC. Acetic acid (364 μL, 6.36 mmol) and a 1 M solution 
of tetrabutylamonium fluoride in THF (3.20 ml, 3.07 mmol) were added and the reaction 
mixture was allowed to reach room temperature and was stirred overnight. The solvent was 
subsequently removed in vacuo and the residue was purified by chromatography on silica gel 
(CH2Cl2:MeOH 40:1) to yield 470 mg (0.62 mmol, 57 %, lit. 79 %) of the product as a white 
powder. 
 
Rf = 0.36 (CH2Cl2:MeOH 10:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 7.91 (m, 1H, AF-1H), 7.88 (d, 1H, 3J = 7.5, AF-
1H), 7.49 (m, 2H, AF-2H), 7.38 – 7.27 (m, 8 H, AF-3H + Bz-5H), 7.12 (d, 3J = 8.7, 2H, Pac-
H2), 6.83 (d, 3J = 8.7, 2H, Pac-H2), 6.22 (m, 1H, C1'-H), 5.56 (br s, 2H, Bz-CH2), 5.20 (br d, 
1H, C3'-OH), 4.92 (s, 2H, Pac-CH2), 4.57 (m, 2H, C5'-OH + C3'-H), 3.93 (s, 2H, AF-C9-H2), 
3.81 (m, 1H, C4'-H), 3.65 (m, 1H, C5'-Ha), 3.53 (m, 1H, C5'-Hb), 3.18 (br m, 1H, C2'-Ha), 2.79 
(sept, 3J = 6.9, 1 H, iPr-H), 2.07 (s, 3H, N8-Ac), 2.04 (m, 1H, C2'-Hb), 1.14 – 1.12 (m, 6H, 
2xiPr-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 167.77, 156.41, 152.40, 143.89, 141.34, 136.25, 
129.24, 128.92, 128.80, 127.54, 127.31, 125.61, 116.28, 114.78, 88.66, 68.63, 67.78, 62.36, 
36.91, 33.01, 24.53. 
IR ν (cm-1) 3745 (w), 3391 (br m), 2957 (m), 1695 (s), 1608 (s), 1507 (s), 1455 (s), 1426 (s), 
1342 (s), 1287 (m), 1220 (s), 1179 (m), 1051 (br w), 940 (w), 828 (m) 734 (s), 697 (w).  
HR-MS (ESI‾) m/z for [C43H41N6O7]‾ ([M-H]‾): calc.: 753.3037, found 753.3074. 
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10.7.8.2 8-(N-acetyl-amino-benzene)-O6-benzyl-N2-isopropylphenoxyacetyl-2'-
deoxyguanosine 46 
 
 
 
The deprotection of the 3' and 5' hydroxy functions of acetylaminobenzene-dG 41 was carried 
out according to the procedure described for the deprotection of acetylaminofluorene-dG 
(section 10.7.8.1). 
 
formulation  
            
 1.19 g (1.33 mmol) 41 
4.00 mL (3.83 mmol) 1 M solution of tetrabutylamonium fluoride in THF 
0.46 mL (8.04 mmol) acetic acid 
32 mL THF 
           
 
yield: 560 mg, 0.84 mmol, 63 % 
Rf = 0.39 (CH2Cl2:MeOH 10:1)  
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 10.64 (s, 1H, N2-H), 7.54 – 7.29 (m, 10H, Phe-
5H + Bz-5H), 7.12 (d, 3J = 8.5, 2H, Pac-H2), 6.83 (d, 3J = 8.7, 2H, Pac-H2), 6.18 (m, 1H, C1'-
H), 5.57 (br s, 2H, Bz-CH2), 5.22 (br d, 1H, C3'-OH), 4.94 (s, 2H, Pac-CH2), 4.62 (br t, 1H, 3J 
= 5.75 Hz, C5'-OH), 4.55 (m, 2H, C3'-H), 3.78 (m, 1H, C4'-H), 3.63 (m, 1H, C5'-Ha), 3.52 (m, 
1H, C5'-Hb), 3.14 (m, 1H, C2'-Ha), 2.80 (sept, 3J = 6.9, 1 H, iPr-H), 2.03 (s, 3H, N8-Ac), 2.02 
(m, 1H, C2'-Hb), 1.14 (d, 3J =6.9, 6H, 2xiPr-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 167.79, 156.39, 152.34, 141.32, 136.23, 129.95, 
129.25, 128.94, 128.82, 127.56, 116.21, 114.74, 88.64, 84.41, 71.07, 68.63, 67.71, 62.31, 
49.03, 37.11, 33.02, 31.14, 24.55. 
IR ν (cm-1) 3854 (w), 3744 (w), 3368 (br m), 2958 (m), 1696 (s), 1609 (s), 1507 (s), 1456 (m), 
1342 (s), 1224 (s), 1051 (m) 695 (s).  
HR-MS (ESI+) m/z for [C36H39N6O7]+ ([M+H]+): calc.: 667.2880, found 667.2859 
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10.7.8.3 8-(N-acetyl-2-amino-naphthalene)-O6-benzyl-N2-isopropylphenoxyacetyl-
2'-deoxyguanosine 47 
 
 
The deprotection of the 3' and 5' hydroxy functions of acetylaminonaphthalene-dG 42 was 
carried out according to the procedure described for the deprotection of acetylaminofluorene-
dG (section 10.7.8.1). 
 
formulation  
            
0.74 g (0.79 mmol) 42 
2.38 mL (2.28 mmol) 1 M solution of tetrabutylamonium fluoride in THF 
0.27 mL (4.71 mmol) acetic acid 
20 mL THF 
           
 
yield: 540 mg, 0.75 mmol, 95 % 
Rf = 0.56 (CH2Cl2:MeOH 10:1)  
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 10.61 (s, 1H, N2-H), 7.52 (m, 7H, Nap-7H),  
7.40-7.34 (m, 5H, Bn-5H), 7.09-7.11(m, 2H, PAC- H3,5), 6.80-6.82 (m, 2H, PAC- H2,6), 6.25-
6.23 (m, 1H, C1'-H), 5.58 (br s, 2H, Bz-CH2), 5.24-5.20 (br d, 1H, C3'-OH), 4.89-4.84 (m, 4H, 
Pac-CH2, C5'-OH + C3'-H), 3.77-3.67 (m, 3H, C4'-H, C5'-Ha + Hb), 3.16 (m, 1H, C2'-Ha), 2.73-
2.84 (sept, 3J = 6.9, 1H, iPr-H), 2.08 (s, 3H, N8-Ac), 1.96 (s, 1H, C2'-Hb), 1.12-1.21 (m, 6H, 
2xiPr-CH3). 
IR ν (cm-1) 3378 (br m), 3059 (w), 2957 (m), 1696 (s), 1609 (s), 1507 (s), 1457 (m), 1427 (m), 
1340 (s), 1282 (m), 1224 (s), 1102 (w), 1052 (w), 941 (w), 828 (w), 793 (w), 747 (m), 696 (w), 
652 (w).  
HR-MS (ESI¯) m/z for [C40H39N6O7]¯ ([M-H]¯): calc.: 715.2880, found: 715.2883. 
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10.7.8.4 8-(N-acetyl-2-amino-anthracene)-O6-benzyl-N2-isopropylphenoxyacetyl-
2'-deoxyguanosine 49 
 
 
The deprotection of the 3' and 5' hydroxy functions of acetylaminoanthracene-dG 44 was 
carried out according to the procedure described for the deprotection of acetylaminofluorene-
dG (section 10.7.8.1). 
formulation  
            
596 mg (0.61 mmol) 44 
1.80 mL (1.72 mmol) 1 M solution of tetrabutylamonium fluoride in THF 
0.20 mL (3.49 mmol) acetic acid 
15 mL THF 
           
 
yield: 346 mg, 0.45 mmol, 74 % 
Rf = 0.55 (CH2Cl2:MeOH 10:1)  
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 10.60 (s, 1H, N2-H), 8.58 (s, 1H, Ant-H9/10), 8.56 
(s, 1H, Ant-H10/9 ), 8.22 – 7.95 (m, 4H, Ant-4H), 7.62 – 7.28 (m, 8 H, Ant-3H + Bz-5H), 7.14 
– 7.08 (m, 2 H, Pac-H3,5),  6.86 – 6.80 (m, 2 H, Pac-H2,6), 6.26 (br m, 1H, C1'-H), 5.58 (br s, 
2H, Bz-CH2), 5.19 (br s, 1H, C3'-OH),  4.93 (s, 2H, Pac-CH2), 4.69 – 4.46 (br m, 2H, C5'-OH 
+ C3'-H), 3.80 (br m, 1H, C4'-H), 3.64 (br m, 1H,  C5'-Ha), 3.51 (br m, 1H,  C5'-Hb),    3.21 (br 
m, 1H, C2'-Ha), 2.79 (sept, J = 6.9, 1H, iPr-H), 2.13 (br s, 4H, N8-Ac + C2'-Hb), 1.13 (d, J = 
6.9, 6H, 2xiPr-CH3).  
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 167.78, 160.26, 156.41, 152.48, 151.93, 146.22, 
141.34, 137.13, 136.24, 131.99, 131.12, 130.15, 129.24, 128.92, 128.80, 128.54, 128.39, 
127.54, 127.03, 126.60, 126.52, 126.44, 116.35, 114.78, 88.67, 84.56, 71.09, 68.67, 67.79, 
62.32, 37.22, 33.01, 24.52, 23.21. 
IR ν (cm-1) 3746 (w), 3379 (br s), 3058 (m), 2957 (m), 1981 (w), 1696 (s), 1609 (s), 1507 (s), 
1457 (m) 1427 (m), 1343 (s), 1287 (m), 1220 (s), 1100 (w), 1051 (m), 949 (w) 890 (w), 828 
(m), 793 (w), 737 (m), 695 (m), 625 (w). 
HR-MS (ESI‾) m/z for [C44H41O7N6]‾ ([M-H]‾): calc.: 765.3037, found 765.3041. 
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10.7.8.5 8-(N-acetyl-1-amino-pyrene)-O6-benzyl-N2-isopropylphenoxyacetyl-2'-
deoxyguanosine 50 
 
 
 
The deprotection of the 3' and 5' hydroxy functions of acetylaminopyrene-dG 45 was carried 
out according to the procedure described for the deprotection of acetylaminofluorene-dG 
(section 10.7.8.1). 
formulation  
            
950 mg (0.93 mmol) 45 
2.80 mL (2.68 mmol) 1 M solution of tetrabutylamonium fluoride in THF 
0.32 mL (5.58 mmol) acetic acid 
22 mL THF 
           
 
yield: 449 mg, 0.57 mmol, 62 % 
Rf = 0.52 (CH2Cl2:MeOH 10:1)  
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 8.42 – 8.12 (m, 5H, Pyr-5H), 7.46 – 7.22 (m, 
8H, Bz-5H, Pyr-3H), 7.11 (d, 3J = 8.6, 2H, Pac-H2), 6.82 (d, 3J = 8.6, 2H, Pac-H2), 6.49 (m, 
1H, C1'-H), 5.49 (br s, 2H, Bz-CH2), 5.32 (br d, 1H, C3'-OH), 4.92 (s, 2H, Pac-CH2), 4.70 (m, 
2H, C5'-OH + C3'-H), 3.97 (m, 1H, C4'-H), 3.75 (m, 1H, C5'-Ha), 3.63 (m, 1H, C5'-Hb), 3.15 (br 
m, 1H, C2'-Ha), 2.78 (sept, 3J = 6.8, 1 H, iPr-H), 2.28 (br s, 3H, N8-Ac), 2.01 (m, 1H, C2'-Hb), 
1.12 (d, 3J = 6.9, 6H, 2xiPr-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 167.77, 156.39, 152.49, 146.77, 141.30, 136.16, 
130.98, 130.65, 129.20, 128.85, 127.55, 127.46, 126.54, 125.05, 123.88, 116.17, 114.73, 
88.82, 71.18, 68.46, 67.71, 62.46, 49.04, 33.02, 24.54. 
IR ν (cm-1) 3854 (w), 3752 (w), 3392 (br m), 2958 (m), 1981 (w), 1696 (s), 1662 (s), 1533 
(m), 1208 (s), 1428 (w), 1436 (m), 1384 (s), 1366 (s), 1343 (s), 1290 (m), 1242 (s), 1217 (s), 
1109 (w), 1066 (m), 1026 (m), 952 (m), 856 (s), 828 (m), 792 (m), 751 (m), 697 (w), 623 (w).  
HR-MS (ESI¯) m/z for [C46H41N6O7]¯ ([M-H]¯): calc.: 789.3037,  found 789.3036. 
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10.7.9  Deprotection of the O6-position of the aromatic amine dG adducts 
10.7.9.1 8-(N-acetyl-2-amino-fluorene)-N2-isopropylphenoxyacetyl-2'-
deoxyguanosine 53 
 
 
8-(N-acetyl-2-amino-fluorene) - O6-benzyl - N2- isopropylphenoxyacetyl - 2'- deoxyguanosine 
(101 mg, 0.13 mmol) 48 was dissolved in EtOH (5 mL). A a 10% powder of Pd/C (10 mg) 
and cyclohexene (504 μL, 5 mmol) were added and the reaction mixture was refluxed for 5 h, 
cooled and purified by chromatography on silica gel (CH2Cl2:MeOH 40:1) to provide 67 mg 
(0.10 mmol, 77 %, lit. 88%) of the product as a white powder. 
Rf = 0.35 (CH2Cl2:MeOH 10:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 11.99 (s, 1H, N1-H) 11.48 (s, 1H, N2-H), 7.95 
(d, 3J = 8.1, 1H, AF-1H), 7.91 (d, 1H, 3J = 7.6, AF-1H), 7.56 (d, 3J = 7.2, 1H, AF-1H), 7.40 – 
7.32 (m, 4 H, AF-4H), 7.12 (d, 3J = 8.5, 2H, Pac-H2), 6.87 (d, 3J = 8.8, 2H, Pac-H2), 6.42 (m, 
1H, C1'-H), 5.18 (br d, 1H, C3'-OH), 4.90 (s, 2H, Pac-CH2), 4.81 (m, 1H, C5'-OH), 4.35 (m, 
1H, C3'-H), 3.92 (s, 2H, AF-C9-H2), 3.81 (m, 1H, C4'-H), 3.61 (m, 1H, C5'-Ha), 3.49 (m, 1H, 
C5'-Hb), 2.93 (br m, 1H, C2'-Ha), 2.80 (m, 1 H, iPr-H), 2.03 – 2.01 (m, 4H, N8-Ac +  C2'-Hb), 
1.14 – 1.11 (m, 6H, 2xiPr-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 156.61, 143.82, 141.17, 127.63, 127.29, 125.60, 
120.70, 114.85, 88.61, 84.45, 71.59, 63.27, 62.56, 36.90, 33.01, 32.78, 30.03, 24.51, 23.20. 
IR ν (cm-1) 3854 (w), 3752 (w), 3366 (br s), 3057 (m), 2957 (m), 1684 (s), 1607 (s), 1560 (m), 
1506 (s), 1455 (m), 1431 (w), 1367 (m), 1336 (m), 1293 (m), 1247 (s), 1178 (m), 1099 (w), 
1082 (w), 1031 (m), 952 (w), 862 (w), 828 (m), 789 (w), 768 (w), 745 (m), 699 (w).  
HR-MS (ESI¯) m/z for [C36H35N6O7]¯ ([M-H]¯): calc.: 663.2567, found: 663.2574. 
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10.7.9.2 8-(N-acetyl-amino-benzene)-N2-isopropylphenoxyacetyl-2'-deoxy-
guanosine 51 
 
 
 
The deprotection of O6-position of acetylaminobenzene-dG 46 was carried out according to 
the procedure described for the deprotection of acetylaminofluorene-dG (section 10.7.9.1). 
 
formulation  
      
560 mg (0.84 mmol) 46 
56 mg Pd/C 10 % 
3.25 mL (32 mmol) cyclohexene 
33 mL ethanol 
      
 
yield: 310 mg, 0.53 mmol, 63 % 
Rf = 0.74 (CH2Cl2:MeOH 10:1)  
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 7.45 – 7.25 (m, 5H, Phe-5H), 7.14 (d, 3J = 8.5, 
2H, Pac-H2), 6.86 (d, 3J = 8.2, 2H, Pac-H2), 6.14 (m, 1H, C1'-H), 5.23 (br d, 1H, C3'-OH), 
4.83 (s, 2H, Pac-CH2), 4.72 (br t, 1H, C5'-OH), 4.43 (m, 2H, C3'-H), 3.78 (m, 1H, C4'-H), 3.61 
(m, 1H, C5'-Ha), 3.49 (m, 1H, C5'-Hb), 3.14 (m, 1H, C2'-Ha), 2.81 (m, 1 H, iPr-H), 2.02 – 2.00 
(m, 4H, N8-Ac + C2'-Hb), 1.14 (d, 3J =6.7, 6H, 2xiPr-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 171.53, 156.11, 154.90, 141.72, 129.83, 127.64, 
119.57, 114.81, 88.46, 71.22, 66.90, 62.36, 49.02, 33.03, 24.51 
IR ν (cm-1) 3370 (br s), 3241 (br s), 2959 (m), 2871 (w), 1981 (w), 1672 (s), 1599 (s), 1558 
(s), 1509 (m), 1435 (w), 1370 (w), 1346 (m), 1309 (m), 1284 (m), 1260 (m), 1184 (s), 1053 
(m), 963 (w), 833 (w), 807 (w), 785 (w), 760 (m), 696 (m), 624 (m).  
HR-MS (ESI‾) m/z for [C29H31N6O7]‾ ([M-H]‾): calc.: 575.2254, found 575.2273 
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10.7.9.3 8-(N-acetyl-2-amino-naphthalene)-N2-isopropylphenoxyacetyl-2'-
deoxyguanosine 52 
 
 
 
The deprotection of O6-position of acetylaminonaphthalene-dG 47 was carried out according 
to the procedure described for the deprotection of acetylaminofluorene-dG (section 10.7.9.1). 
 
formulation  
      
540 mg (0.84 mmol) 47 
54 mg Pd/C 10 % 
2.90 mL (28 mmol) cyclohexene 
30 mL ethanol 
      
 
yield: 320 mg, 0.51 mmol, 68 % 
Rf = 0.68 (CH2Cl2:MeOH 10:1)  
 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 11.92 (s, 1H, N1-H), 11.49 (s, 1H, N2-H),  8.09 – 
7.82 (m, 4H, Nap-4H), 7.67 – 7.44 (m, 3 H, Nap-3H), 7.17 – 7.08 (m, 2 H, Pac-H3,5),  6.91 – 
6.82 (m, 2 H, Pac-H2,6), 6.21 (br m, 1H, C1'-H), 5.23 (br s, 1H, C3'-OH),  4.84 (s, 2H, Pac-
CH2), 4.72 (t, 1H, J = 5.7, C5'-OH), 4.43 (br m, 1H, C3'-H), 3.80 (br m, 1H, C4'-H), 3.68 – 3.58 
(m, 1H,  C5'-Ha), 3.53 – 3.44 (m, 1H,  C5'-Hb),  3.01 (br m, 1H, C2'-Ha), 2.81 (sept, J = 6.9, 1H, 
iPr-H), 2.08 (br s, 4H, N8-Ac + C2'-Hb), 1.14 (d, J = 6.9, 6H, 2xiPr-CH3).  
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 171.97, 156.40, 141.32, 136.23, 133.38, 129.27, 
128.94, 127.56, 116.29, 114.74, 109.99, 88.90, 70.93, 68.63, 67.66, 62.31, 49.03, 33.02, 
24.55, 21.51. 
IR ν (cm-1) 3752 (w), 3354 (br s), 3232 (br s), 2957 (m), 2870 (w), 1988 (w), 1682 (s), 1599 
(s), 1558 (m), 1507 (s), 1434 (w), 1367 (m), 1337 (m), 1281 (br m), 1178 (m), 1082 (w), 1051 
(m), 959 (w), 861 (w), 828 (w), 784 (m), 749 (m), 651 (w). 
HR-MS (ESI‾) m/z for [C33H33N6O7]‾ ([M-H]‾): calc.: 625.2411, found: 625.2436. 
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10.7.9.4 8-(N-acetyl-2-amino-anthracene)-N2-isopropylphenoxyacetyl-2'-
deoxyguanosine 54 
 
 
 
 
The deprotection of O6-position of acetylaminoanthracene-dG 49 was carried out according to 
the procedure described for the deprotection of acetylaminofluorene-dG (section 10.7.9.1). 
 
formulation  
      
192 mg (0.25 mmol) 49 
60 mg Pd/C 10 % 
1.00 mL (9.65 mmol) cyclohexene 
10 mL ethanol 
      
 
yield: 60 mg, 0.09 mmol, 36 % 
Rf = 0.42 (CH2Cl2:MeOH 10:1)  
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 11.92 (s, 1H, N1-H), 11.47 (s, 1H, N2-H), 8.59 
(s, 1H, Ant-H9/10), 8.57 (s, 1H, Ant-H10/9 ), 8.18 – 7.94 (m, 4H, Ant-4H), 7.62 – 7.47 (m, 3 H, 
Ant-3H), 7.17 – 7.11 (m, 2 H, Pac-H3,5),  6.89 – 6.83 (m, 2 H, Pac-H2,6), 6.22 (br m, 1H, C1'-
H), 5.20 (br s, 1H, C3'-OH),  4.83 (s, 2H, Pac-CH2), 4.69 (br t, 1H, C5'-OH), 4.43 (br m, 1H, 
C3'-H), 3.81 (br m, 1H, C4'-H), 3.62 (br m, 1H,  C5'-Ha), 3.49 (br m, 1H,  C5'-Hb),  3.01 (br m, 
1H, C2'-Ha), 2.80 (sept, J = 6.9, 1H, iPr-H), 2.11 (br s, 4H, N8-Ac + C2'-Hb), 1.14 (d, J = 6.9, 
6H, 2xiPr-CH3).  
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 156.13, 154.93, 141.76, 137.32, 132.00, 131.14, 
130.06, 128.55, 128.38, 127.64, 126.95, 126.88, 126.82, 126.59, 126.50, 126.38, 124.95, 
119.70, 114.86, 88.46, 84.37, 71.20, 66.96, 62.35, 37.10 33.02, 24.51, 23.23. 
IR ν (cm-1) 3354 (br m), 3231 (br m), 3050 (w), 2957 (m), 2926 (m), 2869 (m), 1682 (s), 1601 
(s), 1557 (m), 1508 (s), 1458 (w), 1433 (w), 1367 (m), 1339 (m), 1282 (br m), 1254 (br m), 
1179 (w), 1099 (w), 1082 (w), 1052 (w), 958 (w), 828 (w), 804 (w), 783 (w), 739 (m), 716 (w), 
640 (w), 624 (w).  
HR-MS (ESI‾) m/z for [C37H35N6O7]‾ ([M-H]‾): calc.: 675.2567, found: 675.2566.  
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10.7.9.5 8-(N-acetyl-1-amino-pyrene)-N2-isopropylphenoxyacetyl-2'-
deoxyguanosine 55 
 
 
 
 
 
The deprotection of O6-position of acetylaminopyrene-dG 50 was carried out according to the 
procedure described for the deprotection of acetylaminofluorene-dG (section 10.7.9.1). 
 
formulation  
      
400 mg (0.50 mmol) 50 
38 mg Pd/C 10 % 
2.00 mL (19 mmol) cyclohexene 
19 mL ethanol 
      
 
yield: 287 mg, 0.41 mmol, 82 % 
Rf = 0.56 (CH2Cl2:MeOH 10:1)  
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 11.84 (s, 1H, N1-H) 11.45 (s, 1H, N2-H),  8.50 – 
8.11 (m, 8H, Pyr-8H), 7.14 (d, 3J = 8.6, 2H, Pac-H2), 6.86 (d, 3J = 8.6, 2H, Pac-H2), 6.45 (m, 
1H, C1'-H), 5.34 (br d, 1H, C3'-OH), 4.83 (s, 2H, Pac-CH2), 4.78 (m, 1H, C5'-OH), 4.55 (m, 
1H, C3'-H), 3.98 (m, 1H, C4'-H), 3.73 (m, 1H, C5'-Ha), 3.61 (m, 1H, C5'-Hb), 3.27 (br m, 1H, 
C2'-Ha), 2.80 (sept, 3J = 6.7, 1 H, iPr-H), 2.26 (m, 1H, C2'-Hb), 1.97 (s, 3H, N8-Ac), 1.14 (d, 
3J = 6.9, 6H, 2xiPr-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 171.43, 156.11, 154.63, 148.31, 141.73, 134.03, 
130.99, 128.68, 127.65, 127.47, 126.36, 125.41, 123.90, 114.83, 88.66, 71.41, 66.88, 62.31, 
56.01, 36.83, 33.02, 28.85, 24.52. 
IR ν (cm-1) 3391 (br m), 3234 (br m), 2958 (m), 1682 (s), 1602 (s), 1558 (m), 1507 (s), 1458 
(w), 1435 (w), 1369 (m), 1344 (w), 1291 (m), 1257 (m), 1180 (m), 1052 (m), 965 (w), 850 (m), 
829 (w), 784 (w), 710 (w), 682 (w), 632 (w).  
HR-MS (ESI‾) m/z for [C39H35N6O7]‾ ([M-H]‾): calc.: 699.2567 found: 699.2575 
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10.7.10  5'- DMT protection of the bulky dG adducts 
10.7.10.1 8-(N-acetyl-2-amino-fluorene)-(5'-O-dimethoxytrityl)-N2-
isopropylphenoxyacetyl-2'-deoxyguanosine 58 
 
 
 
 
8-(N-acetyl-2-amino-fluorene)-N2-isopropylphenoxyacetyl-2'-deoxyguanosine (133 mg, 0.20 
mmol) 53 was dissolved in pyridine (1 mL). 4,4'-Dimethoxytrityl chloride (102 mg, 0.3 
mmol, 1.5 eq.) was added and the reaction mixture was stirred for 2 h at room temperature, 
concentrated and purified by chromatography on silica gel (CH2Cl2:MeOH 40:1, 1 % 
pyridine) to provide 162 mg (0.17 mmol, 85 %, lit. 76 %) of a white foam.  
 
Rf  = 0.56 (CH2Cl2:MeOH 10:1) 
 
1H-NMR (400 MHz, CDCl3): δ (ppm) = 11.7 (br s, 2H, N1-H + N2-H), 7.75 –  7.66 (m, 2H, 
AF-2H), 7.52 (d, 3J = 7.5 Hz, 1H, AF-1H), 7.40 – 7.23 (m, 6 H, AF-4H + DMT-2H), 7.21 – 
7.09 (m, 9H, Pac-H2 + DMT-7H), 6.87 – 6.67 (m, 6H, Pac-H2 + DMT-4H), 6.19 (m, 1H, C1'-
H), 5.25 (d, 1H, C3'-OH), 4.66 (s, 2H, Pac-CH2), 4.48 (m, 1H, C3'-H), 4.05 (s, 2H, AF-C9-H2), 
3.82 (m, 1H, C4'-H), 3.79 (s, 3H,-OMe), 3.78 (s, 3H,-OMe), 3.42 (m, 1H, C5'-Ha), 3.26 (m, 
1H, C5'-Hb), 3.11 (m, 1H, C2'-Ha), 2.87 (sept, 3J = 6.7 Hz, 1 H, iPr-H), 2.15 (s, 3H, N8-Ac), 
1.95 (m, 1H, C2'-Hb), 1.22 (m, 3H, iPr-CH3), 1.20 (m, 3H, iPr-CH3). 
13C-NMR (101 MHz, CDCl3): δ (ppm) = 158.74, 154.23, 149.82, 144.74, 143.73, 143.65, 
139.46, 136.09, 135.60, 129.96, 129.96, 129.09, 128.00, 127.80, 127.73, 125.07, 123.71, 
115.12, 113.14, 113.02, 86.25, 67.54, 55.23, 55.15, 36.96, 33.32, 29.68, 24.05, 22.60. 
IR ν (cm-1) 3855 (w), 3746 (w), 3198 (br m), 2958 (m), 2360 (m), 2338 (m), 1980 (w), 1682 
(s), 1602 (s), 1557 (m), 1506 (s), 1455 (w), 1436 (m), 1366 (w), 1282 (m), 1246 (s), 1175 (s), 
1031 (m), 959 (w), 827 (m), 767 (w), 736 (m), 702 (m).  
HR-MS (ESI‾) m/z for [C57H53N6O9]‾([M-H]‾): calc.: 965.3874, found 965.3834. 
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10.7.10.2 8-(N-acetyl-amino-benzene)-(5'-O-dimethoxytrityl)-N2-
isopropylphenoxyacetyl-2'-deoxyguaosine 56 
 
 
 
The 5'-DMT protection of acetylaminobenzene-dG 51 was carried out according to the 
procedure described for the protection of acetylaminofluorene-dG (section 10.7.10.1). 
 
formulation  
      
320 mg (0.51 mmol) 51 
260 mg (0.77 mmol, 1.5 eq.) DMT-Cl 
2.90 mL pyridine 
      
 
yield: 472 mg, 0.50 mmol, 98 % 
Rf = 0.81 (CH2Cl2:MeOH 10:1) 
 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 11.74 (s, 2H, N1-H), 11.32 (s, 2H, N2-H), 7.37 – 
7.11 (m, 16H, Phe-5H + DMT-9H + Pac-H2), 6.85 (d, 3J = 8.6, 2H, Pac-H2), 6.70 (m, 4H, 
DMT-4H), 6.24 (m, 1H, C1'-H), 5.17 (br d, 1H, C3'-OH), 4.79 (s, 2H, Pac-CH2), 4.54 (m, 2H, 
C3'-H), 3.99 (m, 1H, C4'-H), 3.64 (s, 6H, 2xOMe), 3.62 (m, 1H, C5'-Ha), 3.36 (m, 1H, C5'-Hb), 
3.10 (m, 1H, C2'-Ha), 2.83 (sept, 3J = 6.9, 1 H, iPr-H), 2.19 (br m, 1H, C2'-Hb), 2.04 (s, 3H, N8-
Ac), 1.14 (d, 3J =6.9, 6H, 2xiPr-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 150.07, 136.55, 130.12, 130.10, 129.73, 128.15, 
127.79, 127.64, 127.63, 127.62, 127.62, 126.79, 124.31, 124.30, 114.83, 114.82, 114.81, 
114.81, 113.53, 113.16, 113.02, 87.08, 84.11, 71.15, 66.86, 58.54, 55.40, 32.91, 24.38, 22.92, 
16.12. 
IR ν (cm-1) 3855 (w), 3746 (w), 3198 (br m), 3057 (m), 2958 (m), 2932 (m), 2869 (m), 2836 
(m), 1683 (s), 1605 (s), 1556 (m), 1506 (s), 1456 (w), 1438 (m), 1367 (m), 1334 (w), 1282 (m), 
1247 (s), 1175 (m), 1075 (m), 1021 (m), 960 (w), 827 (m), 784 (w), 754 (w), 727 (m), 698 (m), 
614 (w).  
HR-MS (ESI‾) m/z for [C50H49O9N6]‾ ([M-H]‾): calc.: 877.3561, found: 877.3593  
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10.7.10.3 8-(N-acetyl-2-amino-naphthalene)-(5'-O-dimethoxytrityl)-N2-
isopropylphenoxyacetyl-2'-deoxyguanosine 57 
 
 
 
The 5'-DMT protection of acetylaminonaphthalene-dG 52 was carried out according to the 
procedure described for the protection of acetylaminofluorene-dG (section 10.7.10.1). 
 
formulation  
      
322 mg (0.51 mmol) 52 
260 mg (0.77 mmol, 1.5 eq.) DMT-Cl 
2.90 mL pyridine 
      
 
yield: 460 mg, 0.49 mmol, 96 % 
Rf = 0.76 (CH2Cl2:MeOH 10:1) 
 
 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 11.74 (s, 1H, N1-H), 11.33 (s, 1H, N2-H),  7.98 – 
7.78 (br m, 4H, Nap-4H), 7.64 – 7.39 (br m, 3 H, Nap-3H), 7.30 – 7.01 (m, 11 H, DMT-9H, + 
Pac-2H),  6.91 – 6.77 (m, 2 H, Pac-2H), 6.73 – 6.50 (br m, 4H, DMT-4H), 6.31 (br m, 1H, 
C1'-H), 5.17 (br s, 1H, C3'-OH),  4.83 (d, J = 16, 1H, Pac-CH2), 4.70 (d, J = 16, 1H, Pac-CH2), 
4.55 (br m, 1H, C3'-H), 4.03 (br m, 1H, C4'-H), 3.64 (s, 3H, OCH3), 3.61 (s, 3H, OCH3), 3.37 
(br m, 1H, C5'-Ha), 3.08 (br m, 1H, C5'-Hb), 2.92  (very br m, 1H,  C2'-Ha), 2.82 (sept, J = 6.9, 
1H, iPr-H), 2.10 (br s, 4H, N8-Ac + C2'-Hb), 1.14 (d, J = 6.9, 6H, 2xiPr-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 150.05, 136.56, 130.10, 130.07, 129.34, 128.15, 
128.01, 127.78, 127.63, 127.63, 127.63, 127.15, 126.78, 124.32, 124.31,114.84, 113.21, 
71.25, 66.85, 66.82, 65.39, 32.91, 24.39, 23.03. 
IR ν (cm-1) 3746 (w), 3204 (br m), 3058 (w), 2999 (w), 2958 (m), 2931 (m), 2869 (w), 2835 
(w), 1981 (w), 1684 (s), 1604 (s), 1556 (m), 1506 (s), 1438 (m), 1367 (m), 1333 (w), 1282 (m), 
1246 (s), 1175 (m), 1114 (w), 1075 (m), 1031 (m), 961 (w), 860 (w), 826 (m), 789 (w), 750 
(m), 702 (m), 669 (w), 651 (w).  
HR-MS (ESI‾) m/z for [C54H51O9N6]‾ ([M-H]‾): calc.: 927.3718, found: 927.3768. 
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10.7.10.4 8-(N-acetyl-2-amino-anthracene)-(5'-O-dimethoxytrityl)-N2-
isopropylphenoxyacetyl-2'-deoxyguanosine 59 
 
 
 
The 5'-DMT protection of acetylaminoanthracene-dG 54 was carried out according to the 
procedure described for the protection of acetylaminofluorene-dG (section 10.7.10.1). 
 
formulation  
      
60 mg (0.09 mmol) 54 
45 mg (0.13 mmol, 1.6 eq.) DMT-Cl 
0.50 mL pyridine 
      
 
yield: 56 mg, 0.06 mmol, 66 % 
Rf = 0.55 (CH2Cl2:MeOH 10:1) 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) =11.74 (s, 1H, N1-H), 11.31 (s, 1H, N2-H),  8.46 
(m, 2H, Ant-2H), 8.16 – 8.01 (m, 4H, Ant-4H), 7.66 – 7.42 (m, 3 H, Ant-3H),  7.28 –  7.22 
(m, 2H, DMT-2H), 7.17 – 6.99 (m, 9 H, DMT-7H, + Pac-2H),  6.89 – 6.80 (m, 2 H, Pac-2H), 
6.69 – 6.52 (br m, 4H, DMT-4H), 6.34 (br m, 1H, C1'-H), 5.15 (br s, 1H, C3'-OH),  4.81 (d, J = 
15.9, 1H, Pac-CH2), 4.70 (d, J = 16.0, 1H, Pac-CH2), 4.54 (br m, 1H, C3'-H), 4.02 (br m, 1H, 
C4'-H), 3.61 (br s, 6H, OCH3), 3.37 (br m, 1H, C5'-Ha), 3.09 (br m, 1H, C5'-Hb), 3.01  (very br 
m, 1H,  C2'-Ha), 2.82 (sept, J = 6.9, 1H, iPr-H), 2.14 (br s, 4H, N8-Ac + C2'-Hb), 1.14 (d, J = 
6.9, 6H, 2xiPr-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 158.13, 156.13, 154.70, 150.04, 145.24, 141.92, 
136.54, 136.03, 131.93, 131.15, 128.22, 127.81, 127.65, 124.32, 119.73, 114.90, 113.17, 
113.06, 87.29, 85.59, 66.98, 55.31, 33.02, 24.50. 
IR ν (cm-1) 3200 (br m), 3054 (m), 3000 (m), 2958 (m), 2363 (w), 1681 (s), 1606 (s), 1504 (s), 
1437 (s), 1367 (w), 1282 (br m), 1247 (s), 1175 (m), 1050 (w), 1031 (m), 901 (br w), 827 (m), 
746 (m), 702 (s), 641 (w), 613 (w). 
HR-MS (ESI¯) m/z for [C58H53N6O9]¯ ([M-H]¯): calc.: 977.3874, found: 977.3848. 
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10.7.10.5 8-(N-acetyl-1-amino-pyrene)-(5'-O-dimethoxytrityl)-N2-    
isopropylphenoxyacetyl-2'-deoxyguanosine 60 
 
 
 
The 5'-DMT protection of acetylaminopyrene-dG 55 was carried out according to the 
procedure described for the protection of acetylaminofluorene-dG (section 10.7.10.1). 
 
formulation  
      
250 mg (0.36 mmol) 55 
185 mg (0.55 mmol, 1.5 eq.) DMT-Cl 
2.00 mL pyridine 
      
 
yield: 351 mg, 0.35 mmol, 99 % 
Rf = 0.68 (CH2Cl2:MeOH 10:1) 
 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 11.66 (s, 1H, N1-H) 11.29 (s, 1H, N2-H),  8.49 – 
8.05 (m, 8H, Pyr-8H), 7.37 – 7.01 (m, 11H, DMT-9H + Pac-H2), 6.84 (d, 3J = 8.8, 2H, Pac-
H2), 6.65 –  6.57 (m, 4H, DMT-4H), 6.51 (m, 1H, C1'-H), 5.27 (br d, 1H, C3'-OH), 4.79 (s, 
2H, Pac-CH2), 4.69 (m, 1H, C3'-H), 4.18 (m, 1H, C4'-H), 3.70 (s, 6H, 2xOMe), 3.57 (m, 1H, 
C5'-Ha), 3.49 (m, 1H, C5'-Hb), 3.17 (br m, 1H, C2'-Ha), 2.81 (sept, 3J = 6.9, 1 H, iPr-H), 2.05 
(br m, 1H, C2'-Hb), 1.91 (s, 3H, N8-Ac), 1.14 (d, 3J = 6.9, 6H, 2xiPr-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 170.90, 158.26, 158.16, 156.12, 150.04, 145.31, 
141.88, 140.65, 136.57, 136.00, 130.99, 130.19, 129.34, 128.21, 128.07, 127.85, 127.65, 
126.80, 125.91, 124.34, 123.91, 114.86, 113.18, 87.33, 85.60, 84.63, 66.90, 55.43, 33.02, 
24.51. 
IR ν (cm-1) 3397 (br w), 3203 (br m), 3052 (m), 2957 (m), 2931 (m), 2869 (w), 2835 (w), 
1916 (w), 1682 (s), 1603 (s), 1556 (m), 1509 (s), 1460 (w), 1437 (m), 1367 (m), 1336 (w), 
1284 (m), 1246 (s), 1174 (s), 1075 (m), 1031 (m), 963 (w), 901 (w), 846 (m), 826 (m), 783 
(w), 753 (w), 726 (w), 702 (m), 681 (w), 633 (w).  
HR-MS (ESI¯) m/z for [C60H53N6O9]¯ ([M-H]¯): calc.:1001.3874, found: 1001.3846. 
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10.7.11     Synthesis of the phosphoramidites  
10.7.11.1 8-(N-acetyl-2-amino-fluorene)-3′-O-(2′-cyanoethoxydiisopropylamino-
phosphino)-(5'-O-dimethoxytrityl)-N2-isopropylphenoxyacetyl-2'-deoxy-
guanosine 63 
 
 
 
8-(N-acetyl-2-amino-fluorene)-(5'-O-dimethoxytrityl)-N2-isopropylphenoxyacetyl-2'-deoxy-
guanosine (150 mg, 0.16 mmol) 58 was dissolved in CH2Cl2 (1.7 mL). 
Diisopropylammonium tetrazolide (106 mg, 0.61 mmol, 4 eq., DIAT) was added and the 
suspension was degassed flushed with argon in a flame dried and degassed apparatus. The 
entire reaction was carried out under argon atmosphere. Bis-(diisopropylamino)-(2-
cyanoethoxy)-phosphine (92 µL, 0.32 mmol, 2 eq.) was added and the reaction mixture was 
stirred for 2 h at room temperature. The solvents were subsequently removed in vacuo and the 
crude product was rapidly purified by chromatography on silica gel (CH2Cl2: MeOH 40:1, 1 
% pyridine) to provide 163 mg (0.14 mmol, 90 %, lit. 76 %) of a white foam.  
 
Rf = 0.80 (CH2Cl2/MeOH 10:1) 
 
1H-NMR (200 MHz, DMSO-d6): δ (ppm) = 11.76 (s, 1H, N1-H), 10.93 (s, 1H, N2-H), 7.91 –  
6.53 (m, 24H, AF-7H + DMT-13H + Pac-H4), 6.28 (m, 1H, C1'-H), 4.78 (s, 2H, Pac-CH2), 
4.64 (m, 1H, C3'-H), 4.13 (m, 1H, C4'-H), 3.83  (m, 2H, AF-C9-2H), 3.63 – 3.62 (m, 6H, 
2xOMe), 3.48 – 3.38 (m, 5H, C5'-Ha + PO-CH2), 3.22 – 3.05 (m, 2H, C5'-Hb + C2'-Ha), 2.85 
(m, 1 H, iPr-H), 2.71 – 2.50 (m, 2H, N-2iPr-2H), 2.34 (m, 1H, C2'-Hb), 2.08 (s, 3H, N8-Ac), 
1.19 – 1.02 (m, 18H, 2Pac-iPr-CH3 + 4N-iPr-CH3). 
Impurities exist due to hydrolysis in DMSO; peaks which are unambiguously identified are 
given. 
31P-NMR {1H} (81 MHz, DMSO-d6): δ (ppm) = 148.83, 148.33. 
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10.7.11.2 8-(N-acetyl-amino-benzene)-3′-O-(2′-cyanoethoxydiisopropylamino-
phosphino)-(5'-O-dimethoxytrityl)-N2-isopropylphenoxyacetyl-2'-deoxy-
guanosine 61 
 
The phosphitylation of acetylaminobenzene-dG 56 was carried out according to the procedure 
described for the protection of acetylaminofluorene-dG (section 10.7.11.1). 
 
formulation  
              
100 mg (0.11 mmol) 56 
80 mg (0.30 mmol) DIAT 
67 µL (0.22 mmol, 2 eq) Bis-(diisopropylamino)-(2-cyanoethoxy)-phosphine 
1 mL CH2Cl2 
            
 
yield: 98 mg, 0.10 mmol, 90 % 
Rf = 0.55 (CH2Cl2:MeOH 10:1) 
 
The 13C-NMR is very complicated; signal splitting is caused by phosphorus coupling and by 
the existence of two diastereomeric forms; significant signals are listed. Impurities exist due 
to hydrolysis in DMSO; peaks which are unambiguously identified are given. 
 
1H-NMR (400 MHz, DMSO-d6): δ (ppm) = 7.37 – 7.11 (m, 16H, Phe-5H + DMT-9H + Pac-
H2),  6.79 – 6.62 (br m, 6 H, Pac-2H + DMT-4H), 6.20 – 6.10 (br m, 1H, C1'-H), 4.75 – 4.66 
(br m, 1H, C3'-H), 4.23 – 4.18 (m, 2H, Pac-CH2), 3.98 – 3.81 (m, 3H, PO-CH2 + C4'-H), 3.81–
3.49 (m, 9H, OCH3+ N-iPr2-2H + C4'-H), 3.46 – 3.35 (br m, 2H, C5'H2), 3.24  (br m, 1H,  C2'-
Ha), 2.90 – 2.71  (m, 3H, iPr-H + CH2-CN), 2.38 (br m, 1H, C2'-Hb), 2.02 (br s, 3H, N8-Ac); 
1.20 –1.07 (m, 18H, 2-Pac-iPr-CH3 +  4N-iPr-CH3). 
13C-NMR (101 MHz, DMSO-d6): δ (ppm) = 173.53, 162.62, 150.95, 150.55, 149.61, 146.33, 
145.30, 119.44, 119.03, 115.19, 113.20, 79.73, 79.32, 78.91, 58.75, 58.60, 58.55, 55.36, 
50.76, 50.59, 46.33, 44.95, 44.88, 42.84, 42.71, 24.92, 24.85, 24.78, 23.07, 23.05, 23.03, 
20.33, 20.26, 19.82, 19.75. 
31P-NMR {1H} (81 MHz, CDCl3): δ (ppm) = 150.57 (s) 
HR-MS (ESI+) m/z for [C59H58N8O10P]+ ([M+H]+): calc.: 1079.4796 found 1079.4798. 
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10.7.11.3 8-(N-acetyl-2-amino-naphthalene)-3′-O-(2′-cyanoethoxydiisopropyl-
amino-phosphino)-(5'-O-dimethoxytrityl)-N2-isopropylphenoxyacetyl-2'-
deoxyguanosine 62 
 
 
 
The phosphitylation of acetylaminonaphthalene-dG 57 was carried out according to the 
procedure described for the protection of acetylaminofluorene-dG (section 10.7.11.1). 
formulation  
              
100 mg (0.11 mmol) 57 
80 mg (0.30 mmol) DIAT 
67 µL (0.22 mmol, 2 eq) Bis-(diisopropylamino)-(2-cyanoethoxy)-phosphine 
1 mL CH2Cl2 
            
 
yield: 96 mg, 0.096 mmol, 87 % 
Rf = 0.67 (CH2Cl2:MeOH 10:1) 
 
 
1H-NMR (400 MHz, CDCl3): δ (ppm) = 11.32 (very br s, 1H, N1-H), 8.70 (very br s, 1H, N2-
H),  7.90 – 7.10 (complex m, 18H, Nap-7H + DMT-9H + Pac-2H),  6.84 – 6.77 (m, 2 H, Pac-
2H), 6.69 – 6.57 (br m, 4H, DMT-4H), 6.19 – 6.05 (br m, 1H, C1'-H), 4.86 – 4.71 (br m, 1H, 
C3'-H), 4.53 – 4.38 (m, 2H, Pac-CH2), 4.26 – 4.07 (m, 3H, PO-CH2 + C4'-H), 3.68 (br s, 6H, 
OCH3),  3.62–3.44 (m, 3H, N-iPr2-H2 + C4'-H), 3.37 - 3.19 (br m, 2H, C5'H2), 2.92  (very br 
m, 1H,  C2'-Ha), 2.86 (sept, J = 6.9, 1H, iPr-H), 2.78 – 2.96 (m, 2H, CH2-CN), 2.39 (br m, 1H, 
C2'-Hb), 2.19 (br s, 3H, N8-Ac); 1.21 (d, J = 6.9, 6H, Pac-iPr-CH3), 1.19 –1.05 (m, 12H, 4N-
iPr-CH3). 
 
The 13C-NMR is very complicated; signal splitting is caused by phosphorus coupling and by 
the existence of two diastereomeric forms; significant signals are listed. Impurities exist due 
to hydrolysis in chloroform; peaks which are unambiguously identified are given. 
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13C-NMR (101 MHz, CDCl3): δ (ppm) = 157.39, 153.78, 153.76, 143.78, 143.75, 142.52, 
134.85, 134.82, 134.75, 132.47, 129.05, 128.99, 128.96, 128.11, 127.19, 127.15, 127.08, 
126.82, 126.71, 126.67, 126.60, 125.70, 125.62, 119.56, 116.53, 116.44, 114.12, 114.05, 
112.15, 112.01, 111.91, 111.87, 84.99, 66.35, 66.29, 63.05, 57.53, 57.33, 57.14, 57.08, 54.18, 
54.12, 44.34, 44.27, 42.34, 42.21, 42.03, 41.90, 32.32, 23.69, 23.67, 23.60, 23.52, 23.44, 
23.39, 23.09, 19.14, 19.07. 
31P-NMR {1H} (81 MHz, CDCl3): δ (ppm) = 150.10 (s) 
HR-MS (ESI‾) m/z for [C63H68N8O10P]‾([M-H]‾): calc.: 1127.4796, found 1127.4740. 
 
 
10.7.11.4 8-(N-acetyl-2-amino-anthracene)-3′-O-(2′-cyanoethoxydiisopropyl-
amino-phosphino)-(5'-O-dimethoxytrityl)-N2-isopropylphenoxyacetyl-2'-
deoxyguanosine 64 
 
 
 
The phosphitylation of acetylaminoanthracene-dG 59 was carried out according to the 
procedure described for the protection of acetylaminofluorene-dG (section 10.7.11.1). 
 
formulation  
              
56 mg (0.056 mmol) 59 
40 mg (0.15 mmol) DIAT 
35 µL (0.12 mmol, 2 eq) Bis-(diisopropylamino)-(2-cyanoethoxy)-phosphine 
0.6 mL CH2Cl2 
            
 
yield: 50 mg, 0.042 mmol, 75 % 
Rf = 0.83 (CH2Cl2:MeOH 10:1) 
 
31P-NMR {1H} (81 MHz, CDCl3): δ (ppm) = 150.54, 150.19. 
 
 
 
 
                  10. Experimental  
144 
 
10.7.11.5 8-(N-acetyl-1-amino-pyrene)-3′-O-(2′-cyanoethoxydiisopropylamino-
phosphino)-(5'-O-dimethoxytrityl)-N2-isopropylphenoxyacetyl-2'-deoxy-
guanosine 65 
 
 
The phosphitylation of acetylaminopyrene-dG 60 was carried out according to the procedure 
described for the protection of acetylaminofluorene-dG (section 10.7.11.1). 
 
formulation  
              
160 mg (0.16 mmol) 60 
110 mg (0.64 mmol) DIAT 
95 µL (0.32 mmol, 2 eq) Bis-(diisopropylamino)-(2-cyanoethoxy)-phosphine 
1.5 mL CH2Cl2 
            
 
yield: 153 mg, 0.12 mmol, 75 % 
Rf = 0.56 (CH2Cl2:MeOH 10:1) 
 
The 13C-NMR is very complicated; signal splitting is caused by phosphorus coupling and by 
the existence of two diastereomeric forms; significant signals are listed. Impurities exist due 
to hydrolysis in chloroform; peaks which are unambiguously identified are given. 
 
1H-NMR (600 MHz, CDCl3): δ (ppm) = 8.50 – 8.10 (m, 8H, Pyr-8H), 7.00 – 6.51 (m, 17H, 
DMT-13H + 2 Pac-H2), 6.48 – 6.39 (br m, 1H, C1'-H), 4.86 – 4.71 (br m, 1H, C3'-H), 5.04  – 
4.93 (m, 2H, Pac-CH2), 4.54 – 4.36 (m, 3H, PO-CH2 + C4'-H), 3.74 – 3.25 (m, 11H, OCH3 + 
2N-iPr-H + C4'-H + C5'-H2), 2.92  (very br m, 1H,  C2'-Ha), 2.88 (sept, J = 6.74, 1H, iPr-H), 
2.79 – 2.73 (m, 2H, CH2-CN), 2.05 (br m, 1H, C2'-Hb), 1.96 (br s, 3H, N8-Ac); 1.34 – 1.15  
(m, 18H, Pac-iPr-CH3 + 4N-iPr-CH3). 
13C-NMR (151 MHz, CDCl3): δ (ppm) = 158.13, 154.74, 149.83, 143.30, 135.84, 130.70, 
130.09, 129.30, 128.22, 127.55, 126.58, 126.15, 125.43, 123.80, 117.49, 116.81, 115.07, 
113.06, 112.70, 85.95, 67.29, 59.83, 58.19, 58.07, 55.28, 50.58, 45.24, 43.24, 42.88, 33.30, 
24.09, 22.98, 20.34, 19.99. 
31P-NMR {1H} (81 MHz, CDCl3): δ (ppm) = 150.01, 149.98. 
 
 
 
                  10. Experimental  
145 
 
10.7.12  (4-Isopropyl)-phenoxy acetyl chloride 
 
 
 
(4-Isopropyl)-phenoxy acetic acid (5 g, 25.7 mmol) and thionyl chloride (3.60 mL, 50 mmol,  
2 eq) were heated to 70 °C for 30 min. After removal of excess thionyl chloride in vacuo, the 
product was purified by vacuum distillation (150 °C bath temperature, BP = 104 °C at 5 
mbar) to provide 4.86 g (22.8 mmol, 89 %) of a colorless liquid.[170] 
 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.21 (m, 2H, H3,5), 6.68 (m, 2H, H2,6), 4.95 (s, 1H, 
CH2), 2.90 (sept, 3J = 6.9 Hz, 1H, CH), 1.52 (d, 3J = 6.9 Hz, 3 H, CH3), 1.42 (d, 3J=6.9 Hz, 
3H, CH3). 
13C-NMR (75 MHz, CDCl3): δ (ppm) = 170.51, 155.01, 143.29, 127.62, 114.76, 73.00. 
IR ν (cm-1) 3589 (w), 3128 (w), 3037 (w), 2961 (s), 2928 (w), 2872 (w), 1877 (br w), 1806 (s), 
1609 (w), 1588 (w), 1509 (s), 1461 (w), 1417 (w), 1289 (w), 1264 (w), 1217 (s), 1182 (m), 
1089 (w), 964 (w), 934 (s), 827 (m), 761 (m), 682 (w), 637 (w).  
 
10.7.13 Phenoxyacetic anhydride 
 
 
To a solution of phenoxyacetic acid (31 g, 209 mmol) in diethyl ether (150 mL) and dioxane 
(150 mL) was added N,N'-dicyclohexylcarbodiimide (22.3 g, 108 mmol, 0.52 eq.). The 
reaction mixture was stirred at room temperature for 3 h, subsequently cooled to 0 °C and 
stirred for an additional hour. The resultant dicyclohexylurea removed by filtration, the 
solution was concentrated in vacuo and kept overnight at -20 °C for crystallization. The 
product was purified by recrystallization from diethyl ether to provide 23.4 g (81 mmol, 87 
%) of white crystals.[171] 
1H-NMR (200 MHz, CDCl3) δ (ppm) = 7.35 (dd (J = 7.3, 7.8), 4 H,  m-aryl), 7.13 (t (J = 7.8), 
2 H, p-aryl), 7.00 (d (J = 7.3), 4 H, o-aryl), 4.82 (s, 4 H, Ph-O-CH2). 
IR ν (cm-1) 3853 (w), 3745 (w), 3061 (m), 2983 (w), 2929 (m), 2574 (m), 2188 (w), 2169 (w), 
1827 (s), 1757 (m), 1731 (m), 1700 (s), 1596 (m), 1585 (m), 1494 (s), 1429 (m), 1418 (m), 
1374 (m), 1307 (w), 1288 (w), 1269 (m), 1224 (s), 1089 (s), 1044 (s), 746 (s), 687 (s), 612 
(w).
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11 Appendix 
11.1 Crystal structure data 
 
 
Pol η –AAA-dG 
 
Pol η –AAF-dG 
 
Data collection   
Space group P 41 21 2 P41212 
Cell dimensions   
    a, b, c (Å) 103.5, 103.5, 292.7 103.44, 103.44, 292.35 
   α, β, γ (°)  90, 90, 90 90, 90, 90 
Wavelength (Å) 0.919 0.9129 
Resolution (Å) 48.0 - 2.7 (2.85-2.7) 49-2.7 (2.85-2.7) 
Rmerge 0.067 (0.377) 0.107 (0.523) 
Mean I / σI 23.0 (6.0) 26.84 (5.99) 
No. of observations 215,900 (30,490) 584,408 (92,986) 
No. of unique reflections 44,732 (6,421) 44,372 (6,887) 
Completeness (%) 99.9 (99.8) 98.2 (96.5) 
Redundancy 4.8 (4.7) 13.1 (13.6) 
   
Refinement   
Resolution (Å) 46.6 - 2.7 48.76 – 2.7 
No. reflections 42,326 44,599 
Rwork / Rfree 21.5 / 25.6 22.0 / 27.2 
No. atoms  9,070 
    Protein 8,147 8,152 
    DNA 826 824 
    Waters 103 89 
    Ions 6 calcium 6 calcium 
B-factors   
    Protein 45.0 29.6 
    DNA 65.3 45.1 
    Waters 36.0 20.5 
R.m.s deviations   
    Bond lengths (Å) 0.0126 0.0120 
    Bond angles (°) 1.439 1.442 
Table 10. Data collection, processing and structure refinement statistics. Numbers in parentheses 
correspond to the high resolution shell. 
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11.2 MALDI-Tof mass spectrometry analysis of the primer extension products 
with AAF-dG containing oligonucleotides 
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11.3 Composition of the LeMaster Medium [164] 
 
 
chemical 1 L 2 L 4 L 
Alanine   0.5 g 1.0 g 2.0 g 
Arginine  HCl   0.58 g 1.16 g  2.32 g 
Aspartic acid 0.41 g  0.80 g 1.6 g 
Cystine 0.03 g 0.06 g 0.12 g 
Glutamic acid  0.67 g 1.34 g 2.68 g 
Glutamine 0.33 g 0.66 g 1.32 g 
Glycine 0.54 g 1.08 g 2.16 g 
Histidine 0.06 g 0.12 g 0.24 g 
Isoleucine 0.23 g 0.46 g 0.92 g 
Leucine 0.23 g 0.46 g 0.92 g 
Lysine HCl 0.42 g 0.84 g 1.68 g 
Phenylalanine 0.13 g 0.26 g 0.52 g 
Proline 0.10 g 0.20 g 0.40 g 
Serine 2.08 g 4.16 g 8.32 g 
Threonine 0.23 g 0.46 g 0.92 g 
Tyrosine 0.17 g 0.34 g 0.68 g 
Valine  0.23 g 0.46 g 0.92 g 
Adenine 0.50 g 1.0 g 2.0 g 
Guanosine 0.67 g 1.34 g 2.68 g 
Thymine 0.17 g 0.34 g 0.68 g 
Uracil 0.50 g 1.0 g 2.0 g 
Sodium acetate 1.50 g 3.0 g  6.0 g 
Succinic acid 1.5 g 3.0 g 6.0 g 
Ammonium chloride 0.75 g 1.50 g 3.0 g 
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Sodium hydroxide 1.08 g 2.16 g 4.32 g 
anhydrous K2HPO4 8.0 g 16.0 g 32.0 g 
add ddH2O, autoclave and adjust pH to pH 7.5 
 
non- autoclavable portion for 100 ml ddH2O (sterile filtered) 
(900 ml autoclaved medium + 100 ml non-autoclavable portion 
Glucose 10 g   
MgSO4 x 7 H2O 0.25 g   
FeSO4 4.2 mg   
conc. H2SO4 8 µL   
Thiamine HCl 5 mg   
DL-selenomethionine 50 mg/L   
 
 
 
 
 
                  11. Appendix  
150 
 
11.4 List of abbreviations 
 
Å    Angström 
AAA   2-Acetylaminoanthracene 
AAB   2-Acetylaminobenzene 
AAF   2-Acetylaminofluorene 
AAN   2-Acetylaminonaphthalene 
AAP   1-Acetylaminopyrene 
AAA-dG  Acetylaminoanthracene-C8-dG adduct 
AAB-dG  Acetylaminobenzene-C8-dG adduct 
AAF-dG  Acetylaminofluorene-C8-dG adduct 
AF-dG   Aminofluorene-C8-dG adduct 
AAN-dG  Acetylaminonaphthene-C8-dG adduct 
AAP-dG  Acetylaminopyrene-C8-dG adduct 
ATT    6-Aza-2-thiothymine 
BNZ   Benzyl 
BER   Base excision repair 
BINAP  rac-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl 
bp   Base pair 
BSA    Bovine serum albumine 
conc.    Concentrated 
dA    2'-Deoxyadenosine 
Da   Dalton 
dba    Dibenzylideneacetone 
dC    2'-Deoxycytidine 
DCM    Dichloromethane 
dG    2'-Deoxyguanosine 
DMF    Dimethylformamide 
DMT    Dimethoxytrityl 
DNA    Deoxyribonucleic acid 
dNTP   Deoxynucleoside triphosphate 
ddNTP  2', 3' Dideoxynucleoside triphosphate 
ds   Double stranded 
dT    2'-Deoxythymidine 
DTT   Dithiothreitol 
E. coli    Escherichia coli 
EDTA   Ethylendiamine tetraacetate 
EI    Electron ionization 
ESI    Elektrospray ionisation 
EtBr    Ethidium bromide 
EtOAc   Ethyl acetate 
eq.    Equivalents 
h   Hour 
HPLC    High pressure liquid chromatography 
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HR-MS   High resolution mass spectrometry 
IR    Infra red 
IPTG    Isopropylthiogalactoside 
kb    Kilobase 
LB    Lysogeny broth 
TFA   Trifluoroacetic acid 
TLC    Thin layer chromatography 
TLS   Translesion Synthesis 
MeCN   Acetonitrile 
min   Minute 
M.p.    Melting point 
mRNA   Messanger ribonucleic acid 
MS    Mass spectrometry 
n    Amount of substance 
NaOtBu  Sodium tert-butoxide 
NER    nucleotide excision repair 
NMR    Nuclear magnetic resonance 
OD    Optical density 
PAGE    Polyacrylamid gel electrophoresis 
PCR   Polymerase Chain Reaction 
Pd2(dba)3  Tris-(dibenzylideneacetone)-dipalladium (0) 
ppm    Parts per million 
RNA    Ribonucleic acid 
rpm    Rotation per minute 
rt    Room temperature 
s   Second 
S. cerevisiae  Saccharomyces cerevisiae 
SDS    Sodium dodecylsulfate 
ss    Single stranded 
TBDMS   tert-Butyldimethylsilyl 
TEMED   N,N,N',N'-Tetramethylendiamine 
THF    Tetrahydrofurane 
Tris    Tris(-hydroxymethyl)-aminomethane 
U    Units 
UV    Ultraviolet 
vol.    Volume 
w/v    Weight per volume 
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